(19) DANMARK

(10) DK/EP 2258376 T3

(12) Oversættelse af europæisk patentskrift

Patent- og Varemærkestyrelsen

(51) Int.Cl.: *A 61 K 31/341 (2006.01)* *A 61 K 31/513 (2006.01)* *A 61 K 31/675 (2006.01)* *A 61 K 31/683 (2006.01)* *A 61 P 31/18 (2006.01)* *C 07 F 9/6561 (2006.01)* *C 07 H 19/16 (2006.01)*

(45) Oversættelsen bekendtgjort den: **2019-04-15**

(80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-02-27**

(86) Europæisk ansøgning nr.: **10178348.8**

(86) Europæisk indleveringsdag: **2005-07-26**

(87) Den europæiske ansøgnings publiceringsdag: **2010-12-08**

(30) Prioritet: **2004-07-27 US 591811 P**

(62) Stamansøgningsnr: **05857701.6**

(84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**

(73) Patenthaver: **GILEAD SCIENCES, INC., 333 Lakeside Drive Foster City, California 94404, USA**

(72) Opfinder: **Markevitch, David, Y., 3165 Sepulveda Blvd, apt. 308, Los Angeles, California 90034, USA**
Boojamra, Constantine, G., 1 Worth Street, San Francisco, California 94114, USA
Lin, Kuei-Ying, 1441 Ramon Drive, Sunnyvale, California 94087, USA
Zhang, Lijun, 4033 Middlefield Road, Palo Alto, California 94303, USA
Mackman, Richard, L., 360 Ashton Avenue, Millbrae, California 94030, USA
Petrakovsky, Oleg, V., 1301 Palos Verdes, Apt. 6, San Mateo, California 94403, USA
Ray, Adrian, S., 19 Pilot Circle, Redwood City, California 94065, USA

(74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**

(54) Benævnelse: **Phosphonatanaloger af HIV-inhibitorforbindelser**

(56) Fremdragne publikationer:
EP-B1- 1 778 249
WO-A-2004/096286
WO-A2-2004/096235
LEE KYEONG ET AL: "Structure-activity relationships of 2'-fluoro-2',3'-unsaturated D-nucleosides as anti-HIV-1 agents" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM010418N, vol. 45, no. 6, 14 March 2002 (2002-03-14) , pages 1313-1320, XP009099383 ISSN: 0022-2623
MACKMAN R L ET AL: "Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148" BIOORGANIC AND MEDICINAL CHEMISTRY 20100515 ELSEVIER LTD GBR LNKD- DOI:10.1016/J.BMC.2010.03.041, vol. 18, no. 10, 15 May 2010 (2010-05-15), pages 3606-3617, XP002605877 ISSN: 0968-0896
RAY A S ET AL: "Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 200802 US LNKD-

Fortsættes ...

DOI:10.1128/AAC.01209-07, vol. 52, no. 2, February 2008 (2008-02), pages 648-654, XP002605878 ISSN: 0066-4804
BIRKUS G ET AL: "Cathepsin a is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 200702 US LNKD- DOI:10.1128/AAC.00968-06, vol. 51, no. 2, February 2007 (2007-02), pages 543-550, XP002605879 ISSN: 0066-4804

DESCRIPTION

FIELD OF THE INVENTION

[0001] The invention relates generally to compounds with antiviral activity and more specifically with anti-HIV properties.

BACKGROUND OF THE INVENTION

[0002] AIDS is a major public health problem worldwide. Although drugs targeting HIV viruses are in wide use and have shown effectiveness, toxicity and development of resistant strains have limited their usefulness. Assay methods capable of determining the presence, absence or amounts of HIV viruses are of practical utility in the search for inhibitors as well as for diagnosing the presence of HIV.

[0003] Human immunodeficiency virus (HIV) infection and related disease is a major public health problem worldwide. The retrovirus human immunodeficiency virus type 1 (HIV-1), a member of the primate lentivirus family (DeClercq E (1994) Annals of the New York Academy of Sciences, 724:438-456; Barre-Sinoussi F (1996) Lancet, 348:31-35), is generally accepted to be the causative agent of acquired immunodeficiency syndrome (AIDS) Tarrago et al. FASEB Journal 1994, 8:497-503). AIDS is the result of repeated replication of HIV-1 and a decrease in immune capacity, most prominently a fall in the number of CD4+ lymphocytes. The mature virus has a single stranded RNA genome that encodes 15 proteins (Frankel et al. (1998) Annual Review of Biochemistry, 67:1-25; Katz et al. (1994) Annual Review of Biochemistry, 63:133-173), including three key enzymes: (i) protease (Prt) (von der Helm K (1996) Biological Chemistry, 377:765-774); (ii) reverse transcriptase (RT) (Hottiger et al. (1996) Biological Chemistry Hoppe-Seyler, 377:97-120), an enzyme unique to retroviruses; and (iii) integrase (Asante et al. (1999) Advances in Virus Research 52:351-369; Wlodawer A (1999) Advances in Virus Research 52:335-350; Esposito et al. (1999) Advances in Virus Research 52:319-333). Protease is responsible for processing the viral precursor polyproteins, integrase is responsible for the integration of the double stranded DNA form of the viral genome into host DNA and RT is the key enzyme in the replication of the viral genome. In viral replication, RT acts as both an RNA- and a DNA-dependent DNA polymerase, to convert the single stranded RNA genome into double stranded DNA. Since virally encoded Reverse Transcriptase (RT) mediates specific reactions during the natural reproduction of the virus, inhibition of HIV RT is an important therapeutic target for treatment of HIV infection and related disease.

[0004] Sequence analysis of the complete genomes from several infective and non-infective HIV-isolates has shed considerable light on the make-up of the virus and the types of molecules that are essential for its replication and maturation to an infective species. The HIV

protease is essential for the processing of the viral gag and gag-pol polypeptides into mature virion proteins. L. Ratner, et al., Nature, 313:277-284 (1985); L. H. Pearl and W. R. Taylor, Nature, 329:351 (1987). HIV exhibits the same gag/pol/env organization seen in other retroviruses. L. Ratner, et al., above; S. Wain-Hobson, et al., Cell, 40:9-17 (1985); R. Sanchez-Pescador, et al., Science, 227:484-492 (1985); and M. A. Muesing, et al., Nature, 313:450-458 (1985).

[0005] Drugs approved in the United States for AIDS therapy include nucleoside inhibitors of RT (Smith et al (1994) Clinical Investigator, 17:226-243), protease inhibitors and non-nucleoside RT inhibitors (NNRTI), (Johnson et al (2000) Advances in Internal Medicine, 45 (1-40; Porche DJ (1999) Nursing Clinics of North America, 34:95-112).

[0006] Inhibitors of HIV protease are useful to limit the establishment and progression of infection by therapeutic administration as well as in diagnostic assays for HIV. Protease inhibitor drugs approved by the FDA include:

- saquinavir (Invirase®, Fortovase®, Hoffman-La Roche, EP-00432695 and EP-00432694)
- ritonavir (Norvir®, Abbott Laboratories)
- indinavir (Crixivan®, Merck & Co.)
- nelfinavir (Viracept®, Pfizer)
- amprenavir (Agenerase®, GlaxoSmithKline, Vertex Pharmaceuticals)
- lopinavir/ritonavir (Kaletra®, Abbott Laboratories)

[0007] Experimental protease inhibitor drugs include:

- fosamprenavir (GlaxoSmithKline, Vertex Pharmaceuticals)
- tipranavir (Boehringer Ingelheim)
- atazanavir (Bristol-Myers Squibb).

[0008] D- and L-2'fluoro-2',3'-unsaturated nucleosides have reportedly been shown to display antiviral activities against HIV-1 (Zhou W (2004) Journal of Medicinal Chemistry 47(13), 3399-3408.

[0009] There is a need for anti-HIV therapeutic agents, i.e. drugs having improved antiviral and pharmacokinetic properties with enhanced activity against development of HIV resistance, improved oral bioavailability, greater potency and extended effective half-life *in vivo*. New HIV antivirals should be active against mutant HIV strains, have distinct resistance profiles, fewer side effects, less complicated dosing schedules, and orally active. In particular, there is a need for a less onerous dosage regimen, such as one pill, once per day. Although drugs targeting HIV RT are in wide use and have shown effectiveness, particularly when employed in

combination, toxicity and development of resistant strains have limited their usefulness.

[0010] Combination therapy of HIV antivirals has proven to be highly effective in suppressing viral replication to unquantifiable levels for a sustained period of time. Also, combination therapy with RT and other HIV inhibitors have shown synergistic effects in suppressing HIV replication. Unfortunately, many patients currently fail combination therapy due to the development of drug resistance, non-compliance with complicated dosing regimens, pharmacokinetic interactions, toxicity, and lack of potency. Therefore, there is a need for new HIV RT inhibitors that are synergistic in combination with other HIV inhibitors.

[0011] Improving the delivery of drugs and other agents to target cells and tissues has been the focus of considerable research for many years. Though many attempts have been made to develop effective methods for importing biologically active molecules into cells, both *in viv*o and *in vitro,* none has proved to be entirely satisfactory. Optimizing the association of the inhibitory drug with its intracellular target, while minimizing intercellular redistribution of the drug, e.g. to neighboring cells, is often difficult or inefficient.

[0012] Most agents currently administered to a patient parenterally are not targeted, resulting in systemic delivery of the agent to cells and tissues of the body where it is unnecessary, and often undesirable. This may result in adverse drug side effects, and often limits the dose of a drug (e.g., cytotoxic agents and other anti-cancer or anti-viral drugs) that can be administered. By comparison, although oral administration of drugs is generally recognized as a convenient and economical method of administration, oral administration can result in either (a) uptake of the drug through the cellular and tissue barriers, e.g. blood/brain, epithelial, cell membrane, resulting in undesirable systemic distribution, or (b) temporary residence of the drug within the gastrointestinal tract. Accordingly, a major goal has been to develop methods for specifically targeting agents to cells and tissues. Benefits of such treatment includes avoiding the general physiological effects of inappropriate delivery of such agents to other cells and tissues, such as uninfected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells.

SUMMARY OF THE INVENTION

[0013] The present invention provides novel compounds with HIV activity, i.e. novel human retroviral RT inhibitors. Therefore, the compounds of the invention may inhibit retroviral RT and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases. The present invention includes novel phosphonate HIV RT inhibitor compounds and phosphonate analogs of known approved and experimental protease inhibitors. The compounds of the invention optionally provide cellular accumulation as set forth below.

[0014] The present invention relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of phosphonate-containing molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.

[0015] Compositions of the invention include new RT compounds having at least one phosphonate group. The invention includes all known approved and experimental protease inhibitors with at least one phosphonate group.

[0016] The disclosure relates generally to compounds, including enantiomers thereof, of Formula 1A, or a pharmaceutically acceptable salt or solvate thereof,



1A

wherein:

A^0 is A^1, A^2, or A^3;

A^1 is



;

A^2 is



;

A^3 is:



;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, Y^3, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

Y^3 is O, $S(O)_{M2}$, S, or $C(R^2)_2$;

R^x is independently H, R^1, R^2, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 and R^{2a} are independently H, R^1, R^3, or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or, when taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c}, R^{3d}, or R^{3e}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is R^{3e}, -CN, N_3 or $-NO_2$;

R^{3b} is $(=Y^1)$;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$,-$OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$,-$N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^{3e} is F, Cl, Br or I;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is H or R^4, wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_{M2}R^5$, or $-SO_{M2}W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

provided that the compound of Formula 1A is not of the structure 556-E.6



556-E.6

or its ethyl diester.

[0017] The invention specifically provides compounds, including enantiomers thereof, of Formula 1J, or a pharmaceutically acceptable salt or solvate thereof,



IJ

wherein:

A^3 is selected from





,



or



2

wherein

R^1 is independently H or alkyl selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl;

R^2 is H or alkyl selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl; and

Y^{2b} is O or N(R^2).

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

[0018] Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying structures and formulas.

DEFINITIONS

[0019] Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:
When tradenames are used herein, applicants intend to independently include the tradename product and the active pharmaceutical ingredient(s) of the tradename product.

[0020] "Base" is a term of art in the nucleoside and nucleotide fields. It is frequently abbreviated as "B." Within the context of the present invention, "Base" or "B" mean, without limitation, at least those bases know to the ordinary artisan or taught in the art. Exemplary definitions 1) to 10) below are illustrative. Preferable "Bases" or "Bs" include purines, more preferably purines of 1) to 10) below. More preferably yet, "Base" or "B" means the purines of 4) to 10) below. Most preferably "Base" or "B" means 10) below.

[0021] In embodiments of this disclosure, Base or B is a group having structure (1) below



wherein

R^{2c} is halo, NH_2, R^{2b} or H;

R^{2b} is $-(R^9)_{m1(}X)m4(R^9)_{m2(X)m5(}R^9)_{m3(}N(R^{2c})_{2)n}$;

X independently is O or S;

M1 - m3 independently are 0-1;

M4-m5 independently are 0-1

n is 0-2;

R^9 independently is unsubstituted C_1-C_{15} alkyl, C_2-C_{15} alkenyl, C_6-C_{15} arylalkenyl, C_6-C_{15} arylalkynyl, C_2-C_{15} alkynyl, C_1-C_6-alkylamino-C_1-C_6 alkyl, C_5-C_{15} aralkyl, C_6-C_{15} heteroaralkyl, C_5-C_6 aryl or C_2-C_6 heterocycloalkyl, or said groups optionally substituted with 1 to 3 of halo, alkoxy, alkylthio, nitro, OH, =O, haloalkyl, CN, R^{10} or N_3;

R^{10} independently is selected from the group consisting of
H,

C_1-C_{15} alkyl, C_2-C_{15} alkenyl, C_6-C_{15} arylalkenyl, C_6-C_{15} arylalkynyl, C_2-C_{15} alkynyl, C_1-C_6-alkylamino-C_1-C_6 alkyl, C_5-C_{15} aralkyl, C_6-C_{15} heteroaralkyl, C_5-C_6 aryl, -C(O)R^9, -C(O)OR^9 and C_2-C_6 heterocycloalkyl,

optionally both R^{10} of N(R^{10})$_2$ are joined together with N to form a saturated or unsaturated C_5-C_6 heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom,

and the foregoing R^{10} groups which are substituted with 1 to 3 of halo, alkoxy, alkythio, nitro, OH, =O, haloalkyl, CN or N_3; and

Z is N or C(R3), provided that the heterocyclic nucleus varies from purine by no more than two Z.

[0022] Alkyl, alkynyl and alkenyl groups in the formula (1) groups are normal, secondary, tertiary or cyclic.

[0023] Ordinarily, n is 1, m1 is 0 or 1, R^9 is C1-C3 alkyl, R^{2b} is H, m2-m5 are all 0; one or two R^{10} groups are not H; R^{10} is C_1-C_6 alkyl (including C_3-C_6 cycloalkyl, particularly cyclopropyl); and one R^{10} is H. If Z is C(R3) at the 5 and/or 7 positions, R3 is halo, usually fluoro.

[0024] The compounds of this invention are noteworthy in their ability to act effectively against HIV which bears resistance mutations in the polymerase gene, in particular, HIV which is resistant to tenofovir, FTC and other established anti-HIV agents.

1) B is a heterocyclic amine base.
In the specification "Heterocyclic amine base" is defined as a monocyclic, bicyclic, or polycyclic ring system comprising one or more nitrogens. For example, B includes the naturally-occurring heterocycles found in nucleic acids, nucleotides and nucleosides, and analogs thereof.
B is selected from the group consisting of



,


,




,


,


and


wherein:

U, G, and J are each independently CH or N;

D is N, CH, C-CN, C-NO_2, C-C_{1-3} alkyl, C-$NHCONH_2$, C-$CONT_{11}T_{11}$, C-$CSNT_{11}T_{11}$, C-$COOT_{11}$,

C-C(=NH)NH_2, C-hydroxy, C-C_{1-3} alkoxy, C-amino, C-C_{1-4}alkylamino, C-di(C_{1-4}alkyl)amino, C-halogen, C-(1,3-oxazol-2-yl), C-(1,3 thiazol-2-yl), or C-(imidazol-2-yl); wherein alkyl is unsubstituted or substituted with one to three groups independently selected from halogen, amino, hydroxy, carboxy, and C_{1-3} alkoxy;

E is N or CT_5;

W is O or S;

T_1 is H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-4}alkylamino, CF_3, or halogen;

T_2 is H, OH, SH, NH_2, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{3-6}cycloalkylamino, halo, C_{1-4}alkyl, C_{1-4}alkoxy, or CF_3;

T_3 is H, amino, C_{1-4}alkylamino, C_{3-6}cycloalkylamino, or di(C_{1-4}alkyl)amino;

T_4 is H, halo, CN, carboxy, C_{1-4}alkyloxycarbonyl, N_3, amino, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, hydroxy, C_{1-6}alkoxy, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, or (C_{1-4}alkyl)$_{0-2}$aminomethyl;

T_5 is independently H or C_{1-6}alkyl; and

T_6 is H, CF_3, C_{1-4}alkyl, amino, C_{1-4}alkylamino, C_{3-6}cycloalkylamino, or di(C_{1-4}alkyl)amino;

3) B is selected from







and



wherein:

T_{10} is H, OH, F, Cl, Br, I, OT_{17}, SH, ST_{17}, NH_2, or NHT_{18} ;

T_{11} is N, CF, CCl, CBr, CI, CT_{19}, CST_{19}, or COT_{19} ;

T_{12} is N or CH;

T_{13} is N, CH, CCN, CCF_3, CC≡≡CH or $CC(O)NH_2$

T_{14} is H, OH, NH_2, SH, SCH_3, SCH_2CH_3, $SCH_2C{\equiv}CH$, $SCH_2CH{=}CH_2$, SC_3H_7, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $N(CH_2CH_3)_2$, $NH(CH_2C{\equiv}CH)$, $NH(CH_2CH{=}CH_2)$, $NH(C_3H_7)$ or halogen

(F, Cl, Br or I);

T_{15} is H, OH, F, Cl, Br, I, SCH_3, SCH_2CH_3, $SCH_2C{\equiv}CH$, $SCH_2CH{=}CH_2$, SC_3H_7, OT_{17}, NH_2, or NHT_{18}; and

T_{16} is O, S or Se.

T_{17} is $C_{1\text{-}6}$alkyl (including CH_3, CH_2CH_3, $CH_2C{\equiv}CH$, $CH_2CH{=}CH_2$, and C_3H_7);

T_{18} is $C_{1\text{-}6}$alkyl (including CH_3, CH_2CH_3, $CH_2C{\equiv}CH$, $CH_2CH{=}CH_2$, and C_3H_7);
T_{19} is H, $C_{1\text{-}9}$alkyl, $C_{2\text{-}9}$alkenyl, $C_{2\text{-}9}$alkynyl or $C_{7\text{-}9}$aryl-alkyl unsubstituted or substituted by OH, O, N, F, Cl, Br or I (including CH_3, CH_2CH_3, $CH{=}CH_2$, $CH{=}CHBr$, CH_2CH_2Cl, CH_2CH_2F, $CH_2C{\equiv}CH$, $CH_2CH{=}CH_2$, C_3H_7, CH_2OH, CH_2OCH_3, $CH_2OC_2H_5$, $CH_2OC{\equiv}CH$, $CH_2OCH_2CH{=}CH_2$, $CH_2C_3H_7$, CH_2CH_2OH, $CH_2CH_2OCH_3$, $CH_2CH_2OC_2H_5$, $CH_2CH_2OC{\equiv}CH$, $CH_2CH_2OCH_2CH{=}CH_2$, $CH_2CH_2OC_3H_7$;

4) B is adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, or pyrazolo[3,4-d]pyrimidine;

5) B is

hypoxanthine,

inosine,

thymine,

uracil,

xanthine,

an 8-aza derivative of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine or xanthine;

a 7-deaza-8-aza derivative of adenine, guanine, 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine or xanthine;

a 1-deaza derivative of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine or xanthine;

a 7-deaza derivative of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine or xanthine;

a 3-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine or xanthine;

6-azacytosine;

5-fluorocytosine;

5-chlorocytosine;

5-iodocytosine;

5-bromocytosine;

5-methylcytosine;

5-bromovinyluracil;

5-fluorouracil;

5-chlorouracil;

5-iodouracil;

5-bromouracil;

5-trifluoromethyluracil;

5-methoxymethyluracil;

5-ethynyluracil; or

5-propynyluracil

6) B is a guanyl, 3-deazaguanyl, 1-deazaguanyl, 8-azaguanyl, 7-deazaguanyl, adenyl, 3-deazaadenyl, 1-dezazadenyl, 8-azaadenyl, 7-deazaadenyl, 2,6-diaminopurinyl, 2-aminopurinyl, 6-chloro-2-aminopurinyl 6-thio-2-aminopurinyl, cytosinyl, 5-halocytosinyl, or 5-(C_1-C_3alkyl)cytosinyl.

7) B is



wherein T^7 and T^8 are each independently O or S and T^9 is H, amino, hydroxy, Cl, or Br.

8) B is thymine, adenine, uracil, a 5-halouracil, a 5-alkyluracil, guanine, cytosine, a 5-halocytosine, a 5-alkylcytosine, or 2,6-diaminopurine.

9) B is guanine, cytosine, uracil, or thymine.

10) B is adenine.

[0025] "Bioavailability" is the degree to which the pharmaceutically active agent becomes available to the target tissue after the agent's introduction into the body. Enhancement of the bioavailability of a pharmaceutically active agent can provide a more efficient and effective treatment for patients because, for a given dose, more of the pharmaceutically active agent will be available at the targeted tissue sites.

[0026] The terms "phosphonate" and "phosphonate group" include functional groups or moieties within a molecule that comprises a phosphorous that is 1) single-bonded to a carbon, 2) double-bonded to a heteroatom, 3) single-bonded to a heteroatom, and 4) single-bonded to another heteroatom, wherein each heteroatom can be the same or different. The terms "phosphonate" and "phosphonate group" also include functional groups or moieties that comprise a phosphorous in the same oxidation state as the phosphorous described above, as well as functional groups or moieties that comprise a prodrug moiety that can separate from a compound so that the compound retains a phosphorous having the characteriatics described above. For example, the terms "phosphonate" and "phosphonate group" include phosphonic acid, phosphonic monoester, phosphonic diester, phosphonamidate, and phosphonthioate functional groups. In one specific embodiment of the invention, the terms "phosphonate" and "phosphonate group" include functional groups or moieties within a molecule that comprises a phosphorous that is 1) single-bonded to a carbon, 2) double-bonded to an oxygen, 3) single-bonded to an oxygen, and 4) single-bonded to another oxygen, as well as functional groups or moieties that comprise a prodrug moiety that can separate from a compound so that the compound retains a phosphorous having such characteriatics. In another specific embodiment of the invention, the terms "phosphonate" and "phosphonate group" include functional groups or moieties within a molecule that comprises a phosphorous that is 1) single-bonded to a carbon, 2) double-bonded to an oxygen, 3) single-bonded to an oxygen or nitrogen, and 4) single-bonded to another oxygen or nitrogen, as well as functional groups or moieties that comprise a prodrug moiety that can separate from a compound so that the compound retains a phosphorous having such characteriatics.

[0027] The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the drug substance, *i.e.* active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrug is thus a covalently modified analog or latent form of a therapeutically-active compound.

[0028] "Prodrug moiety" refers to a labile functional group which separates from the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process (Bundgaard, Hans, "Design and Application of Prodrugs" in A Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 113-191). Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention

include amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphases. Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to optimize drug delivery, bioavailability and efficacy. A prodrug moiety may include an active metabolite or drug itself.

[0029] Exemplary prodrug moieties include the hydrolytically sensitive or labile acyloxymethyl esters $-CH_2OC(=O)R^9$ and acyloxymethyl carbonates $-CH_2OC(=O)OR^9$ where R^9 is C_1-C_6 alkyl, C_1-C_6 substituted alkyl, C_6-C_{20} aryl or C_6-C_{20} substituted aryl. The acyloxyalkyl ester was first used as a prodrug strategy for carboxylic acids and then applied to phosphates and phosphonates by Farquhar et al. (1983) J. Pharm. Sci. 72: 324; also US Patent Nos. 4816570, 4968788, 5663159 and 5792756. Subsequently, the acyloxyalkyl ester was used to deliver phosphonic acids across cell membranes and to enhance oral bioavailability. A close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester (carbonate), may also enhance oral bioavailability as a prodrug moiety in the compounds of the combinations of the invention. An exemplary acyloxymethyl ester is pivaloyloxymethoxy, (POM) $-CH_2OC(=O)C(CH_3)_3$. An exemplary acyloxymethyl carbonate prodrug moiety is pivaloyloxymethylcarbonate (POC) $-CH_2OC(=O)OC(CH_3)_3$.

[0030] The phosphonate group may be a phosphonate prodrug moiety. The prodrug moiety may be sensitive to hydrolysis, such as a pivaloyloxymethyl carbonate (POC) or POM group. Alternatively, the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphonamidate-ester group.

[0031] Aryl esters of phosphorus groups, especially phenyl esters, are reported to enhance oral bioavailability (De Lombaert et al. (1994) J. Med. Chem. 37: 498). Phenyl esters containing a carboxylic ester ortho to the phosphate have also been described (Khamnei and Torrence, (1996) J. Med. Chem. 39:4109-4115). Benzyl esters are reported to generate the parent phosphonic acid. In some cases, substituents at the *ortho*-or *para-position* may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of enzymes, *e.g.,* esterases, oxidases, etc., which in turn undergoes cleavage at the benzylic C-O bond to generate the phosphoric acid and the quinone methide intermediate. Examples of this class of prodrugs are described by Mitchell et al. (1992) J. Chem. Soc. Perkin Trans. II 2345; Glazier WO 91/19721. Still other benzylic prodrugs have been described containing a carboxylic ester-containing group attached to the benzylic methylene (Glazier WO 91/19721). Thio-containing prodrugs are reported to be useful for the intracellular delivery of phosphonate drugs. These proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined with another thiol group to form a disulfide. Deesterification or reduction of the disulfide generates the free thio intermediate which subsequently breaks down to the phosphoric acid and episulfide (Puech et al. (1993) Antiviral Res., 22: 155-174; Benzaria et al. (1996) J. Med. Chem. 39: 4958). Cyclic phosphonate esters have also been described as prodrugs of phosphorus-containing compounds (Erion et al., US Patent No. 6,312,662).

[0032] "Protecting group" refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. Chemical protecting groups and strategies for protection/deprotection are well known in the art. *See e.g.,* Protective Groups in Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, *e.g.,* making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive.

[0033] Protected compounds may also exhibit altered, and in some cases, optimized properties *in vitro* and *in vivo,* such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug *in vivo.* Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency *in vivo* than the parental drug. Protecting groups are removed either *in vitro,* in the instance of chemical intermediates, or *in vivo,* in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g., alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

[0034] Any reference to any of the compounds of the invention also includes a reference to a physiologically acceptable salt thereof. Examples of physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX_4^+ (wherein X is C_1-C_4 alkyl). Physiologically acceptable salts of an hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and *p*-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound of an hydroxy group include the anion of said compound in combination with a suitable cation such as Na^+ and $NX4^+$ (wherein X is independently selected from H or a C_1-C_4 alkyl group).

[0035] For therapeutic use, salts of active ingredients of the compounds of the invention will be physiologically acceptable, *i.e.* they will be salts derived from a physiologically acceptable acid or base. However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.

[0036] "Alkyl" is C_1-C_{18} hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. The alkyl groups used for the present invention are methyl (Me, -CH_3), ethyl (Et, -CH_2CH_3), 1-propyl (n-Pr, n-propyl, -$CH_2CH_2CH_3$), 2-propyl (i-Pr, i-propyl, -$CH(CH_3)_2$), 1-butyl (n-Bu, n-butyl, -$CH_2CH_2CH_2CH_3$), 2-methyl-1-propyl (i-Bu, i-butyl, -$CH_2CH(CH_3)_2$), 2-butyl (s-Bu, s-butyl, -$CH(CH_3)CH_2CH_3$), 2-methyl-2-propyl (t-Bu, t-butyl, -$C(CH_3)_3$), 1-pentyl (n-pentyl, -$CH_2CH_2CH_2CH_2CH_3$), 2-pentyl (-$CH(CH_3)CH_2CH_2CH_3$), 3-pentyl (-$CH(CH_2CH_3)_2$), 2-methyl-2-butyl (-$C(CH_3)_2CH_2CH_3$), 3-methyl-2-butyl (-$CH(CH_3)CH(CH_3)_2$), 3-methyl-1-butyl (-$CH_2CH_2CH(CH_3)_2$), 2-methyl-1-butyl (-$CH_2CH(CH_3)CH_2CH_3$), 1-hexyl (-$CH_2CH_2CH_2CH_2CH_2CH_3$), 2-hexyl (-$CH(CH_3)CH_2CH_2CH_2CH_3$), 3-hexyl (-$CH(CH_2CH_3)(CH_2CH_2CH_3)$), 2-methyl-2-pentyl (-$C(CH_3)_2CH_2CH_2CH_3$), 3-methyl-2-pentyl (-$CH(CH_3)CH(CH_3)CH_2CH_3$), 4-methyl-2-pentyl (-$CH(CH_3)CH_2CH(CH_3)_2$), 3-methyl-3-pentyl (-$C(CH_3)(CH_2CH_3)_2$), 2-methyl-3-pentyl (-$CH(CH_2CH_3)CH(CH_3)_2$), 2,3-dimethyl-2-butyl (-$C(CH_3)_2CH(CH_3)_2$), 3,3-dimethyl-2-butyl (-$CH(CH_3)C(CH_3)_3$.

[0037] "Alkenyl" is C_2-C_{18} hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, *i.e.* a carbon-carbon, sp^2 double bond. Examples include, ethylene or vinyl (-$CH=CH_2$), allyl (-$CH_2CH=CH_2$), cyclopentenyl (-C_5H_7), and 5-hexenyl (-CH_2 $CH_2CH_2CH_2CH=CH_2$).

[0038] "Alkynyl" is C_2-C_{18} hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, *i.e.* a carbon-carbon, *sp* triple bond. Examples include, acetylenic (-C=CH) and propargyl (-$CH_2C=CH$),

[0039] "Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, methylene (-CH_2-) 1,2-ethyl (-CH_2CH_2-) and 1,3-propyl (-$CH_2CH_2CH_2$-), 1,4-butyl (-$CH_2CH_2CH_2CH_2$-).

[0040] "Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene radicals include, 1,2-ethylene (-CH=CH-).

[0041] "Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene radicals include, acetylene (-C=C-), propargyl (-$CH_2C=C$-), and 4-pentynyl (-$CH_2CH_2CH_2C=CH$-).

[0042] "Aryl" means a monovalent aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, radicals derived from benzene, substituted benzene, naphthalene, anthracene and biphenyl.

[0043] "Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, benzyl, 2-phenylethan-1-yl, , naphthylmethyl, 2-naphthylethan-1-yl, naphthobenzyl and 2-naphthophenylethan-1-yl. The arylalkyl group comprises 6 to 20 carbon atoms, e.g., the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.

[0044] "Substituted alkyl", "substituted aryl", and "substituted arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent. Typical substituents include, -X, -R, $-O^-$, -OR, -SR, $-S^-$, $-NR_2$, $-NR_3$, =NR, $-CX_3$, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, $-NO_2$, $=N_2$, $-N_3$, NC(=O)R, -C(=O)R,-C(=O)NRR $-S(=O)_2O^-$, $-S(=O)_2OH$, $-S(=O)_2R$, $-OS(=O)_2OR$, $-S(=O)_2NR$, -S(=O)R, $-OP(=O)O_2RR$-$P(=O)O_2RR$ $-P(=O)(O^-)_2$, $-P(=O)(OH)_2$, -C(=O)R, -C(=O)X, -C(S)R, -C(O)OR, $-C(O)O^-$, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR, -C(NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is independently -H, alkyl, aryl, heterocycle, protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups may also be similarly substituted.

[0045] "Heterocycle" as used herein includes by way of example these heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566. In one specific embodiment of the invention "heterocycle" includes a "carbocycle" as defined herein, wherein one or more (*e.g.* 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (*e.g.* O, N, or S).

[0046] Examples of heterocycles include by way of example pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazoly, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl,

phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatinoyl, and bis-tetrahydrofuranyl:



[0047] By way of example, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

[0048] By way of example, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

[0049] "Carbocycle" refers to a saturated, unsaturated or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, *e.g.,* arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and naphthyl.

[0050] "Linker" or "link" refers to a chemical moiety comprising a covalent bond or a chain or group of atoms that covalently attaches a phosphonate group to a drug. Linkers include portions of substituents A^1 and A^3, which include moieties such as: repeating units of alkyloxy (*e.g.,* polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (*e.g.,* polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide.

[0051] The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

[0052] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0053] "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.

[0054] "Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

[0055] The term "treatment" or "treating," to the extent it relates to a disease or condition includes preventing the disease or condition from occurring, inhibiting the disease or condition,eliminating the disease or condition, and/or relieving one or more symptoms of the disease or condition.

[0056] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, *i.e.,* they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

Protecting Groups

[0057] In the context of the present invention, protecting groups include prodrug moieties and chemical protecting groups.

[0058] Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthetic procedures, *i.e.* routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical protecting group "PG" will be dependent upon the chemistry of the reaction to be protected against (*e.g.,* acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of deprotection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the artisan.

[0059] Various functional groups of the compounds of the invention may be protected. For example, protecting groups for -OH groups (whether hydroxyl, carboxylic acid, phosphonic acid, or other functions) include "ether- or ester-forming groups". Ether- or ester-forming groups are capable of functioning as chemical protecting groups in the synthetic schemes set forth herein. However, some hydroxyl and thio protecting groups are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.

[0060] A very large number of hydroxyl protecting groups and amide-forming groups and corresponding chemical cleavage reactions are described in Protective Groups in Organic Synthesis, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991, ISBN 0-471-62301-6) ("Greene"). See also Kocienski, Philip J.; Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994)In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages 155-184. For protecting groups for carboxylic acid, phosphonic acid, phosphonate, sulfonic acid and other protecting groups for acids see Greene as set forth below. Such groups include by way of example, esters, amides and hydrazides.

Specific Embodiments of the Invention

[0061] Specific values described for radicals, substituents, and ranges, as well as specific embodiments of the invention described herein, are for illustration only; they do not exclude other defined values or other values within defined ranges.

[0062] In a specific embodiment of the invention A^3 is of the formula:





wherein

R^1 is independently H or alkyl selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

[0063] In another specific embodiment of the invention A^3 is of the formula:



wherein

R^1 is independently H or alkyl selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

[0064] In another specific embodiment of the invention A^3 is of the formula:



2

wherein

R^2 is H or alkyl selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

Y^{2b} is O or N(R^2).

[0065] In another specific embodiment of the invention A^3 is of the formula:



wherein

R^2 is H or alkyl selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

Linking Groups and Linkers

[0066] Also disclosed are conjugates that comprise an HIV inhibiting compound that is optionally linked to one or more phosphonate groups either directly (e.g. through a covalent bond) or through a linking group (i.e. a linker). The nature of the linker is not critical provided it does not interfere with the ability of the phosphonate containing compound to function as a therapeutic agent. The phosphonate or the linker can be linked to the compound (*e.g.* a compound of formula A) at any synthetically feasible position on the compound by removing a hydrogen or any portion of the compound to provide an open valence for attachment of the phosphonate or the linker.

[0067] In one embodiment the linking group or linker (which can be designated "L") can include all or a portions of the group A^0, A^1, A^2, or W^3 described herein.

[0068] In another embodiment of the invention the linking group or linker has a molecular weight of from about 20 daltons to about 400 daltons.

[0069] In another embodiment the linking group or linker has a length of about 5 angstroms to about 300 angstroms.

[0070] In another embodiment the linking group or linker separates the DRUG and a P(=Y^1) residue by about 5 angstroms to about 200 angstroms, inclusive, in length.

[0071] In another embodiment the linking group or linker is a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 2 to 25 carbon atoms,

wherein one or more (*e.g.* 1, 2, 3, or 4) of the carbon atoms is optionally replaced by (-O-), and wherein the chain is optionally substituted on carbon with one or more (*e.g.* 1, 2, 3, or 4) substituents selected from $(C_1$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkyl, $(C_1$-$C_6)$alkanoyl, $(C_1$-$C_6)$alkanoyloxy, $(C_1$-$C_6)$alkoxycarbonyl, $(C_1$-$C_6)$alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=O), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy.

[0072] In another embodiment the linking group or linker is of the formula W-A wherein A is $(C_1$-$C_{24})$alkyl, $(C_2$-$C_{24})$alkenyl, $(C_2$-$C_{24})$alkynyl, $(C_3$-$C_8)$cycloalkyl, $(C_6$-$C_{10})$aryl or a combination thereof, wherein W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-,-N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or $(C_1$-$C_6)$alkyl.

[0073] In another embodiment the linking group or linker is a divalent radical formed from a peptide.

[0074] In another embodiment the linking group or linker is a divalent radical formed from an amino acid.

[0075] In another embodiment the linking group or linker is a divalent radical formed from poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-lysine or poly-L-lysine-L- tyrosine.

[0076] In another embodiment the linking group or linker is of the formula W-$(CH_2)_n$ wherein, n is between about 1 and about 10; and W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-, -C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or $(C_1$-$C_6)$alkyl.

[0077] In another embodiment the linking group or linker is methylene, ethylene, or propylene.

[0078] In another embodiment the linking group or linker is attached to the phosphonate group through a carbon atom of the linker.

Intracellular Targeting

[0079] The incorporated phosphonate group of the compounds of the invention may cleave *in vivo* in stages after they have reached the desired site of action, *i.e.* inside a cell. One mechanism of action inside a cell may entail a first cleavage, *e.g.* by esterase, to provide a negatively-charged "locked-in" intermediate. Cleavage of a terminal ester grouping in a compound of the invention thus affords an unstable intermediate which releases a negatively charged "locked in" intermediate.

[0080] After passage inside a cell, intracellular enzymatic cleavage or modification of the

phosphonate or prodrug compound may result in an intracellular accumulation of the cleaved or modified compound by a "trapping" mechanism. The cleaved or modified compound may then be "locked-in" the cell by a significant change in charge, polarity, or other physical property change which decreases the rate at which the cleaved or modified compound can exit the cell, relative to the rate at which it entered as the phosphonate prodrug. Other mechanisms by which a therapeutic effect are achieved may be operative as well. Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphatases.

[0081] From the foregoing, it will be apparent that many different drugs can be derivatized in accord with the present invention. Numerous such drugs are specifically mentioned herein. However, it should be understood that the discussion of drug families and their specific members for derivatization according to this invention is not intended to be exhaustive, but merely illustrative.

HIV-Inhibitory Compounds

[0082] The compounds of the invention include those with HIV-inhibitory activity. The compounds of the invention bear one phosphonate group, which may be a prodrug moiety.

[0083] The term "HIV-inhibitory compound" includes those compounds that inhibit HIV.

[0084] Typically, compounds of the invention have a molecular weight of from about 400 amu to about 10,000 amu; in a specific embodiment of the invention, compounds have a molecular weight of less than about 5000 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 2500 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 1000 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 800 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 600 amu; and in another specific embodiment of the invention, compounds have a molecular weight of less than about 600 amu and a molecular weight of greater than about 400 amu.

[0085] The compounds of the invention also typically have a logD(polarity) less than about 5. In one embodiment the invention provides compounds having a logD less than about 4; in another one embodiment the invention provides compounds having a logD less than about 3; in another one embodiment the invention provides compounds having a logD greater than about -5; in another one embodiment the invention provides compounds having a logD greater than about -3; and in another one embodiment the invention provides compounds having a logD greater than about 0 and less than about 3.

[0086] Selected substituents within the compounds of the invention are present to a recursive

degree. In this context, "recursive substituent" means that a substituent may recite another instance of itself. Because of the recursive nature of such substituents, theoretically, a large number may be present in any given embodiment. For example, R^x contains a R^y substituent. R^y can be R^2, which in turn can be R^3. If R^3 is selected to be R^{3c}, then a second instance of R^x can be selected. One of ordinary skill in the art of medicinal chemistry understands that the total number of such substituents is reasonably limited by the desired properties of the compound intended. Such properties include, by of example and not limitation, physical properties such as molecular weight, solubility or log P, application properties such as activity against the intended target, and practical properties such as ease of synthesis.

[0087] By way of example, W^3, R^y and R^3 are all recursive substituents in certain embodiments. Typically, each of these may independently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, times in a given embodiment. More typically, each of these may independently occur 12 or fewer times in a given embodiment. More typically yet, W^3 will occur 0 to 8 times, R^y will occur 0 to 6 times and R^3 will occur 0 to 10 times in a given embodiment. Even more typically, W^3 will occur 0 to 6 times, R^y will occur 0 to 4 times and R^3 will occur 0 to 8 times in a given embodiment.

[0088] Recursive substituents are an intended aspect of the invention. One of ordinary skill in the art of medicinal chemistry understands the versatility of such substituents. To the degree that recursive substituents are present in an embodiment of the invention, the total number will be determined as set forth above.

[0089] Whenever a compound described herein is substituted with more than one of the same designated group, *e.g.*, "R^1" or "R^{6a}", then it will be understood that the groups may be the same or different, *i.e.*, each group is independently selected. Wavy lines indicate the site of covalent bond attachments to the adjoining groups, moieties, or atoms.

[0090] In one embodiment of the invention, the compound is in an isolated and purified form. Generally, the term "isolated and purified" means that the compound is substantially free from biological materials (e.g. blood, tissue, cells, etc.). In one specific embodiment of the invention, the term means that the compound or conjugate of the invention is at least about 50 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the invention is at least about 75 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the invention is at least about 90 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the invention is at least about 98 wt.% free from biological materials; and in another embodiment, the term means that the compound or conjugate of the invention is at least about 99 wt.% free from biological materials. In another specific embodiment, the invention provides a compound or conjugate of the invention that has been synthetically prepared (e.g., *ex vivo*).

Cellular Accumulation

[0091] In one embodiment, the invention provides compounds capable of accumulating in human PBMC (peripheral blood mononuclear cells). PBMC refer to blood cells having round lymphocytes and monocytes. Physiologically, PBMC are critical components of the mechanism against infection. PBMC may be isolated from heparinized whole blood of normal healthy donors or buffy coats, by standard density gradient centrifugation and harvested from the interface, washed (*e.g.* phosphate-buffered saline) and stored in freezing medium. PBMC may be cultured in multi-well plates. At various times of culture, supernatant may be either removed for assessment, or cells may be harvested and analyzed (Smith R. et al (2003) Blood 102(7):2532-2540). The compounds of this embodiment may further comprise a phosphonate or phosphonate prodrug. More typically, the phosphonate or phosphonate prodrug can have the structure A^3 as described herein.

[0092] Typically, compounds of the invention demonstrate improved intracellular half-life of the compounds or intracellular metabolites of the compounds in human PBMC when compared to analogs of the compounds not having the phosphonate or phosphonate prodrug. Typically, the half-life is improved by at least about 50%, more typically at least in the range 50-100%, still more typically at least about 100%, more typically yet greater than about 100%.

[0093] In one embodiment of the invention the intracellular half-life of a metabolite of the compound in human PBMCs is improved when compared to an analog of the compound not having the phosphonate or phosphonate prodrug. In such embodiments, the metabolite may be generated intracellularly, e.g. generated within human PBMC. The metabolite may be a product of the cleavage of a phosphonate prodrug within human PBMCs. The phosphonate-containing phosphonate prodrug may be cleaved to form a metabolite having at least one negative charge at physiological pH. The phosphonate prodrug may be enzymatically cleaved within human PBMC to form a phosphonate having at least one active hydrogen atom of the form P-OH.

Stereoisomers

[0094] The compounds of the invention may have chiral centers, e.g., chiral carbon or phosphorus atoms. The compounds of the invention thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers. In addition, the compounds of the invention include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the depictions are provided as the chiral isomers or racemic mixtures. Both racemic and diastereomeric mixtures, as well as the individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are all within the scope of the invention. The racemic mixtures are separated into their individual, substantially optically pure isomers through well-known techniques such as, for example, the separation of diastereomeric salts formed with

optically active adjuncts, *e.g.,* acids or bases followed by conversion back to the optically active substances. In most instances, the desired optical isomer is synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.

[0095] The compounds of the invention can also exist as tautomeric isomers in certain cases. All though only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the invention. For example, ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole systems and all their possible tautomeric forms are within the scope of the invention.

Salts and Hydrates

[0096] The compositions of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non-toxic salts containing, for example, Na^+, Li^+, K^+, Ca^{+2} and Mg^{+2}. Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. Monovalent salts are preferred if a water soluble salt is desired.

[0097] Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention. Examples of metal salts which are prepared in this way are salts containing Li^+, Na^+, and K^+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound.

[0098] In addition, salts may be formed from acid addition of certain organic and inorganic acids, *e.g.,* HCl, HBr, H_2SO_4 H_3PO_4 or organic sulfonic acids, to basic centers, typically amines, or to acidic groups. Finally, it is to be understood that the compositions herein comprise compounds of the invention in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.

[0099] Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids. Any of the amino acids described above are suitable, especially the naturally-occurring amino acids found as protein components, although the amino acid typically is one bearing a side chain with a basic or acidic group, *e.g.,* lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.

Methods of Inhibition of HIV

[0100] Another aspect of the invention relates to methods of inhibiting the activity of HIV comprising the step of treating a sample suspected of containing HIV with a composition of the invention.

[0101] Compositions of the invention may act as inhibitors of HIV, as intermediates for such inhibitors or have other utilities as described below. The inhibitors will generally bind to locations on the surface or in a cavity of the liver. Compositions binding in the liver may bind with varying degrees of reversibility. Those compounds binding substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, the substantially irreversibly binding compositions are useful as probes for the detection of HIV. Accordingly, the invention relates to methods of detecting NS3 in a sample suspected of containing HIV comprising the steps of: treating a sample suspected of containing HIV with a composition comprising a compound of the invention bound to a label; and observing the effect of the sample on the activity of the label. Suitable labels are well known in the diagnostics field and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups and chromogens. The compounds herein are labeled in conventional fashion using functional groups such as hydroxyl or amino.

[0102] Within the context of the invention samples suspected of containing HIV include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein. Typically the sample will be suspected of containing HIV. Samples can be contained in any medium including water and organic solvent/water mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.

[0103] The treating step of the invention comprises adding the composition of the invention to the sample or it comprises adding a precursor of the composition to the sample. The addition step comprises any method of administration as described above.

[0104] If desired, the activity of HIV after application of the composition can be observed by any method including direct and indirect methods of detecting HIV activity. Quantitative, qualitative, and semiquantitative methods of determining HIV activity are all contemplated. Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.

[0105] Many organisms contain HIV. The compounds of this invention are useful in the treatment or prophylaxis of conditions associated with HIV activation in animals or in man.

[0106] However, in screening compounds capable of inhibiting HIV it should be kept in mind that the results of enzyme assays may not correlate with cell culture assays. Thus, a cell based assay should be the primary screening tool.

Screens for HIV Inhibitors

[0107] Compositions of the invention are screened for inhibitory activity against HIV by any of the conventional techniques for evaluating enzyme activity. Within the context of the invention, typically compositions are first screened for inhibition of HIV *in vitro* and compositions showing inhibitory activity are then screened for activity *in vivo*. Compositions having *in vitro* Ki (inhibitory constants) of less then about 5 X 10^{-6} M, typically less than about 1 X 10^{-7} M and preferably less than about 5 X 10^{-8} M are preferred for *in vivo* use.

[0108] Useful *in vitro* screens have been described in detail.

Pharmaceutical Formulations

[0109] The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers binders. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid. The pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 0. While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.

[0110] The formulations include those suitable for the foregoing administration routes. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0111] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount

of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.

[0112] A tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.

[0113] For administration to the eye or other external tissues *e.g.,* mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.

[0114] If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, *i.e.* an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.

[0115] The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

[0116] Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

[0117] The choice of suitable oils or fats for the formulation is based on achieving the desired

cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.

[0118] Pharmaceutical formulations according to the present invention comprise one or more compounds of the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

[0119] Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

[0120] Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (*e.g.*, lecithin), a condensation product of an alkylene oxide with a fatty acid (*e.g.*, polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (*e.g.,* heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester

derived from a fatty acid and a hexitol anhydride (*e.g.,* polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.

[0121] Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

[0122] Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0123] The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.

[0124] The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

[0125] The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular

mode of administration. For example, a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight:weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 µg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.

[0126] Formulations suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.

[0127] Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0128] Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

[0129] Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns (including particle sizes in a range between 0.1 and 500 microns in increments microns such as 0.5, 1, 30 microns, 35 microns, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of conditions associated with HIV activity.

[0130] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0131] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

[0132] The formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition

requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.

[0133] It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0134] The invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefor.

[0135] Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.

[0136] Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provided compositions comprising one or more compounds of the invention formulated for sustained or controlled release.

[0137] Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses), the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. It can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg/kg body weight per day. More typically, from about .01 to about 5 mg/kg body weight per day. More typically, from about .05 to about 0.5 mg/kg body weight per day. For example, the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, preferably between 5 mg and 500 mg, and may take the form of single or multiple doses.

Routes of Administration

[0138] One or more compounds of the invention (herein referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural). It will be appreciated that the preferred route may vary with for example the condition of the

recipient. An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.

Combination Therapy

[0139] The compounds of the invention may be employed in combination with other therapeutic agents for the treatment or prophylaxis of the infections or conditions indicated above. Examples of such further therapeutic agents include agents that are effective for the treatment or prophylaxis of viral, parasitic or bacterial infections or associated conditions or for treatment of tumors or related conditions include 3'-azido-3'-deoxythymidine (zidovudine, AZT), 2'-deoxy-3'-thiacytidine (3TC), 2',3'-dideoxy-2',3'-didehydroadenosine (D4A), 2',3'-dideoxy-2',3'-didehydrothymidine (D4T), carbovir (carbocyclic 2',3'-dideoxy-2',3'-didehydroguanosine), 3'-azido-2',3'-dideoxyuridine, 5-fluorothymidine, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), 2-chlorodeoxyadenosine, 2-deoxycoformycin, 5-fluorouracil, 5-fluorouridine, 5-fluoro-2'-deoxyuridine, 5-trifluoromethyl-2'-deoxyuridine, 6-azauridine, 5-fluoroorotic acid, methotrexate, triacetyluridine, 1-(2'-deoxy-2'-fluoro-1-β-arabinosyl)-5-iodocytidine (FIAC), tetrahydro-imidazo(4,5, 1-jk)-(1,4)-benzodiazepin-2(1H)-thione (TIBO), 2'-nor-cyclicGMP, 6-methoxypurine arabinoside (ara-M), 6-methoxypurine arabinoside 2'-O-valerate, cytosine arabinoside (ara-C), 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine (ddC), 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI), acyclic nucleosides such as acyclovir, penciclovir, famciclovir, ganciclovir, HPMPC, PMEA, PMEG, PMPA, PMPDAP, FPMPA, HPMPA, HPMPDAP, (2R, 5R)-9->tetrahydro-5-(phosphonomethoxy)-2-furanyladenine, (2R, SR)-1->tetrahydro-5-(phosphonomethoxy)-2-furanylthymine, other antivirals including ribavirin (adenine arabinoside), 2-thio-6-azauridine, tubercidin, aurintricarboxylic acid, 3-deazaneoplanocin, neoplanocin, rimantidine, adamantine, and foscarnet (trisodium phosphonoformate), antibacterial agents including bactericidal fluoroquinolones (ciprofloxacin, pefloxacin), aminoglycoside bactericidal antibiotics (streptomycin, gentamicin amicacin) β-lactamase inhibitors (cephalosporins, penicillins), other antibacterials including tetracycline, isoniazid, rifampin, cefoperazone, claithromycin and azithromycin, antiparasite or antifungal agents including pentamidine (1,5-bis(4'-aminophenoxy)pentane), 9-deaza-inosine, sulfamethoxazole, sulfadiazine, quinapyramine, quinine, fluconazole, ketoconazole, itraconazole, Amphotericin B, 5-fluorocytosine, clotrimazole, hexadecylphosphocholine and nystatin, renal excretion inhibitors such as probenicid, nucleoside transport inhibitors such as dipyridamole, dilazep and nitrobenzylthioinosine, immunomodulators such as FK506, cyclosporin A, thymosin α-1, cytokines including TNF and TGF-β, interferons including IFN-α, IFN-β, and IFN-γ, interleukins including various interleukins, macrophage/granulocyte colony stimulating factors including GM-CSF, G-CSF, M-CSF, cytokine antagonists including anti-TNF antibodies, anti-interleukin antibodies, soluble interleukin receptors, protein kinase C inhibitors.

[0140] In addition, the therapeutic agents disclosed in Tables 98 and 99 directed to HIV may be used in combination with compounds of the present invention. For example, Table 98 discloses exemplary HIV/AIDS therapeutics, and Table 99 discloses Exemplary HIV Antivirals with their corresponding U.S. Patent numbers.

Table 98 Exemplary HIV/AIDS Therapeutics

Highest Phase	Code Name	Generic Name	Brand Name	Therapeutic Group	Mechanism of Action Group	Organization
Launched-1987	AZT BW-A509U Cpd S	Azidothymidine Zidovudine	AZTEC Retrovir	Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline (Originator)
Launched-1992	NSC-606170	Dideoxycytidine	Hivid	Anti-HIV Agents	Reverse Transcriptase Inhibitors	National Cancer Institute (US) (Originator)
	Ro-24-2027/000 Ro-242027	Zalcitabine				Roche
	ddC ddCyd					
Launched-1994	BMY-27857	Sanilvudine	Zerit	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Bristol-Myers Squibb (Originator)
	DTH	Stavudine		Chemical Delivery Systems		INSERM (Originator)
	d4T ddcThd					
Launched-1991	BMY-40900	Didanosine	Videx	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Bristol-Myers Squibb (Originator)
	DDI	Dideoxyinosine				Bristol-Myers Squibb (Orphan Drug)
	NSC-612049					
	d2I					
	ddIno					
Launched-1989	rIL-2	Aldesleukin	Macrolin	Anti-HIV Agents	IL-2	Chiron (Originator)
	rhIL-2	Recombinant interleukin-2	Proleukin	Breast Cancer Therapy Immunostimulants Leukemia Therapy Melanoma Therapy Myelodysplastic Syndrome Therapy Mycloid Leukemia Therapy Non-Hodgkin's Lymphoma Therapy Renal Cancer Therapy		Nat. Inst. Allergy & Infectious Dis.
Launched-1995	R-56	Saquinavir mesilate	Fortovase	Anti-HIV Agents	HIV Protease Inhibitors	Chugai Pharmaceutical

	Ro-31-8959/003		Invirase			(Originator) Chugai Pharmaceutical (Orphan Drug) Roche (Originator)
			Fortovase (soft gel capsules)			
Launched-1989		Human leukocyte interferon alpha	Alferon LDO	Anti-Cytomegalovirus Drugs		Guangdong
		Interferon alfa-n3 (human leukocyte derived)	Alferon N Gel	Anti-HIV Agents		HemispheRx
			Alferon N Injection	Anti-Hepatitis C Virus Drugs		Interferon Sciences (Originator)
			Alternol	Anti-Papilloma Virus Drugs		
			Cellferon	Antiviral Drugs		
				Genital Warts, Treatment for Multiple Sclerosis,		
				Agents for		
				Oncolytic Drugs Severe Acute Respiratory Syndrome (SARS), Treatment of Treatment of Female Sexual Dysfunction		
Launched-1996	BI-RG-587	Nevirapine	Viramune	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Boehringer Ingelheim (Originator) Nippon Boehringer Ingelheim
	BIRG-0587					Roxane
Launched-1999	1592U89 sulfate	Abacavir sulfate	Ziagen	Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline (Originator) GlaxoSmithKline (Orphan Drug)
Phase I/II	CD4-IgG	CD4-Immunoadhesin		AIDS Medicines		Genentech (Originator)
	rCD4-IgG	Recombinant CD4-immunoglobulin G		Immunomodulators		Nat. Inst. Allergy & Infectious Dis.
		Recombinant soluble CD4-immunoglobulin G				
Launched-1995	(-)-BCH-189	Lamivudine	3TC	Agents for Liver Cirrhosis	Reverse Transcriptase	GlaxoSmithKline

	(-)SddC		Epivir	Anti-HIV Agents	Inhibitors	Shire BioChem (Originator)
	3TC		Epivir-HBV	Anti-Hepatitis B Virus Drugs		
	GG-714 GR-109714X BCH-790 (fomer codc)		Heptodin Heptovir Lamivir Zeffix			
			Zefix			
Phase II	KNI-272	Kynostatin-272		Anti-HIV Agents	HIV Protease Inhibitors	Japan Energy (Originator)
Launched-2003	NSC-651714 (-)-FTC	Emtricitabine	Coviracil	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Emory University (Originator)
	524W91 BW-524W91		Emtriva	Anti-Hepatitis B Virus Drugs		Gilead Japan Tobacco
Launched-1997	U-90152S	Delavirdine mesilate	Rescriptor	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Agouron Pfizer (Originator) Pfizer (Orphan Drug)
Pre-Registered	AG-1661	HIV-1 Immunogen	Remune	AIDS Vaccines		Immune Response (Originator)
	RG-83894					Roemmers
	RG-83894-103					Trinity Medical Group
Launched-1996	L-735524 MK-639	Indinavir sulfate	Crixivan	Anti-HIV Agents	HIV Protease Inhibitors	Banyu Merck & Co. (Originator)
Phase I	phAZT	Azidothymidine phosphonate Nicavir		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Russian Academy of Sciences (Originator)
Phase II	NSC-675451	Phosphazid ( )-Calanolide A		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Advanced Life Sciences
	NSC-664737 (racemate)	Calanolide A		Treatment of Tuberculosis		Sarawak MediChem US Department of Health & Human Services (Originator)
Phase II	5A8			Anti-HIV Agents	Anti-CD4	Biogen Idec (Originator)
	Hu-5A8				Humanized Monoclonal Antibodies	Tanox
	TNX-355				Viral Entry Inhibitors	
Launched-1999	141W94 KVX-478	Amprenavir	Agenerase Prozei	Anti-HIV Agents	HIV Protease Inhibitors	GlaxoSmithKline Kissei
	VX-478					Vertex (Originator)

Launched-1998	DMP-266 L-743726 L-743725 ((+)-enantiomer) L-741211 (racemate)	Efavirenz	Stocrin Sustiva	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Banyu Banyu (Orphan Drug) Bristol-Myers Squibb (Originator)
Launched-1996	A-84538 ABT-538	Ritonavir	Norvir	Anti-HIV Agents	HIV Protease Inhibitors	Abbott (Originator) Dainippon Pharmaceutical
Launched-1997	AG-1343 LY-312857 AG-1346 (free base)	Nelfinavir mesilate	Viracept	Anti-HIV Agents	HIV Protease Inhibitors	Agouron (Originator) Japan Tobacco Mitsubishi Pharma Roche
Phase III	PRO-2000 PRO-2000/5			Anti-HIV Agents Microbicides	Viral Entry Inhibitors	Indevus Medical Research Council Paligent (Originator)
Phase III	Gd-Tex GdT2B2 PCI-0120	Gadolinium texaphyrin Motexafin gadolinium	Xcytrin	Anti-HIV Agents Antineoplastic Enhancing Agents Brain Cancer Therapy Glioblastoma MultiformeTherapy Head and Neck Cancer Therapy Lung Cancer Therapy Lymphocytic Leukemia Therapy Multiple Myeloma Therapy Non-Hodgkin's Lymphoma Therapy Non-Small Cell Lung Cancer Therapy Radiosensitizers Renal Cancer Therapy Solid Tumors Therapy		National Cancer Institute Pharmacyclics (Originator)
Launched-2003	DP-178 R-698	Enfuvirtide Pentafuside	Fuzeon	Anti-HIV Agents	Viral Fusion Inhibitors	Duke University (Originator) Roche

	T-20					Trimeris (Originator)
Phase II	BC-IL	Buffy coat interleukins	MultiKine	AIDS Medicines		Cel-Sci (Originator) University of Maryland
				Cancer Immunotherapy		
				Cervical Cancer Therapy		
				Head and Neck Cancer Therapy		
				Prostate Cancer Therapy		
Phase II	FP-21399			Anti-HIV Agents	Viral Fusion Inhibitors	EMD Lexigen (Originator) Fuji Photo Film (Originator)
Phase II	AXD-455	Semapimod hydrochloride		Anti-HIV Agents	Deoxyhypusine Synthase Inhibitors	Axxima
	CNI-1493			Antipsoriatics	Mitogen-Activated Protein Kinase (MAPK) Inhibitors	Cytokine PharmaSciences
				Inflammatory Bowel Disease, Agents for	Nitric Oxide Synthase Inhibitors	Picower Institute for Medical Research (Originator)
				Pancreatic Disorders, Treatment of		
				Renal Cancer Therapy		
Phase II	ALVAC MN120 TMGMP			AIDS Vaccines		ANRS
	ALVAC vCP205					Merck & Co.
	vCP205					Nat. Inst. Allergy & Infectious Dis.
						Sanofi Pasteur (Originator)
						Virogenetics (Originator)
						Walter Reed Army Institute
Phase I/II	CY-2301		Theradigm-HIV	AIDS Vaccines		Epimmune (Originator)
	EP HIV-1090 EP-1090			DNA Vaccines		IDM Nat. Inst. Allergy & Infectious Dis.
						National Institutes

						of Health
Phase II	CD4-IgG2			Anti-HIV Agents	Viral Entry Inhibitors	Epicyte
	PRO-542					Formatech
						GTC Biotherapeutics Progenics (Originator)
Phase I	UC-781			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Biosyn
				Microbicides		Cellegy
						Uniroyal
						(Originator) University of Pittsburgh (Originator)
Preclinical			ProVax	AIDS Vaccines		Progenics (Originator)
Phase II	ACH-126443	Elvucitabine		Anti-HIV Agents	DNA Polymerase Inhibitors	Achillion
	L-D4FC			Anti-Hepatitis B Virus Drugs	Reverse Transcriptase Inhibitors	Vion
	beta-L-Fd4C					Yale University (Originator)
Preclinical	CV-N	Cyanovirin N		Anti-HIV Agents Microbicides	Viral Entry Inhibitors	Biosyn National Cancer Institute (US) (Originator)
Launched-2005	PNU-140690 U-140690 PNU-140690E (diNa salt)	Tipranavir	Aptivus	Anti-HIV Agents	HIV Protease Inhibitors	Boehringer Ingelheim Pfizer (Originator)
Phase I/II	ADA	Azodicarbonamide		Anti-HIV Agents		National Cancer Institute (US) (Originator)
	NSC-674447					Rega Institute for Medical Research (Originator)
Launched-2001	Bis(POC)PMPA	Tenofovir disoproxil fumarate	Viread	AIDS Medicines	Reverse Transcriptase Inhibitors	Gilead (Originator)
	GS-4331-05			Anti-HIV Agents		Japan Tobacco Japan Tobacco (Orphan Drug)
Phase II	PA-457			Anti-HIV Agents	Viral Maturation Inhibitors	Biotech Research Laboratories (Originator)
	YK-FH312					Panacos

						University North Carolina, Chapel Hill (Originator)
Phase II	SP-01		Anticort	Anti-HIV Agents	HMG-CoA Reductase mRNA Expression Inhibitors	ViroLogic Altachem
	SP-01A			Oncolytic Drugs	Viral Entry Inhibitors	Georgetown University (Originator) Samaritan Pharmaceuticals
Launched-2003	BMS-232632-05 CGP-73547	Atazanavir sulfate	Reyataz	Anti-HIV Agents	HIV Protease Inhibitors	Bristol-Myers Squibb Bristol-Myers Squibb (Orphan Drug)
	BMS-232632 (free base)					Novartis (Originator)
Launched-1997	AZT/3TC	Lamivudine/Zidovudine	Combivir	Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline (Originator)
		Zidovudine/Lamivudine				
Phase III	AIDSVAX B/B			AIDS Vaccines		Genentech (Originator)
	AIDSVAX gp120 B/B					Nat. Inst. Allergy & Infectious Dis. VaxGen
Phase II	(-)-BCH-10652 (-)-dOTC			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Avexa Shire Pharmaceuticals (Originator)
	AVX-754 BCH-10618 SPD-754					
Phase II	D-D4FC		Reverset	Anti-HIV Agents	DNA Polymerase Inhibitors	Bristol-Myers Squibb (Originator)
	DPC-817				Reverse Transcriptase Inhibitors	Incyte
	RVT					Pharmasset
	beta-D-D4FC					
Phase I/II	VIR-201			AIDS Vaccines		Virax (Originator)
Preclinical	DDE-46			Anti-HIV	Antimitotic	Paradigm

	WIII-07			Agents Oncolytic Drugs Vaginal Spermicides	Drugs Apoptosis Inducers Caspase 3 Activators Caspase 8 Activators Caspase 9 Activators Microtubule inhibitors	Pharmaceuticals Parker Hughes Institute (Originator)
Preclinical	HI-113 STAMP d4T-pBPMAP	Sampidine Stampidine		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Parker Hughes Institute (Originator)
Preclinical	WHI-05			Anti-HIV Agents Vaginal Spermicides		Paradigm Pharmaceuticals Parker Hughes Institute (Originator)
Preclinical	1F7 CTB-1 MAb 1F7			Anti-HIV Agents Anti-Hepatitis C Virus Drugs	Murine Monoclonal Antibodies	ImmPheron Immune Network InNexus Sidney Kimmel Cancer Center (Originator) University of British Columbia
IND Filed	MDI-P			Anti-HIV Agents Antibacterial Drugs Asthma Therapy Cystic Fibrosis, Treatment of Septic Shock, Treatment of		Dana-Farber Cancer Institute Medical Discoveries (Originator)
Phase I	PA-14 PRO-140			Anti-HIV Agents	Anti-CD195 (CCR5) Humanized Monoclonal Antibodies Viral Entry Inhibitors	Epicyte Progenics (Originator) Protein Design Labs
Phase II	EpiBr HE-2000		Immunitin Inactivin	Anti-HIV Agents Anti-Hepatitis B Virus Drugs		Colthurst (Originator) Edenland

				Anti-Hepatitis C Virus Drugs		Hollis-Eden (Originator)
				Antimalarials		
				Cystic Fibrosis, Treatment of		
				Immunomodulators		
				Treatment of Tuberculosis		
Phase II	ALVAC vCP1452			AIDS Vaccines		ANRS
	vCP1452					Nat. Inst. Allergy & Infectious Dis.
						Sanofi Pasteur (Originator)
						Virogenetics (Originator)
Phase II	(=)-FTC		Racivir	Anti-HIV Agents		Pharmasset (Originator)
	PSI-5004			Anti-Hepatitis B Virus Drugs		
Phase III		Cellulose sulfate		Female Contraceptives	Viral Entry Inhibitors	Polydex (Originator)
		Ushercell		Microbicides		
Phase I	SF-2 rgp120			AIDS Vaccines		Chiron (Originator)
	rgp120/SF-2					Nat. Inst. Allergy & Infectious Dis.
Phase I	MIV-150			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Medivir (Originator)
				Microbicides		Population Council
Phase I/II			ytolin	Anti-HIV Agents	Anti-CD11a/CD18 (LFA-1) Murine Monoclonal Antibodies	Amerimmune (Originator)
						Cytodyn
Phase III	10D1 mAb			Anti-HIV Agents	Anti-CD152 (CTLA-4) Human Monoclonal Antibodies	Bristol-Myers Squibb
	Anti-CTLA-4 MAb			Breast Cancer Therapy		Medarex (Originator)
	MDX-010			Head and Neck Cancer Therapy		Medarex (Orphan Drug)
	MDX-CTLA4			Melanoma Therapy		National Cancer Institute
	MDX-101 (formerly)			Prostate Cancer Therapy		
				Renal Cancer Therapy		

Phase II/III	1018-ISS			AIDS Medicines	Oligonucleotides	Dynavax (Originator)
	ISS-1018			Antiallergy/Anti asthmatic Drugs		Gilead
				Drugs for Allergic Rhinitis		Sanofi Pasteur
				Immunomodulators		
				Non-Hodgkin's Lymphoma Therapy Vaccine adjuvants		
Phase I/II	HGTV43		Stealth Vector	Anti-HIV Agents Gene Delivery Systems		Enzo (Originator)
Phase II	R-147681	Dapivirine		Anti-HIV Agents	Reverse Transcriptase Inhibitors	IPM
	TMC-120			Microbicides		Janssen (Originator) Tibotec (Originator)
Phase II	DPC-083			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Bristol-Myers Squibb (Originator)
Launched-2000		Lamivudine/zidovudine/abacavir sulfate	Trizivir	Anti-HIV Agents		GlaxoSmithKline (Originator)
Launched-2003	908	Fosamprenavir calcium	Lexiva	Anti-HIV Agents	HIV Protease Inhibitors	GlaxoSmithKline (Originator)
	GW-433908G		Telzir	Chemical Delivery Systems		Vertex (Originator)
	GW-433908 (free acid) VX-175 (free acid)					
Phase I		DNA HIV vaccine		AIDS Vaccines		GlaxoSmithKline
		PowderJect HIV DNA vaccine				PowderMed (Originator)
Phase III	PC-515		Carraguard	Microbicides		Population Council (Originator)
Phase II	R-165335	Etravirine		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Janssen (Originator)
	TMC-125					Tibotec (Originator)
Preclinical	SP-1093V			Anti-HIV Agents	DNA Polymerase Inhibitors Reverse Transcriptase Inhibitors	McGill University Supratek (Originator)

Phase III	AIDSVAX B/E AIDSVAX gp120 B/E			AIDS Vaccines		Genentech (Originator) VaxGen Walter Reed Army Institute
Launched-2000	ABT-378/r ABT-378/ritonavir	Lopinavir/ritonavir	Kaletra	Anti-HIV Agents Severe Acute Respiratory Syndrome (SARS), Treatment of	HIV Protease Inhibitors	Abbott (Originator) Gilead
Phase I	BCH-13520 SPD-756			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Shire Pharmaceuticals (Originator)
Phase I/II	BAY-50-4798	Adargileukin alfa		Anti-HIV Agents Immunomodulators Oncolytic Drugs	IL-2	Bayer (Originator)
Phase I	204937			Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline
	MIV-210			Anti-Hepatitis B Virus Drugs		Medivir (Originator)
Phase III			BufferGel	Microbicides Vaginal Spermicides		Johns Hopkins University (Originator) National Institutes of Health ReProtect (Originator)
Phase I	Ad5-FLgag Ad5-gag			AIDS Vaccines DNA Vaccines		Merck & Co. (Originator)
Phase III	ALVAC *E120TMG*			AIDS Vaccines		Nat. Inst. Allergy & Infectious Dis.
	ALVAC vCP1521					Sanofi Pasteur (Originator)
	vCP1521					Virogenetics (Originator)
Phase II	MVA-BN Nef MVA-HIV-1 LAI-nef MVA-nef			AIDS Vaccines		Walter Reed Army Institute Bavarian Nordic (Originator)
Phase I	DNA/MVA SHIV-89.6	Multiprotein DNA/MVA vaccine		AIDS Vaccines		Emory University (Originator) GeoVax Nat. Inst. Allergy & Infectious Dis.

Phase II	MVA.HIVA			AIDS Vaccines		Impfstoffwerk Dessau-Tornau GmbH (Originator) International AIDS Vaccine Initiative Uganda Virus Research Institute University of Oxford
Phase I	LFn-p24	HIV-Therapore vaccine		AIDS Vaccines		Avant (Originator) Nat. Inst. Allergy & Infectious Dis. Walter Reed Army Institute
Phase III	C31G	Glyminox	Oramed	Anti-HIV Agents		Biosyn (Originator)
			SAVVY	Antibacterial Drugs Antifungal Agents Microbicides Treatment of Opportunistic Infections Vaginal Spermicides		Cellegy
Phase	BR1-7013 SPL-7013		VivaGel	Microbicides		Biomolecular Research Institute (Originator) Starpharma
Phase I/II	SDS SLS	Sodium dodecyl sulfate Sodium lauryl sulfate	Invisible Condom	Anti-HIV Agents Anti-Herpes Simplex Virus Drugs Antiviral Drugs Microbicides Vaginal Spermicides		Universite Laval (Originator)
Phase I/II	2F5			Anti-HIV Agents	Human Monoclonal Antibodies Viral Entry Inhibitors	Epicyte Polymun (Originator) Universitaet Wien (Originator)

Phase I	AK-671 SCH-351125 SCH-C Schering C	*Aplaviroc*		Anti-HIV Agents	Chemokine CCR5 Antagonists Viral Entry Inhibitors	Schering-Plough (Originator)
Phase I	DNA/PLG microparticles			AIDS Vaccines DNA Vaccines		Chiron (Originator) Nat. Inst. Allergy & Infectious Dis.
Phase I	AAV2-gag-PR-DELTA-RT tgAAC-09 tgAAC09 AAV			AIDS Vaccines DNA Vaccines		International AIDS Vaccine Initiative Targeted Genetics (Originator)
Phase I	AVX-101 AVX-101 VEE			AIDS Vaccines DNA Vaccines		AlphaVax (Originator) Nat. Inst. Allergy & Infectious Dis.
Phase I	gp160 MN/LAI-2			AIDS Vaccines		ANRS Sanofi Pasteur (Originator) Walter Reed Army Institute
Preclinical	THPB	2-OH-propyl-beta-cyclodextrin O-(2-Hydroxypropyl)-beta-cyclodextrin	Trappsol HPB	Anti-HIV Agents		Cyclodextrin Technologies Development (Originator)
Preclinical	MPI-49839			Anti-HIV Agents		Myriad Genetics (Originator)
Phase I	BMS-378806 BMS-806			Anti-HIV Agents	Viral Entry Inhibitors	Bristol-Myers Squibb (Originator)
Phase I	T-cell HIV Vaccine			AIDS Vaccines		Hadassah Medical Organization (Originator) Weizmann Institute of Science
Phase III	TMC-114 UIC-94017	Darunavir		Anti-HIV Agents	HIV Protease Inhibitors	Johnson & Johnson Tibotec (Originator) University of Illinois (Originator)
Preclinical	MV-026048			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Medivir (Originator) Roche

Preclinical	K5-N_3OS(II)			Anti-HIV Agents	Angiogenesis Inhibitors	Glycores 2000
				Microbicides	Viral Fusion Inhibitors	San Raffaele Scientific Institute
				Oncolytic Drugs		Universita degli Studi di Bari (Originator)
						Universita degli Studi di Brescia (Originator)
Phase III	UK-427857	Maraviroc		Anti-HIV Agents	Chemokine CCR5 Antagonists	Pfizer (Originator)
					Viral Entry Inhibitors	
Phase I	BILR-355			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Boehringer Ingelheim (Originator)
	BILR-355-BS					
Launched-2004		Abacavir sulfate/lamivudine	Epzicom	Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline (Originator)
			Kivexa			
Preclinical			DermaVir	AIDS Vaccines		Genetic Immunity (Originator)
				DNA Vaccines		Research Institute Genetic Human Ther.
Phase I/II	2G12			Anti-HIV Agents	Human Monoclonal Antibodies	Epicyte
					Viral Entry Inhibitors	Polymun (Originator)
						Universitaet Wien (Originator)
Phase I	L-000870810 L-870810			Anti-HIV Agents	HIV Integrase Inhibitors	Merck & Co. (Originator)
Phase I	L-870812			Anti-HIV Agents	HIV Integrase Inhibitors	Merck & Co. (Originator)
Phase I	VRX-496			Anti-HIV Agents		University of Pennsylvania
				Antisense Therapy		VIRxSYS (Originator)
Preclinical	SAMMA			Microbicides	Viral Entry Inhibitors	Mount Sinai School of Medicine (Originator)
						Rush University Medical Center (Originator)
Phase I	Ad5gag2			AIDS Vaccines		Merck & Co. (Originator)

	MRKAd5 HIV-1 gag				Nat. Inst. Allergy & Infectious Dis.
	MRKAd5gag				Sanofi Pasteur
Phase I	BG-777		Anti-Cytomegalovirus Drugs Anti-HIV Agents Anti-Influenza Virus Drugs Antibacterial Drugs Immunomodulators		Virocell (Originator)
Preclinical		Sulphonated Hesperidin	Contraceptives Microbicides		Panjab University (Originator)
Phase II	695634 GW-5634 GW-695634		Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline (Originator)
Phase II	GW-678248 GW-8248		Anti-HIV Agents	Reverse Transcriptase Inhibitors	GlaxoSmithKline (Originator)
Preclinical	R-1495		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Medivir Roche
Preclinical	SMP-717		Anti-Cytomegalovirus Drugs Anti-HIV Agents	Reverse Transcriptase Inhibitors	Advanced Life Sciences (Originator)
Phase I/II	AMD-070		Anti-HIV Agents	Chemokine CXCR4 (SDF-1) Antagonists Viral Entry Inhibitors	AnorMED (Originator) Nat. Inst. Allergy & Infectious Dis. National Institutes of Health
Preclinical	TGF-alpha		Anti-HIV Agents Antiparkinsonian Drugs		Centocor Kaleidos Pharma National Cancer Institute (US) (Originator) National Institutes of Health (Originator)
Phase II	873140		Anti-HIV Agents	Chemokine CCR5 Antagonists	GlaxoSmithKline

	AK-602				Viral Entry Inhibitors	Ono (Originator)
	GW-873140					
	ONO-4128					
Phase I	TAK-220			Anti-HIV Agents	Chemokine CCR5 Antagonists	Takeda (Originator)
					Viral Entry Inhibitors	
Launched		V-1 Immunitor		AIDS Vaccines		Immunitor (Originator)
				Treatment of AIDS-Associated Disorders		
Phase I	TAK-652			Anti-HIV Agents	Chemokine CCR5 Antagonists Viral Entry Inhibitors	Takeda (Originator)
IND Filed	R15K		BlockAide/ CR	Anti-HIV Agents	Viral Entry Inhibitors	Adventrx Pharmaceuticals
						M.D. Anderson Cancer Center (Originator)
Phase II	R-278474	Rilpivirine		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Janssen (Originator)
	TMC-278					
Preclinical	KPC-2			Anti-HIV Agents		Kucera Pharmaceutical (Originator)
Preclinical	INK-20			Anti-HIV Agents Chemical Delivery Systems		Kucera Pharmaceutical (Originator)
Phase I	CCR5 mAb			Anti-HIV Agents	Anti-CD195 (CCR5)	Human Genome Sciences (Originator)
	CCR5mAb004				Human Monoclonal Antibodies Viral Entry Inhibitors	
Preclinical	MIV-170			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Medivir (Originator)
Phase I	DP6-001	HIV DNA vaccine		AIDS Vaccines		Advanced BioScience CytRx
				DNA Vaccines		
						University of Massachusetts

						(Originator)
Phase II	AG-001859			Anti-HIV Agents	HIV Protease Inhibitors	Pfizer (Originator)
	AG-1859					
Phase I/II			GTU-MultiHIV	AIDS Vaccines		FIT Biotech (Originator)
				DNA Vaccines		International AIDS Vaccine Initiative
Preclinical			EradicAide	AIDS Vaccines		Adventrx Pharmaceuticals
						M.D. Anderson Cancer Center (Originator)
Launched-2004		Tenofovir disoproxil fumarate/emtricitabine	Truvada	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Gilead (Originator) Japan Tobacco
Preclinical			BlockAide/VP	Anti-HIV Agents	Viral Entry Inhibitors	Adventrx Pharmaceuticals (Originator)
Preclinical	TPFA		Thiovir	Anti-HIV Agents	Reverse Transcriptase Inhibitors	Adventrx Pharmaceuticals
				Cervical Cancer Therapy		National Cancer Institute
				Genital Warts, Treatment for		University of Southern California (Originator)
Phase I/II	MetX	MetaboliteX		Anti-HIV Agents		Tripep (Originator)
	alpha-HGA					
Preclinical	NV-05A			Anti-HIV Agents	Reverse Transcriptase Inhibitors	Idenix (Originator)
Phase I/II	IR-103			AIDS Vaccines		Immune Response
Preclinical	MX-100			Anti-HIV Agents	HIV Protease Inhibitors	Pharmacor (Originator)
	PL-100					Procyon Biopharma (Originator)
Phase I				Anti-HIV Agents Gene Therapy		ViroLogic Fresenius (Originator) Georg-Speyer-Haus (Originator)
Phase I	SCH-D			Anti-HIV Agents	Chemokine CCR5 Antagonists	Schering-Plough (Originator)
	Sch-417690				Viral Entry Inhibitors	
Preclinical		ImmuneVex-HIV		AIDS Vaccines		BioVex (Originator)
Phase I	CYT-99-007			Anti-HIV Agents		Cytheris (Originator)

	rhIL-7			Immunomodulators		Nat. Inst. Allergy & Infectious Dis. National Cancer Institute
Phase I		recombinant o-gp140/MF59 adjuvant		AIDS Vaccines		Chiron (Originator)
Phase II	BMS-488043			Anti-HIV Agents	Viral Entry Inhibitors	Nat. Inst. Allergy & Infectious Dis. Bristol-Myers Squibb (Originator)
Preclinical	KP-1212 SN-1212			Anti-HIV Agents		Koronis (Originator)
Preclinical	AMD-887			Anti-HIV Agents	Chemokine CCR5 Antagonists Viral Entry Inhibitors	AnorMED (Originator)
Phase I	KP-1461			Anti-HIV Agents		Koronis (Originator)
	SN-1461			Chemical Delivery Systems		
Preclinical			DES-10	Anti-HIV Agents		AusAm Biotechnologies (Originator)
				Anti-Herpes Virus Drugs		National Institutes of Health
Preclinical	APP-069			Anti-HIV Agents		Aphios (Originator)
Preclinical	PC-815	MIV-150/Carraguard MIV-150/PC-515		Anti-HIV Agents Microbicides		Medivir (Originator) Population Council (Originator)
Preclinical	FGI-345			Anti-HIV Agents		Functional Genetics (Originator)
Preclinical	RPI-MN			Anti-HIV Agents		Nutra Pharma (Originator)
						ReceptoPharm (Originator)
Preclinical		Tenofovir disoproxil fumarate/emtricitabine/efavirenz		Anti-HIV Agents	Reverse Transcriptase Inhibitors	Bristol-Myers Squibb (Originator) Gilead (Originator) Merck & Co. (Originator)
Preclinical	MVA-BN HIV Polytope			AIDS Vaccines		Bavarian Nordic (Originator)
Preclinical	MVA-BN HIV Multiantigen			AIDS Vaccines		Bavarian Nordic (Originator)

Preclinical	PBS-119			Immunostimulants		Phoenix Biosciences (Originator)
Phase II		HIV-1 Tat Toxoid vaccine		AIDS Vaccines		Neovacs
		Tat Toxoid vaccine				Sanofi Pasteur
						Univ. Maryland Biotechnology Institute
Phase III	TNP	Thymus nuclear protein		Anti-HIV Agents		Viral Genetics
	VGV-1					
Phase I	VCR-ADV-014			AIDS Vaccines		GenVec (Originator)
	VRC-HIVADV014-00-VP					Nat. Inst. Allergy & Infectious Dis.
Preclinical	SP-010			Anti-HIV Agents		Georgetown University (Originator)
	SP-10			Cognition Disorders, Treatment of		Samaritan Pharmaceuticals
Phase I/II	GS-9137			Anti-HIV Agents	HIV Integrase Inhibitors	Gilead
	JTK-303					Japan Tobacco (Originator)
Phase I/II		RNA-loaded dendritic cell vaccine		AIDS Vaccines Cancer Vaccines		Argos Therapeutics (Originator)
				Melanoma Therapy		
				Renal Cancer Therapy		
Phase I		IFN-alpha kinoid	Antiferon	AIDS Vaccines		Neovacs (Originator)
				Systemic Lupus Erythematosus, Agents for Vaccines		Sanofi Pasteur
Phase II	DNA.HIVA			AIDS Vaccines		International AIDS Vaccine Initiative
	HIVA			DNA Vaccines		ML Laboratories (Originator)
						Uganda Virus Research Institute
						University of Oxford
Phase I	DEBIO-025			Anti-HIV Agents		Debiopharm (Originator)
	UNIL-025			Anti-Hepatitis C Virus Drugs Ischemic Stroke, Treatment of		
Preclinical		HIV vaccine		AIDS Vaccines		Berna Biotech (Originator)

		MV-HIV vaccine				
Phase I	825780			DNA Vaccines Viral Vaccines		GlaxoSmithKline (Originator)
Phase I	C-1605			AIDS Medicines		Merck & Co. (Originator)
Phase I	ADMVA			AIDS Vaccines		Aaron Diamond AIDS Research Center Impfstoffwerk Dessau-Tornau GmbH (Originator) International AIDS Vaccine Initiative
Preclinical	BL-1050			AIDS Medicines		BioLineRx Hebrew University (Originator) Yissum
Phase I	CAP	Cellulose acetate phthalate		Microbicides Vaginal Spermicides	Viral Entry Inhibitors	New York Blood Center
Preclinical	QR-437			Anti-HIV Agents		Quigley Pharma (Originator)
Phase II	MRKAd5 HIV-1 gag/pol/nef MRKAd5 HIV-1 trivalent MRKAd5gag/pol/nef			AIDS Vaccines		Merck & Co. (Originator) Nat. Inst. Allergy & Infectious Dis.
Preclinical			CarryVac-HIV	AIDS Vaccines		Tripep (Originator) Vaccine Research Institute of San Diego
Preclinical			HIV-RAS	AIDS Medicines		Tripep (Originator)
Preclinical	PL-337			Anti-HIV Agents	HIV Protease Inhibitors	Procyon Biopharma (Originator)
Phase I	DNA-C DNA-HIV-C			AIDS Vaccines		EuroVacc Foundation Universitaet Regensburg (Originator)
Phase II		Lipo-5		AIDS Vaccines		ANRS INSERM

				INSERM (Originator)
				Nat. Inst. Allergy & Infectious Dis.
				Sanofi Pasteur (Originator)
Phase I		Lipo-6T	AIDS Vaccines	ANRS
				INSERM (Originator)
				Sanofi Pasteur (Originator)
Phase I	EnvPro		AIDS Vaccines	St. Jude Children's Res. Hosp. (Originator)
Phase I	TCB-M358		AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Therion (Originator)
Phase I	TBC-M335		AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Therion (Originator)
Phase I	TBC-F357		AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Therion (Originator)
Phase I	TBC-F349		AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Therion (Originator)
Phase I	TBC-M358/TBC-M355		AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Therion (Originator)
Phase I	TBC-F357/TBC-F349		AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Therion (Originator)
Phase I	HIV CTL MEP	Multiepitope CTL peptide vaccine	AIDS Vaccines	Nat. Inst. Allergy & Infectious Dis.
				Wyeth Pharmaceuticals (Originator)
Phase I	VRC-DNA-009		AIDS Vaccines	National Institutes of Health (Originator)
	VRC-HIVDNA009-00-VP		DNA Vaccines	

Preclinical	REP-9	Anti-HIV Agents	Oligonucleotides	REPLICor (Originator)
		Antiviral Drugs		
Preclinical	PPL-100	Anti-HIV Agents	HIV Protease Inhibitors	Procyon Biopharma (Originator)
		Chemical Delivery Systems		
Phase I/II	BI-201	Anti-HIV Agents	Human Monoclonal Antibodies	BioInvent (Originator)

Table 99 - Exemplary HIV Antivirals and Patent Numbers

Ziagen (Abacavir sulfate, US 5,034,394)
Epzicom (Abacavir sulfate/lamivudine, US 5,034,394)
Hepsera (Adefovir dipivoxil, US 4,724,233)
Agenerase (Amprenavir, US 5,646,180)
Reyataz (Atazanavir sulfate, US 5,849,911)
Rescriptor (Delavirdine mesilate, US 5,563,142)
Hivid (Dideoxycytidine; Zalcitabine, US 5,028,595)
Videx (Dideoxyinosine; Didanosine, US 4,861,759)
Sustiva (Efavirenz, US 5,519,021)
Emtriva (Emtricitabine, US 6,642,245)
Lexiva (Fosamprenavir calcium, US 6,436,989)
Virudin; Triapten; Foscavir (Foscarnet sodium, US 6,476,009)
Crixivan (Indinavir sulfate, US 5,413,999)
Epivir (Lamivudine, US 5 047,407)
Combivir (Lamivudine/Zidovudine, US 4,724,232)
Aluviran (Lopinavir)
Kaletra (Lopinavir/ritonavir, US 5,541,206)
Viracept (Nelfinavir mesilate, US 5,484,926)
Viramune (Nevirapine, US 5,366,972)
Norvir (Ritonavir, US 5,541,206)
Invirase; Fortovase (Saquinavir mesilate, US 5,196,438)
Zerit (Stavudine, US 4,978,655)
Truvada (Tenofovir disoproxil fumarate/emtricitabine, US 5,210,085)
Aptivus (Tipranavir)
Retrovir (Zidovudine; Azidothymidine, US 4,724,232)

Metabolites of the Compounds of the Invention

[0141] Also disclosed are the *in vivo* metabolic products of the compounds described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation and esterification of the administered compound, primarily due to enzymatic processes. Accordingly, the disclosure includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products typically are identified by preparing a radiolabelled (*e.g.,* C^{14} or H^{3}) compound of the invention, administering it parenterally in a detectable dose (*e.g.,* greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, *e.g.,* by MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found *in vivo,* are useful in diagnostic assays for therapeutic dosing of the compounds of the invention even if they possess no HIV -inhibitory activity of their own.

[0142] Recipes and methods for determining stability of compounds in surrogate gastrointestinal secretions are known. Compounds are defined herein as stable in the gastrointestinal tract where less than about 50 mole percent of the protected groups are deprotected in surrogate intestinal or gastric juice upon incubation for 1 hour at 37 °C. Simply because the compounds are stable to the gastrointestinal tract does not mean that they cannot be hydrolyzed *in vivo*. The phosphonate prodrugs of the invention typically will be stable in the digestive system but are substantially hydrolyzed to the parental drug in the digestive lumen, liver or other metabolic organ, or within cells in general.

Exemplary Methods of Making the Compounds of the Invention.

[0143] The invention also relates to methods of making the compositions of the invention. The compositions are prepared by any of the applicable techniques of organic synthesis. Many such techniques are well known in the art. However, many of the known techniques are elaborated in Compendium of Organic Synthetic Methods (John Wiley & Sons, New York), Vol. 1, Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and Vol. 6, Michael B. Smith; as well as March, J., Advanced Organic Chemistry, Third Edition, (John Wiley & Sons, New York, 1985), Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry. In 9

Volumes, Barry M. Trost, Editor-in-Chief (Pergamon Press, New York, 1993 printing).

[0144] A number of exemplary methods for the preparation of the compositions of the invention are provided below.

[0145] Generally, the reaction conditions such as temperature, reaction time, solvents and work-up procedures, will be those common in the art for the particular reaction to be performed. The cited reference material, together with material cited therein, contains detailed descriptions of such conditions. Typically the temperatures will be -100°C to 200°C, solvents will be aprotic or protic, and reaction times will be 10 seconds to 10 days. Work-up typically consists of quenching any unreacted reagents followed by partition between a water/organic layer system (extraction) and separating the layer containing the product.

[0146] Oxidation and reduction reactions are typically carried out at temperatures near room temperature (about 20 °C), although for metal hydride reductions frequently the temperature is reduced to 0 °C to -100 °C, solvents are typically aprotic for reductions and may be either protic or aprotic for oxidations. Reaction times are adjusted to achieve desired conversions.

[0147] Condensation reactions are typically carried out at temperatures near room temperature, although for non-equilibrating, kinetically controlled condensations reduced temperatures (0 °C to-100 °C) are also common. Solvents can be either protic (common in equilibrating reactions) or aprotic (common in kinetically controlled reactions).

[0148] Standard synthetic techniques such as azeotropic removal of reaction by-products and use of anhydrous reaction conditions (*e.g.,* inert gas environments) are common in the art and will be applied when applicable.

Schemes and Examples

[0149] General aspects of these exemplary methods are described below and in the Examples. Each of the products of the following processes is optionally separated, isolated, and/or purified prior to its use in subsequent processes.

[0150] Generally, the reaction conditions such as temperature, reaction time, solvents and work-up procedures will be those common in the art for the particular reaction to be performed. The cited reference material, together with material cited therein, contains detailed descriptions of such conditions. Typically the temperatures will be -100°C to 200°C, solvents will be aprotic or protic, and reaction times will be 10 seconds to 10 days. Work-up typically consists of quenching any unreacted reagents followed by partition between a water/organic layer system (extraction) and separating the layer containing the product.

[0151] Oxidation and reduction reactions are typically carried out at temperatures near room temperature (about 20°C), although for metal hydride reductions frequently the temperature is

reduced to 0°C to -100°C, solvents are typically aprotic for reductions and may be either protic or aprotic for oxidations. Reaction times are adjusted to achieve desired conversions.

[0152] Condensation reactions are typically carried out at temperatures near room temperature, although for non-equilibrating, kinetically controlled condensations reduced temperatures (0°C to-100°C) are also common. Solvents can be either protic (common in equilibrating reactions) or aprotic (common in kinetically controlled reactions).

[0153] Standard synthetic techniques such as azeotropic removal of reaction by-products and use of anhydrous reaction conditions (*e.g.,* inert gas environments) are common in the art and will be applied when applicable.

[0154] The terms "treated", "treating" and "treatment", when used in connection with a chemical synthetic operation, mean contacting, mixing, reacting, allowing to react, bringing into contact, and other terms common in the art for indicating that one or more chemical entities is treated in such a manner as to convert it to one or more other chemical entities. This means that "treating compound one with compound two" is synonymous with "allowing compound one to react with compound two", "contacting compound one with compound two", "reacting compound one with compound two", and other expressions common in the art of organic synthesis for reasonably indicating that compound one was "treated", "reacted", "allowed to react", etc., with compound two. For example, treating indicates the reasonable and usual manner in which organic chemicals are allowed to react. Normal concentrations (0.01M to 10M, typically 0.1M to 1M), temperatures (-100 °C to 250 °C, typically -78 °C to 150 °C, more typically -78 °C to 100 °C, still more typically 0 °C to 100 °C), reaction vessels (typically glass, plastic, metal), solvents, pressures, atmospheres (typically air for oxygen and water insensitive reactions or nitrogen or argon for oxygen or water sensitive), etc., are intended unless otherwise indicated. The knowledge of similar reactions known in the art of organic synthesis are used in selecting the conditions and apparatus for "treating" in a given process. In particular, one of ordinary skill in the art of organic synthesis selects conditions and apparatus reasonably expected to successfully carry out the chemical reactions of the described processes based on the knowledge in the art.

[0155] Modifications of each of the exemplary schemes and in the examples (hereafter "exemplary schemes") leads to various analogs of the specific exemplary materials produce. The above-cited citations describing suitable methods of organic synthesis are applicable to such modifications.

[0156] In each of the exemplary schemes it may be advantageous to separate reaction products from one another and/or from starting materials. The desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium, and

low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.

[0157] Another class of separation methods involves treatment of a mixture with a reagent selected to bind to or render otherwise separable a desired product, unreacted starting material, reaction by product, or the like. Such reagents include adsorbents or absorbents such as activated carbon, molecular sieves, and ion exchange media. Alternatively, the reagents can be acids in the case of a basic material, bases in the case of an acidic material, binding reagents such as antibodies, binding proteins, selective chelators such as crown ethers, or liquid/liquid ion extraction reagents (LIX).

[0158] Selection of appropriate methods of separation depends on the nature of the materials involved. For example, boiling point, and molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography and stability of materials in acidic and basic media in multiphase extraction. One skilled in the art will apply techniques most likely to achieve the desired separation.

[0159] A single stereoisomer, *e.g.,* an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Stereochemistry of Carbon Compounds, (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113:(3) 283-302). Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.

[0160] Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine and α-methyl-β-phenylethylamine (amphetamine), with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.

[0161] Alternatively, by method (2), the substrate to be resolved is reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched xanthene. A method of determining optical purity involves making chiral esters, such as a menthyl ester, *e.g.,* (-)

menthyl chloroformate in the presence of base, or Mosher ester, α-methoxy-α-(trifluoromethyl)phenyl acetate (Jacob III. (1982) J. Org. Chem. 47:4165), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers of atropisomeric compounds can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111). By method (3), a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (Chiral Liquid Chromatography (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) J. of Chromatogr. 513:375-378). Enriched or purified enantiomers can be distinguished by methods used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism.

Examples General Section

[0162] A number of exemplary methods for the preparation of compounds of the invention are provided herein, for example, in the Examples hereinbelow. Certain compounds of the invention can be used as intermediates for the preparation of other compounds of the invention. For example, the interconversion of various phosphonate compounds of the invention is illustrated below. Examples that do not relate to the claims are provided for reference.

INTERCONVERSIONS OF THE PHOSPHONATES R-LINK-P(O)(OR^1)$_2$, R-LINK-P(O)(OR^1)(OH) AND R-LINK-P(O)(OH)$_2$.

[0163] The following schemes **32-38** describe the preparation of phosphonate esters of the general structure R-link-P(O)(OR^1)$_2$, in which the groups R^1 may be the same or different. The R^1 groups attached to a phosphonate ester, or to precursors thereto, may be changed using established chemical transformations. The interconversion reactions of phosphonates are illustrated in Scheme **S32.** The group R in Scheme **32** represents the substructure, *i.e.* the drug "scaffold, to which the substituent link-P(O)(OR^1)$_2$ is attached, either in the compounds of the invention, or in precursors thereto. At the point in the synthetic route of conducting a phosphonate interconversion, certain functional groups in R may be protected. The methods employed for a given phosphonate transformation depend on the nature of the substituent R^1, and of the substrate to which the phosphonate group is attached. The preparation and hydrolysis of phosphonate esters is described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 9ff.

[0164] In general, synthesis of phosphonate esters is achieved by coupling a nucleophile amine or alcohol with the corresponding activated phosphonate electrophilic precursor. For example, chlorophosphonate addition on to 5'-hydroxy of nucleoside is a well known method

for preparation of nucleoside phosphate monoesters. The activated precursor can be prepared by several well known methods. Chlorophosphonates useful for synthesis of the prodrugs are prepared from the substituted-1,3-propanediol (Wissner, et al, (1992) J. Med Chem. 35:1650). Chlorophosphonates are made by oxidation of the corresponding chlorophospholanes (Anderson, et al, (1984) J. Org. Chem. 49:1304) which are obtained by reaction of the substituted diol with phosphorus trichloride. Alternatively, the chlorophosphonate agent is made by treating substituted-1,3-diols with phosphorusoxychloride (Patois, et al, (1990) J. Chem. Soc. Perkin Trans. I, 1577). Chlorophosphonate species may also be generated in situ from corresponding cyclic phosphites (Silverburg, et al., (1996) Tetrahedron lett., 37:771-774), which in turn can be either made from chlorophospholane or phosphoramidate intermediate. Phosphoroflouridate intermediate prepared either from pyrophosphate or phosphoric acid may also act as precursor in preparation of cyclic prodrugs (Watanabe et al., (1988) Tetrahedron lett., 29:5763-66).

[0165] Phosphonate prodrugs of the present invention may also be prepared from the free acid by Mitsunobu reactions (Mitsunobu, (1981) Synthesis, 1; Campbell, (1992) J. Org. Chem. 57:6331), and other acid coupling reagents including, but not limited to, carbodiimides (Alexander, et al, (1994) Collect. Czech. Chem. Commun. 59:1853; Casara et al, (1992) Bioorg. Med. Chem. Lett 2:145; Ohashi et al, (1988) Tetrahedron Lett., 29:1189), and benzotriazolyloxytris-(dimethylamino)phosphonium salts (Campagne et al (1993) Tetrahedron Lett. 34:6743).

[0166] Aryl halides undergo Ni^{+2} catalyzed reaction with phosphite derivatives to give aryl phosphonate containing compounds (Balthazar, et al (1980) J. Org. Chem. 45:5425). Phosphonates may also be prepared from the chlorophosphonate in the presence of a palladium catalyst using aromatic triflates (Petrakis et al (1987) J. Am. Chem. Soc. 109:2831; Lu et al (1987) Synthesis 726). In another method, aryl phosphonate esters are prepared from aryl phosphates under anionic rearrangement conditions (Melvin (1981) Tetrahedron Lett. 22:3375; Casteel et al (1991) Synthesis, 691). N-Alkoxy aryl salts with alkali met al derivatives of cyclic alkyl phosphonate provide general synthesis for heteroaryl-2-phosphonate linkers (Redmore (1970) J. Org. Chem. 35:4114). These above mentioned methods can also be extended to compounds where the W^5 group is a heterocycle. Cyclic-1,3-propanyl prodrugs of phosphonates are also synthesized from phosphonic diacids and substituted propane-1,3-diols using a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC) in presence of a base (*e.g.,* pyridine). Other carbodiimide based coupling agents like 1,3-disopropylcarbodiimide or water soluble reagent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) can also be utilized for the synthesis of cyclic phosphonate prodrugs.

[0167] The conversion of a phosphonate diester **S32.1** into the corresponding phosphonate monoester **S32.2** (Scheme **32,** Reaction **1)** is accomplished by a number of methods. For example, the ester **S32.1** in which R^1 is an aralkyl group such as benzyl, is converted into the monoester compound **S32.2** by reaction with a tertiary organic base such as diazabicyclooctane (DABCO) or quinuclidine, as described in J. Org. Chem. (1995) 60:2946.

The reaction is performed in an inert hydrocarbon solvent such as toluene or xylene, at about 110 °C. The conversion of the diester **S32.1** in which R^1 is an aryl group such as phenyl, or an alkenyl group such as allyl, into the monoester **S32.2** is effected by treatment of the ester **S32.1** with a base such as aqueous sodium hydroxide in acetonitrile or lithium hydroxide in aqueous tetrahydrofuran. Phosphonate diesters **S32.1** in which one of the groups R^1 is aralkyl, such as benzyl, and the other is alkyl, is converted into the monoesters **S32.2** in which R^1 is alkyl by hydrogenation, for example using a palladium on carbon catalyst. Phosphonate diesters in which both of the groups R^1 are alkenyl, such as allyl, is converted into the monoester **S32.2** in which R^1 is alkenyl, by treatment with chlorotris(triphenylphosphine)rhodium (Wilkinson's catalyst) in aqueous ethanol at reflux, optionally in the presence of diazabicyclooctane, for example by using the procedure described in J. Org. Chem. (1973) 38:3224, for the cleavage of allyl carboxylates.

[0168] The conversion of a phosphonate diester **S32.1** or a phosphonate monoester **S32.2** into the corresponding phosphonic acid **S32.3** (Scheme **32,** Reactions **2** and **3)** can be effected by reaction of the diester or the monoester with trimethylsilyl bromide, as described in J. Chem. Soc., Chem. Comm., (1979) 739. The reaction is conducted in an inert solvent such as, for example, dichloromethane, optionally in the presence of a silylating agent such as bis(trimethylsilyl)trifluoroacetamide, at ambient temperature. A phosphonate monoester **S32.2** in which R^1 is aralkyl such as benzyl, is converted into the corresponding phosphonic acid **S32.3** by hydrogenation over a palladium catalyst, or by treatment with hydrogen chloride in an ethereal solvent such as dioxane. A phosphonate monoester **S32.2** in which R^1 is alkenyl such as, for example, allyl, is converted into the phosphonic acid **S32.3** by reaction with Wilkinson's catalyst in an aqueous organic solvent, for example in 15% aqueous acetonitrile, or in aqueous ethanol, for example using the procedure described in Helv. Chim. Acta. (1985) 68:618. Palladium catalyzed hydrogenolysis of phosphonate esters **S32.1** in which R^1 is benzyl is described in J. Org. Chem. (1959) 24:434. Platinum-catalyzed hydrogenolysis of phosphonate esters **S32.1** in which R^1 is phenyl is described in J. Am. Chem. Soc. (1956) 78:2336.

[0169] The conversion of a phosphonate monoester **S32.2** into a phosphonate diester **S32.1** (Scheme **32,** Reaction **4)** in which the newly introduced R^1 group is alkyl, aralkyl, haloalkyl such as chloroethyl, or aralkyl is effected by a number of reactions in which the substrate **S32.2** is reacted with a hydroxy compound R^1OH, in the presence of a coupling agent. Typically, the second phosphonate ester group is different than the first introduced phosphonate ester group, *i.e.* R^1 is followed by the introduction of R^2 where each of R^1 and R^2 is alkyl, aralkyl, haloalkyl such as chloroethyl, or aralkyl (Scheme **32,** Reaction **4a)** whereby **S32.2** is converted to **S32.1a.** Suitable coupling agents are those employed for the preparation of carboxylate esters, and include a carbodiimide such as dicyclohexylcarbodiimide, in which case the reaction is preferably conducted in a basic organic solvent such as pyridine, or (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PYBOP, Sigma), in which case the reaction is performed in a polar solvent such as dimethylformamide, in the presence of a

tertiary organic base such as diisopropylethylamine, or Aldrithiol-2 (Aldrich) in which case the reaction is conducted in a basic solvent such as pyridine, in the presence of a triaryl phosphine such as triphenylphosphine. Alternatively, the conversion of the phosphonate monoester **S32.2** to the diester **S32.1** is effected by the use of the Mitsunobu reaction, as described above. The substrate is reacted with the hydroxy compound R^1OH, in the presence of diethyl azodicarboxylate and a triarylphosphine such as triphenyl phosphine. Alternatively, the phosphonate monoester **S32.2** is transformed into the phosphonate diester **S32.1,** in which the introduced R^1 group is alkenyl or aralkyl, by reaction of the monoester with the halide R^1Br, in which R^1 is as alkenyl or aralkyl. The alkylation reaction is conducted in a polar organic solvent such as dimethylformamide or acetonitrile, in the presence of a base such as cesium carbonate. Alternatively, the phosphonate monoester is transformed into the phosphonate diester in a two step procedure. In the first step, the phosphonate monoester **S32.2** is transformed into the chloro analog $RP(O)(OR^1)Cl$ by reaction with thionyl chloride or oxalyl chloride and the like, as described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 17, and the thus-obtained product $RP(O)(OR^1)Cl$ is then reacted with the hydroxy compound R^1OH, in the presence of a base such as triethylamine, to afford the phosphonate diester **S32.1.**

[0170] A phosphonic acid R-link-$P(O)(OH)_2$ is transformed into a phosphonate monoester $RP(O)(OR^1)(OH)$ (Scheme **32,** Reaction **5)** by means of the methods described above of for the preparation of the phosphonate diester R-link-$P(O)(OR^1)_2$ **S32.1,** except that only one molar proportion of the component R^1OH or R^1Br is employed. Dialkyl phosphonates may be prepared according to the methods of: Quast et al (1974) Synthesis 490; Stowell et al (1990) Tetrahedron Lett. 3261; US 5663159.

[0171] A phosphonic acid R-link-$P(O)(OH)_2$ **S32.3** is transformed into a phosphonate diester R-link-$P(O)(OR^1)_2$ **S32.1** (Scheme **32,** Reaction **6)** by a coupling reaction with the hydroxy compound R^1OH, in the presence of a coupling agent such as Aldrithiol-2 (Aldrich) and triphenylphosphine. The reaction is conducted in a basic solvent such as pyridine. Alternatively, phosphonic acids **S32.3** are transformed into phosphonic esters **S32.1** in which R^1 is aryl, by means of a coupling reaction employing, for example, dicyclohexylcarbodiimide in pyridine at ca 70 °C. Alternatively, phosphonic acids **S32.3** are transformed into phosphonic esters **S32.1** in which R^1 is alkenyl, by means of an alkylation reaction. The phosphonic acid is reacted with the alkenyl bromide R^1Br in a polar organic solvent such as acetonitrile solution at reflux temperature, the presence of a base such as cesium carbonate, to afford the phosphonic ester **S32.1.**

Scheme 32





Preparation of phosphonate carbamates.

[0172] Phosphonate esters may contain a carbamate linkage. The preparation of carbamates is described in Comprehensive Organic Functional Group Transformations, A. R. Katritzky, ed., Pergamon, 1995, Vol. 6, p. 416ff, and in Organic Functional Group Preparations, by S. R. Sandler and W. Karo, Academic Press, 1986, p. 260ff. The carbamoyl group may be formed by reaction of a hydroxy group according to the methods known in the art, including the teachings of Ellis, US 2002/0103378 A1 and Hajima, US 6018049.

[0173] Scheme **33** illustrates various methods by which the carbamate linkage is synthesized. As shown in Scheme **33,** in the general reaction generating carbamates, an alcohol **S33.1,** is converted into the activated derivative **S33.2** in which Lv is a leaving group such as halo, imidazolyl, benztriazolyl and the like, as described herein. The activated derivative **S33.2** is then reacted with an amine **S33.3,** to afford the carbamate product **S33.4.** Examples **1 - 7** in Scheme **33** depict methods by which the general reaction is effected. Examples **8 - 10** illustrate alternative methods for the preparation of carbamates.

[0174] Scheme **33,** Example **1** illustrates the preparation of carbamates employing a chloroformyl derivative of the alcohol **S33.5.** In this procedure, the alcohol **S33.5** is reacted with phosgene, in an inert solvent such as toluene, at about 0 °C, as described in Org. Syn. Coll. Vol. 3, 167, 1965, or with an equivalent reagent such as trichloromethoxy chloroformate, as described in Org. Syn. Coll. Vol. 6, 715, 1988, to afford the chloroformate **S33.6.** The latter compound is then reacted with the amine component **S33.3,** in the presence of an organic or

inorganic base, to afford the carbamate **S33.7.** For example, the chloroformyl compound **S33.6** is reacted with the amine **S33.3** in a water-miscible solvent such as tetrahydrofuran, in the presence of aqueous sodium hydroxide, as described in Org. Syn. Coll. Vol. 3, 167, 1965, to yield the carbamate **S33.7.** Alternatively, the reaction is performed in dichloromethane in the presence of an organic base such as diisopropylethylamine or dimethylaminopyridine.

[0175] Scheme **33,** Example **2** depicts the reaction of the chloroformate compound **S33.6** with imidazole to produce the imidazolide **S33.8.** The imidazolide product is then reacted with the amine **S33.3** to yield the carbamate **S33.7.** The preparation of the imidazolide is performed in an aprotic solvent such as dichloromethane at 0°, and the preparation of the carbamate is conducted in a similar solvent at ambient temperature, optionally in the presence of a base such as dimethylaminopyridine, as described in J. Med. Chem., 1989, 32, 357.

[0176] Scheme **33** Example **3,** depicts the reaction of the chloroformate **S33.6** with an activated hydroxyl compound R"OH, to yield the mixed carbonate ester **S33.10.** The reaction is conducted in an inert organic solvent such as ether or dichloromethane, in the presence of a base such as dicyclohexylamine or triethylamine. The hydroxyl component R"OH is selected from the group of compounds **S33.19 - S33.24** shown in Scheme **33,** and similar compounds. For example, if the component R"OH is hydroxybenztriazole **S33.19,** N-hydroxysuccinimide **S33.20,** or pentachlorophenol, **S33.21,** the mixed carbonate **S33.10** is obtained by the reaction of the chloroformate with the hydroxyl compound in an ethereal solvent in the presence of dicyclohexylamine, as described in Can. J. Chem., 1982, 60, 976. A similar reaction in which the component R"OH is pentafluorophenol **S33.22** or 2-hydroxypyridine **S33.23** is performed in an ethereal solvent in the presence of triethylamine, as described in Syn., 1986, 303, and Chem. Ber. 118, 468, 1985.

[0177] Scheme **33** Example **4** illustrates the preparation of carbamates in which an alkyloxycarbonylimidazole **S33.8** is employed. In this procedure, an alcohol **S33.5** is reacted with an equimolar amount of carbonyl diimidazole **S33.11** to prepare the intermediate **S33.8.** The reaction is conducted in an aprotic organic solvent such as dichloromethane or tetrahydrofuran. The acyloxyimidazole **S33.8** is then reacted with an equimolar amount of the amine $R'NH_2$ to afford the carbamate **S33.7.** The reaction is performed in an aprotic organic solvent such as dichloromethane, as described in Tet. Lett., 42, 2001, 5227, to afford the carbamate **S33.7.**

[0178] Scheme **33,** Example **5** illustrates the preparation of carbamates by means of an intermediate alkoxycarbonylbenztriazole **S33.13.** In this procedure, an alcohol ROH is reacted at ambient temperature with an equimolar amount of benztriazole carbonyl chloride **S33.12,** to afford the alkoxycarbonyl product **S33.13.** The reaction is performed in an organic solvent such as benzene or toluene, in the presence of a tertiary organic amine such as triethylamine, as described in Synthesis., 1977, 704. The product is then reacted with the amine $R'NH_2$ to afford the carbamate **S33.7.** The reaction is conducted in toluene or ethanol, at from ambient temperature to about 80 °C as described in Synthesis., 1977, 704.

[0179] Scheme **33,** Example **6** illustrates the preparation of carbamates in which a carbonate $(R''O)_2CO$, **S33.14,** is reacted with an alcohol **S33.5** to afford the intermediate alkyloxycarbonyl intermediate **S33.15.** The latter reagent is then reacted with the amine $R'NH_2$ to afford the carbamate **S33.7.** The procedure in which the reagent **S33.15** is derived from hydroxybenztriazole **S33.19** is described in Synthesis, 1993, 908; the procedure in which the reagent **S33.15** is derived from N-hydroxysuccinimide **S33.20** is described in Tet. Lett., 1992, 2781; the procedure in which the reagent **S33.15** is derived from 2-hydroxypyridine **S33.23** is described in Tet. Lett., 1991, 4251; the procedure in which the reagent **S33.15** is derived from 4-nitrophenol **S33.24** is described in Synthesis. 1993, 103. The reaction between equimolar amounts of the alcohol ROH and the carbonate **S33.14** is conducted in an inert organic solvent at ambient temperature.

[0180] Scheme **33,** Example **7** illustrates the preparation of carbamates from alkoxycarbonyl azides **S33.16.** In this procedure, an alkyl chloroformate **S33.6** is reacted with an azide, for example sodium azide, to afford the alkoxycarbonyl azide **S33.16.** The latter compound is then reacted with an equimolar amount of the amine $R'NH_2$ to afford the carbamate **S33.7.** The reaction is conducted at ambient temperature in a polar aprotic solvent such as dimethylsulfoxide, for example as described in Synthesis., 1982, 404.

[0181] Scheme **33,** Example **8** illustrates the preparation of carbamates by means of the reaction between an alcohol ROH and the chloroformyl derivative of an amine **S33.17.** In this procedure, which is described in Synthetic Organic Chemistry, R. B. Wagner, H. D. Zook, Wiley, 1953, p. 647, the reactants are combined at ambient temperature in an aprotic solvent such as acetonitrile, in the presence of a base such as triethylamine, to afford the carbamate **S33.7.**

[0182] Scheme **33,** Example **9** illustrates the preparation of carbamates by means of the reaction between an alcohol ROH and an isocyanate **S33.18.** In this procedure, which is described in Synthetic Organic Chemistry, R. B. Wagner, H. D. Zook, Wiley, 1953, p. 645, the reactants are combined at ambient temperature in an aprotic solvent such as ether or dichloromethane and the like, to afford the carbamate **S33.7.**

[0183] Scheme **33,** Example **10** illustrates the preparation of carbamates by means of the reaction between an alcohol ROH and an amine $R'NH_2$. In this procedure, which is described in Chem. Lett. 1972, 373, the reactants are combined at ambient temperature in an aprotic organic solvent such as tetrahydrofuran, in the presence of a tertiary base such as triethylamine, and selenium. Carbon monoxide is passed through the solution and the reaction proceeds to afford the carbamate **S33.7.**

Scheme 33. Preparation of carbamates.

General reaction



Examples

... $R'NH_2$ **S33.3** ...

(1) ROH **S33.5** → ROCOCl **S33.6** → ROCONHR' **S33.7**

(2) ROH **S33.5** → ROCOCl **S33.6** →  **S33.8**

$R'NH_2$ **S33.3** → ROCONHR' **S33.7**

(3) ROH **S33.5** → ROCOCl **S33.6** → (R"OH **S33.9**) → ROCOOR" **S33.10** → ($R'NH_2$ **S33.3**) → ROCONHR' **S33.7**

(4) ROH **S33.5** →  **S33.11** →  **S33.8** → ($R'NH_2$ **S33 .3**) → ROCONHR' **S33.7**

(5) ROH **S33.5** →  **S33.12** →  **S33.13** → ($R'NH_2$ **S33.3**) → ROCONHR' **S33.7**

(6) ROH **S33.5** → ($(R''O_2)C=O$ **S33.14**) → ROCOR" **S33.15** → ($R'NH_2$ **S33.3**) → ROCONHR' **S33.7**

(7) ROH **S33.5** → ROCOCl **S33.6** → $ROCON_3$ **S33.16**

$R'NH_2$ **33.3** → ROCONHR' **33.7**

(8) ROH **S33.5** → (R'NHCOCl **S33.17**) → ROCONHR' **S33.7**

(9) ROH **S33.5** → (R'NCO **S33.18**) → ROCONHR' **S33.7**

(10) ROH **S33.5** → ($R'NH_2$ **S33.3**) → ROCONHR' **S33.7**

R"OH =



S33.19



S33.20



S33.21



S33.22



S33.23



S33.24

PREPARATION OF CARBOALKOXY-SUBSTITUTED PHOSPHONATE BISAMIDATES, MONOAMIDATES, DIESTERS AND MONOESTERS.

[0184] A number of methods are available for the conversion of phosphonic acids into amidates and esters. In one group of methods, the phosphonic acid is either converted into an isolated activated intermediate such as a phosphoryl chloride, or the phosphonic acid is activated in situ for reaction with an amine or a hydroxy compound.

[0185] The conversion of phosphonic acids into phosphoryl chlorides is accomplished by reaction with thionyl chloride, for example as described in J. Gen. Chem. USSR, 1983, 53, 480, Zh. Obschei Khim., 1958, 28, 1063, or J. Org. Chem., 1994, 59, 6144, or by reaction with oxalyl chloride, as described in J. Am. Chem. Soc., 1994, 116, 3251, or J. Org. Chem., 1994, 59, 6144, or by reaction with phosphorus pentachloride, as described in J. Org. Chem., 2001, 66, 329, or in J. Med. Chem., 1995, 38, 1372. The resultant phosphoryl chlorides are then reacted with amines or hydroxy compounds in the presence of a base to afford the amidate or ester products.

[0186] Phosphonic acids are converted into activated imidazolyl derivatives by reaction with carbonyl diimidazole, as described in J. Chem. Soc., Chem. Comm. (1991) 312, or Nucleosides & Nucleotides (2000) 19:1885. Activated sulfonyloxy derivatives are obtained by the reaction of phosphonic acids with trichloromethylsulfonyl chloride or with triisopropylbenzenesulfonyl chloride, as described in Tet. Lett. (1996) 7857, or Bioorg. Med. Chem. Lett. (1998) 8:663. The activated sulfonyloxy derivatives are then reacted with amines or hydroxy compounds to afford amidates or esters.

[0187] Alternatively, the phosphonic acid and the amine or hydroxy reactant are combined in the presence of a diimide coupling agent. The preparation of phosphonic amidates and esters by means of coupling reactions in the presence of dicyclohexyl carbodiimide is described, for example, in J. Chem. Soc., Chem. Comm. (1991) 312 or Coll. Czech. Chem. Comm. (1987) 52:2792. The use of ethyl dimethylaminopropyl carbodiimide for activation and coupling of phosphonic acids is described in Tet. Lett., (2001) 42:8841, or Nucleosides & Nucleotides

(2000) 19:1885.

[0188] A number of additional coupling reagents have been described for the preparation of amidates and esters from phosphonic acids. The agents include Aldrithiol-2, and PYBOP and BOP, as described in J. Org. Chem., 1995, 60, 5214, and J. Med. Chem. (1997) 40:3842, mesitylene-2-sulfonyl-3-nitro-1,2,4-triazole (MSNT), as described in J. Med. Chem. (1996) 39:4958, diphenylphosphoryl azide, as described in J. Org. Chem. (1984) 49:1158, 1-(2,4,6-triisopropylbenzenesulfonyl-3-nitro-1,2,4-triazole (TPSNT) as described in Bioorg. Med. Chem. Lett. (1998) 8:1013, bromotris(dimethylamino)phosphonium hexafluorophosphate (BroP), as described in Tet. Lett., (1996) 37:3997, 2-chloro-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinane, as described in Nucleosides Nucleotides 1995, 14, 871, and diphenyl chlorophosphate, as described in J. Med. Chem., 1988, 31, 1305.

[0189] Phosphonic acids are converted into amidates and esters by means of the Mitsunobu reaction, in which the phosphonic acid and the amine or hydroxy reactant are combined in the presence of a triaryl phosphine and a dialkyl azodicarboxylate. The procedure is described in Org. Lett., 2001, 3, 643, or J. Med. Chem., 1997, 40, 3842.

[0190] Phosphonic esters are also obtained by the reaction between phosphonic acids and halo compounds, in the presence of a suitable base. The method is described, for example, in Anal. Chem., 1987, 59, 1056, or J. Chem. Soc. Perkin Trans., I, 1993, 19, 2303, or J. Med. Chem., 1995, 38, 1372, or Tet. Lett., 2002, 43, 1161.

[0191] Schemes **34-37** illustrate the conversion of phosphonate esters and phosphonic acids into carboalkoxy-substituted phosphonbisamidates (Scheme **34),** phosphonamidates (Scheme **35),** phosphonate monoesters (Scheme **36)** and phosphonate diesters, (Scheme **37).** Scheme 38 illustrates synthesis of gem-dialkyl amino phosphonate reagents.

[0192] Scheme **34** illustrates various methods for the conversion of phosphonate diesters **S34.1** into phosphonbisamidates **S34.5.** The diester **S34.1,** prepared as described previously, is hydrolyzed, either to the monoester **S34.2** or to the phosphonic acid **S34.6.** The methods employed for these transformations are described above. The monoester **S34.2** is converted into the monoamidate **S34.3** by reaction with an aminoester **S34.9,** in which the group R^2 is H or alkyl; the group R^{4b} is a divalent alkylene moiety such as, for example, $CHCH_3$, $CHCH_2CH_3$, $CH(CH(CH_3)_2)$, $CH(CH_2Ph)$, and the like, or a side chain group present in natural or modified aminoacids; and the group R^{5b} is C_1-C_{12} alkyl, such as methyl, ethyl, propyl, isopropyl, or isobutyl; C_6-C_{20} aryl, such as phenyl or substituted phenyl; or C_6-C_{20} arylalkyl, such as benzyl or benzyhydryl. The reactants are combined in the presence of a coupling agent such as a carbodiimide, for example dicyclohexyl carbodiimide, as described in J. Am. Chem. Soc., (1957) 79:3575, optionally in the presence of an activating agent such as hydroxybenztriazole, to yield the amidate product **S34.3.** The amidate-forming reaction is also effected in the presence of coupling agents such as BOP, as described in J. Org. Chem. (1995) 60:5214, Aldrithiol, PYBOP and similar coupling agents used for the preparation of amides and esters.

Alternatively, the reactants **S34.2** and **S34.9** are transformed into the monoamidate **S34.3** by means of a Mitsunobu reaction. The preparation of amidates by means of the Mitsunobu reaction is described in J. Med. Chem. (1995) 38:2742. Equimolar amounts of the reactants are combined in an inert solvent such as tetrahydrofuran in the presence of a triaryl phosphine and a dialkyl azodicarboxylate. The thus-obtained monoamidate ester **S34.3** is then transformed into amidate phosphonic acid **S34.4.** The conditions used for the hydrolysis reaction depend on the nature of the R^1 group, as described previously. The phosphonic acid amidate **S34.4** is then reacted with an aminoester **S34.9,** as described above, to yield the bisamidate product **S34.5,** in which the amino substituents are the same or different. Alternatively, the phosphonic acid **S34.6** may be treated with two different amino ester reagents simulataneously, *i.e.* **S34.9** where R^2, R^{4b} or R^{5b} are different. The resulting mixture of bisamidate products **S34.5** may then be separable, *e.g.* by chromatography.

Scheme 34



[0193] An example of this procedure is shown in Scheme **34,** Example **1.** In this procedure, a dibenzyl phosphonate **S34.14** is reacted with diazabicyclooctane (DABCO) in toluene at reflux, as described in J. Org. Chem., 1995, 60, 2946, to afford the monobenzyl phosphonate **S34.15.** The product is then reacted with equimolar amounts of ethyl alaninate **S34.16** and dicyclohexyl carbodiimide in pyridine, to yield the amidate product **S34.17.** The benzyl group is then removed, for example by hydrogenolysis over a palladium catalyst, to give the monoacid product **S34.18** which may be unstable according to J. Med. Chem. (1997) 40(23):3842. This

compound **S34.18** is then reacted in a Mitsunobu reaction with ethyl leucinate **S34.19,** triphenyl phosphine and diethylazodicarboxylate, as described in J. Med. Chem., 1995, 38, 2742, to produce the bisamidate product **S34.20.**

[0194] Using the above procedures, but employing in place of ethyl leucinate **S34.19** or ethyl alaninate **S34.16,** different aminoesters **S34.9,** the corresponding products **S34.5** are obtained.

[0195] Alternatively, the phosphonic acid **S34.6** is converted into the bisamidate **S34.5** by use of the coupling reactions described above. The reaction is performed in one step, in which case the nitrogen-related substituents present in the product **S34.5** are the same, or in two steps, in which case the nitrogen-related substituents can be different.

[0196] An example of the method is shown in Scheme 34, Example 2. In this procedure, a phosphonic acid **S34.6** is reacted in pyridine solution with excess ethyl phenylalaninate **S34.21** and dicyclohexylcarbodiimide, for example as described in J. Chem. Soc., Chem. Comm., 1991, 1063, to give the bisamidate product **S34.22.**

[0197] Using the above procedures, but employing, in place of ethyl phenylalaninate, different aminoesters **S34.9,** the corresponding products **S34.5** are obtained.

[0198] As a further alternative, the phosphonic acid **S34.6** is converted into the mono or bis-activated derivative **S34.7,** in which Lv is a leaving group such as chloro, imidazolyl, triisopropylbenzenesulfonyloxy etc. The conversion of phosphonic acids into chlorides **S34.7** (Lv = Cl) is effected by reaction with thionyl chloride or oxalyl chloride and the like, as described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 17. The conversion of phosphonic acids into monoimidazolides **S34.7** (Lv = imidazolyl) is described in J. Med. Chem., 2002, 45, 1284 and in J. Chem. Soc. Chem. Comm., 1991, 312. Alternatively, the phosphonic acid is activated by reaction with triisopropylbenzenesulfonyl chloride, as described in Nucleosides and Nucleotides, 2000, 10, 1885. The activated product is then reacted with the aminoester **S34.9,** in the presence of a base, to give the bisamidate **S34.5.** The reaction is performed in one step, in which case the nitrogen substituents present in the product **S34.5** are the same, or in two steps, via the intermediate **S34.11,** in which case the nitrogen substituents can be different.

[0199] Examples of these methods are shown in Scheme 34, Examples 3 and 5. In the procedure illustrated in Scheme 34, Example 3, a phosphonic acid **S34.6** is reacted with ten molar equivalents of thionyl chloride, as described in Zh. Obschei Khim., 1958, 28, 1063, to give the dichloro compound **S34.23.** The product is then reacted at reflux temperature in a polar aprotic solvent such as acetonitrile, and in the presence of a base such as triethylamine, with butyl serinate **S34.24** to afford the bisamidate product **S34.25.**

[0200] Using the above procedures, but employing, in place of butyl serinate **S34.24,** different aminoesters **S34.9,** the corresponding products **S34.5** are obtained.

[0201] In the procedure illustrated in Scheme 34, Example 5, the phosphonic acid **S34.6** is reacted, as described in J. Chem. Soc. Chem. Comm., 1991, 312, with carbonyl diimidazole to give the imidazolide **S34.S32.** The product is then reacted in acetonitrile solution at ambient temperature, with one molar equivalent of ethyl alaninate **S34.33** to yield the monodisplacement product **S34.S34.** The latter compound is then reacted with carbonyl diimidazole to produce the activated intermediate **S34.35,** and the product is then reacted, under the same conditions, with ethyl N-methylalaninate **S34.33a** to give the bisamidate product **S34.36.**

[0202] Using the above procedures, but employing, in place of ethyl alaninate **S34.33 or** ethyl N-methylalaninate **S34.33a,** different aminoesters **S34.9,** the corresponding products **S34.5** are obtained.

[0203] The intermediate monoamidate **S34.3** is also prepared from the monoester **S34.2** by first converting the monoester into the activated derivative **S34.8** in which Lv is a leaving group such as halo, imidazolyl etc, using the procedures described above. The product **S34.8** is then reacted with an aminoester **S34.9** in the presence of a base such as pyridine, to give an intermediate monoamidate product **S34.3.** The latter compound is then converted, by removal of the R^1 group and coupling of the product with the aminoester **S34.9,** as described above, into the bisamidate **S34.5.**

[0204] An example of this procedure, in which the phosphonic acid is activated by conversion to the chloro derivative **S34.26,** is shown in Scheme 34, Example 4. In this procedure, the phosphonic monobenzyl ester **S34.15** is reacted, in dichloromethane, with thionyl chloride, as described in Tet. Letters., 1994, 35, 4097, to afford the phosphoryl chloride **S34.26.** The product is then reacted in acetonitrile solution at ambient temperature with one molar equivalent of ethyl 3-amino-2-methylpropionate **S34.27** to yield the monoamidate product **S34.28.** The latter compound is hydrogenated in ethylacetate over a 5% palladium on carbon catalyst to produce the monoacid product **S34.29.** The product is subjected to a Mitsunobu coupling procedure, with equimolar amounts of butyl alaninate **S34.30,** triphenyl phosphine, diethylazodicarboxylate and triethylamine in tetrahydrofuran, to give the bisamidate product **S34.31.**

[0205] Using the above procedures, but employing, in place of ethyl 3-amino-2-methylpropionate **S34.27** or butyl alaninate **S34.30,** different aminoesters **S34.9,** the corresponding products **S34.5** are obtained.

[0206] The activated phosphonic acid derivative **S34.7** is also converted into the bisamidate **S34.5** via the diamino compound **S34.10.** The conversion of activated phosphonic acid derivatives such as phosphoryl chlorides into the corresponding amino analogs **S34.10,** by reaction with ammonia, is described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976. The bisamino compound **S34.10** is then reacted at elevated temperature with a haloester **S34.12** (Hal = halogen, *i.e.* F, Cl, Br, I), in a polar organic solvent such as dimethylformamide, in the presence of a base such as 4, 4-dimethylaminopyridine

(DMAP) or potassium carbonate, to yield the bisamidate **S34.5.** Alternatively, **S34.6** may be treated with two different amino ester reagents simulataneously, *i.e.* **S34.12** where R^{4b} or R^{5b} are different. The resulting mixture of bisamidate products **S34.5** may then be separable, *e.g.* by chromatography.

[0207] An example of this procedure is shown in Scheme 34, Example 6. In this method, a dichlorophosphonate **S34.23** is reacted with ammonia to afford the diamide **S34.37.** The reaction is performed in aqueous, aqueous alcoholic or alcoholic solution, at reflux temperature. The resulting diamino compound is then reacted with two molar equivalents of ethyl 2-bromo-3-methylbutyrate **S34.38,** in a polar organic solvent such as N-methylpyrrolidinone at ca. 150 °C, in the presence of a base such as potassium carbonate, and optionally in the presence of a catalytic amount of potassium iodide, to afford the bisamidate product **S34.39.**

[0208] Using the above procedures, but employing, in place of ethyl 2-bromo-3-methylbutyrate **S34.38,** different haloesters **S34.12** the corresponding products **S34.5** are obtained.

[0209] The procedures shown in Scheme 34 are also applicable to the preparation of bisamidates in which the aminoester moiety incorporates different functional groups. Scheme 34, Example **7** illustrates the preparation of bisamidates derived from tyrosine. In this procedure, the monoimidazolide **S34.32** is reacted with propyl tyrosinate **S34.40,** as described in Example **5,** to yield the monoamidate **S34.41.** The product is reacted with carbonyl diimidazole to give the imidazolide **S34.42,** and this material is reacted with a further molar equivalent of propyl tyrosinate to produce the bisamidate product **S34.43.**

[0210] Using the above procedures, but employing, in place of propyl tyrosinate **S34.40,** different aminoesters **S34.9,** the corresponding products **S34.5** are obtained. The aminoesters employed in the two stages of the above procedure can be the same or different, so that bisamidates with the same or different amino substituents are prepared.

[0211] Scheme 35 illustrates methods for the preparation of phosphonate monoamidates.

[0212] In one procedure, a phosphonate monoester **S34.1** is converted, as described in Scheme 34, into the activated derivative **S34.8.** This compound is then reacted, as described above, with an aminoester **S34.9,** in the presence of a base, to afford the monoamidate product **S35.1.**

[0213] The procedure is illustrated in Scheme 35, Example 1. In this method, a monophenyl phosphonate **S35.7** is reacted with, for example, thionyl chloride, as described in J. Gen. Chem. USSR., 1983, 32, 367, to give the chloro product **S35.8.** The product is then reacted, as described in Scheme 34, with ethyl alaninate **S3**, to yield the amidate **S35.10.**

[0214] Using the above procedures, but employing, in place of ethyl alaninate **S35.9,** different aminoesters **S34.9,** the corresponding products **S35.1** are obtained.

[0215] Alternatively, the phosphonate monoester **S34.1** is coupled, as described in Scheme 34, with an aminoester **S34.9** to produce the amidate **S335.1.** If necessary, the R^1 substituent is then altered, by initial cleavage to afford the phosphonic acid **S35.2.** The procedures for this transformation depend on the nature of the R^1 group, and are described above. The phosphonic acid is then transformed into the ester amidate product **S35.3,** by reaction with the hydroxy compound R^3OH, in which the group R^3 is aryl, heterocycle, alkyl, cycloalkyl, haloalkyl etc, using the same coupling procedures (carbodiimide, Aldrithiol-2, PYBOP, Mitsunobu reaction etc) described in Scheme 34 for the coupling of amines and phosphonic acids.

Scheme 34 Example 1



Scheme 34 Example 2



Scheme 34 Example 3



Scheme 34 Example 4



Scheme 34 Example 5



Scheme 34 Example 6



Scheme 34 Example 7



[0216] Examples of this method are shown in Scheme 35, Examples 2 and 3. In the sequence shown in Example 2, a monobenzyl phosphonate **S35.11** is transformed by reaction with ethyl alaninate, using one of the methods described above, into the monoamidate **S35.12.** The benzyl group is then removed by catalytic hydrogenation in ethylacetate solution over a 5% palladium on carbon catalyst, to afford the phosphonic acid amidate **S35.13.** The product is

then reacted in dichloromethane solution at ambient temperature with equimolar amounts of 1-(dimethylaminopropyl)-3-ethylcarbodiimide and trifluoroethanol **S35.14,** for example as described in Tet. Lett., 2001, 42, 8841, to yield the amidate ester **S35.15.**

[0217] In the sequence shown in Scheme 35, Example 3, the monoamidate **S35.13** is coupled, in tetrahydrofuran solution at ambient temperature, with equimolar amounts of dicyclohexyl carbodiimide and 4-hydroxy-N-methylpiperidine **S35.16,** to produce the amidate ester product **S35.17.**

[0218] Using the above procedures, but employing, in place of the ethyl alaninate product **S35.12** different monoacids **S35.2,** and in place of trifluoroethanol **S35.14** or 4-hydroxy-N-methylpiperidine **S35.16,** different hydroxy compounds R^3OH, the corresponding products **S35.3** are obtained.

[0219] Alternatively, the activated phosphonate ester **S34.8** is reacted with ammonia to yield the amidate **S35.4.** The product is then reacted, as described in Scheme 34, with a haloester **S35.5,** in the presence of a base, to produce the amidate product **S35.6.** If appropriate, the nature of the R^1 group is changed, using the procedures described above, to give the product **S35.3.** The method is illustrated in Scheme 35, Example **4.** In this sequence, the monophenyl phosphoryl chloride **S35.18** is reacted, as described in Scheme **34,** with ammonia, to yield the amino product **S35.19.** This material is then reacted in N-methylpyrrolidinone solution at 170° with butyl 2-bromo-3-phenylpropionate **S35.20** and potassium carbonate, to afford the amidate product **S35.21.**

[0220] Using these procedures, but employing, in place of butyl 2-bromo-3-phenylpropionate **S35.20,** different haloesters **S35.5,** the corresponding products **S35.6** are obtained.

[0221] The monoamidate products **S35.3** are also prepared from the doubly activated phosphonate derivatives **S34.7.** In this procedure, examples of which are described in Synlett., 1998, 1, 73, the intermediate **S34.7** is reacted with a limited amount of the aminoester **S34.9** to give the mono-displacement product **S34.11.** The latter compound is then reacted with the hydroxy compound R^3OH in a polar organic solvent such as dimethylformamide, in the presence of a base such as diisopropylethylamine, to yield the monoamidate ester **S35.3.**

[0222] The method is illustrated in Scheme 35, Example 5. In this method, the phosphoryl dichloride **S35.22** is reacted in dichloromethane solution with one molar equivalent of ethyl N-methyl tyrosinate **S35.23** and dimethylaminopyridine, to generate the monoamidate **S35.24.** The product is then reacted with phenol **S35.25** in dimethylformamide containing potassium carbonate, to yield the ester amidate product **S35.26.**

[0223] Using these procedures, but employing, in place of ethyl N-methyl tyrosinate **S35.23** or phenol **S35.25,** the aminoesters **34.9** and/or the hydroxy compounds R^3OH, the corresponding products **S35.3** are obtained.

Scheme 35



Scheme 35 Example 1



Scheme 35 Example 2



Scheme 35 Example 3



Scheme 35 Example 4



Scheme 35 Example 5



[0224] Scheme 36 illustrates methods for the preparation of carboalkoxy-substituted phosphonate diesters in which one of the ester groups incorporates a carboalkoxy substituent.

[0225] In one procedure, a phosphonate monoester **S34.1,** prepared as described above, is coupled, using one of the methods described above, with a hydroxyester **S36.1,** in which the groups R^{4b} and R^{5b} are as described in Scheme 34. For example, equimolar amounts of the reactants are coupled in the presence of a carbodiimide such as dicyclohexyl carbodiimide, as described in Aust. J. Chem., 1963, 609, optionally in the presence of dimethylaminopyridine, as described in Tet., 1999, 55, 12997. The reaction is conducted in an inert solvent at ambient temperature.

[0226] The procedure is illustrated in Scheme 36, Example 1. In this method, a monophenyl phosphonate **S36.9** is coupled, in dichloromethane solution in the presence of dicyclohexyl carbodiimide, with ethyl 3-hydroxy-2-methylpropionate **S36.10** to yield the phosphonate mixed diester **S36.11.**

[0227] Using this procedure, but employing, in place of ethyl 3-hydroxy-2-methylpropionate **S36.10,** different hydroxyesters **S33.1,** the corresponding products **S33.2** are obtained.

[0228] The conversion of a phosphonate monoester **S34.1** into a mixed diester **S36.2** is also accomplished by means of a Mitsunobu coupling reaction with the hydroxyester **S36.1,** as described in Org. Lett., 2001, 643. In this method, the reactants **34.1** and **S36.1** are combined in a polar solvent such as tetrahydrofuran, in the presence of a triarylphosphine and a dialkyl azodicarboxylate, to give the mixed diester **S36.2.** The R^1 substituent is varied by cleavage, using the methods described previously, to afford the monoacid product **S36.3.** The product is then coupled, for example using methods described above, with the hydroxy compound R^3OH, to give the diester product **S36.4.**

[0229] The procedure is illustrated in Scheme 36, Example 2. In this method, a monoallyl phosphonate **S36.12** is coupled in tetrahydrofuran solution, in the presence of triphenylphosphine and diethylazodicarboxylate, with ethyl lactate **S36.13** to give the mixed diester **S36.14.** The product is reacted with tris(triphenylphosphine) rhodium chloride (Wilkinson catalyst) in acetonitrile, as described previously, to remove the allyl group and produce the monoacid product **S36.15.** The latter compound is then coupled, in pyridine solution at ambient temperature, in the presence of dicyclohexyl carbodiimide, with one molar equivalent of 3-hydroxypyridine **S36.16** to yield the mixed diester **S36.17.**

[0230] Using the above procedures, but employing, in place of the ethyl lactate **S36.13** or 3-hydroxypyridine, a different hydroxyester **S36.1** and/or a different hydroxy compound R^3OH, the corresponding products **S36.4** are obtained.

[0231] The mixed diesters **S36.2** are also obtained from the monoesters **S34.1** via the intermediacy of the activated monoesters **S36.5.** In this procedure, the monoester **S34.1** is converted into the activated compound **S36.5** by reaction with, for example, phosphorus pentachloride, as described in J. Org. Chem., 2001, 66, 329, or with thionyl chloride or oxalyl chloride (Lv = Cl), or with triisopropylbenzenesulfonyl chloride in pyridine, as described in Nucleosides and Nucleotides, 2000, 19, 1885, or with carbonyl diimidazole, as described in J. Med. Chem., 2002, 45, 1284. The resultant activated monoester is then reacted with the hydroxyester **S36.1,** as described above, to yield the mixed diester **S36.2.**

[0232] The procedure is illustrated in Scheme 36, Example 3. In this sequence, a monophenyl phosphonate **S36.9** is reacted, in acetonitrile solution at 70 °C, with ten equivalents of thionyl chloride, so as to produce the phosphoryl chloride **S36.19.** The product is then reacted with ethyl 4-carbamoyl-2-hydroxybutyrate **S36.20** in dichloromethane containing triethylamine, to give the mixed diester **S36.21.**

[0233] Using the above procedures, but employing, in place of ethyl 4-carbamoyl-2-hydroxybutyrate **S36.20,** different hydroxyesters **S36.1,** the corresponding products **S36.2** are obtained.

[0234] The mixed phosphonate diesters are also obtained by an alternative route for

incorporation of the R^3O group into intermediates **S36.3** in which the hydroxyester moiety is already incorporated. In this procedure, the monoacid intermediate **S36.3** is converted into the activated derivative **S36.6** in which Lv is a leaving group such as chloro, imidazole, and the like, as previously described. The activated intermediate is then reacted with the hydroxy compound R^3OH, in the presence of a base, to yield the mixed diester product **S36.4.**

[0235] The method is illustrated in Scheme 36, Example 4. In this sequence, the phosphonate monoacid **S36.22** is reacted with trichloromethanesulfonyl chloride in tetrahydrofuran containing collidine, as described in J. Med. Chem., 1995, 38, 4648, to produce the trichloromethanesulfonyloxy product **S36.23.** This compound is reacted with 3-(morpholinomethyl)phenol **S36.24** in dichloromethane containing triethylamine, to yield the mixed diester product **S36.25.**

[0236] Using the above procedures, but employing, in place of with 3-(morpholinomethyl)phenol **S36.24,** different alcohols R^3OH, the corresponding products **S36.4** are obtained.

[0237] The phosphonate esters **S36.4** are also obtained by means of alkylation reactions performed on the monoesters **S34.1.** The reaction between the monoacid **S34.1** and the haloester **S36.7** is performed in a polar solvent in the presence of a base such as diisopropylethylamine, as described in Anal. Chem., 1987, 59, 1056, or triethylamine, as described in J. Med. Chem., 1995, 38, 1372, or in a non-polar solvent such as benzene, in the presence of 18-crown-6, as described in Syn. Comm., 1995, 25, 3565.

[0238] The method is illustrated in Scheme 36, Example 5. In this procedure, the monoacid **S36.26** is reacted with ethyl 2-bromo-3-phenylpropionate **S36.27** and diisopropylethylamine in dimethylformamide at 80 °C to afford the mixed diester product **S36.28.**

[0239] Using the above procedure, but employing, in place of ethyl 2-bromo-3-phenylpropionate **S36.27,** different haloesters **S36.7,** the corresponding products **S36.4** are obtained.

Scheme 36





Scheme 36 Example 1



Scheme 36 Example 2



Scheme 36 Example 3





Scheme 36 Example 4



S36.22 **S36.23**



S36.24

S36.25

Scheme 36 Example 5



S36.26 **S36.27** **S36.28**

[0240] Scheme 37 illustrates methods for the preparation of phosphonate diesters in which both the ester substituents incorporate carboalkoxy groups.

[0241] The compounds are prepared directly or indirectly from the phosphonic acids **S34.6.** In one alternative, the phosphonic acid is coupled with the hydroxyester **S37.2,** using the conditions described previously in Schemes 34-36, such as coupling reactions using dicyclohexyl carbodiimide or similar reagents, or under the conditions of the Mitsunobu reaction, to afford the diester product **S37.3** in which the ester substituents are identical.

[0242] This method is illustrated in Scheme 37, Example 1. In this procedure, the phosphonic acid **S34.6** is reacted with three molar equivalents of butyl lactate **S37.5** in the presence of Aldrithiol-2 and triphenyl phosphine in pyridine at ca. 70 °C, to afford the diester **S37.6.**

[0243] Using the above procedure, but employing, in place of butyl lactate **S37.5,** different hydroxyesters **S37.2,** the corresponding products **S37.3** are obtained.

[0244] Alternatively, the diesters **S37.3** are obtained by alkylation of the phosphonic acid **S34.6** with a haloester **S37.1.** The alkylation reaction is performed as described in Scheme 36 for the preparation of the esters **S36.4.**

[0245] This method is illustrated in Scheme 37, Example 2. In this procedure, the phosphonic acid **S34.6** is reacted with excess ethyl 3-bromo-2-methylpropionate **S37.7** and diisopropylethylamine in dimethylformamide at ca. 80 °C, as described in Anal. Chem., 1987, 59, 1056, to produce the diester **S37.8.**

[0246] Using the above procedure, but employing, in place of ethyl 3-bromo-2-methylpropionate **S37.7,** different haloesters **S37.1,** the corresponding products **S37.3** are obtained.

[0247] The diesters **S37.3** are also obtained by displacement reactions of activated derivatives **S34.7** of the phosphonic acid with the hydroxyesters **S37.2.** The displacement reaction is performed in a polar solvent in the presence of a suitable base, as described in Scheme 36. The displacement reaction is performed in the presence of an excess of the hydroxyester, to afford the diester product **S37.3** in which the ester substituents are identical, or sequentially with limited amounts of different hydroxyesters, to prepare diesters **S37.3** in which the ester substituents are different.

[0248] The methods are illustrated in Scheme 37, Examples 3 and 4. As shown in Example 3, the phosphoryl dichloride **S35.22** is reacted with three molar equivalents of ethyl 3-hydroxy-2-(hydroxymethyl)propionate **S37.9** in tetrahydrofuran containing potassium carbonate, to obtain the diester product **S37.10.**

[0249] Using the above procedure, but employing, in place of ethyl 3-hydroxy-2-(hydroxymethyl)propionate **S37.9,** different hydroxyesters **S37.2,** the corresponding products **S37.3** are obtained.

[0250] Scheme 37, Example 4 depicts the displacement reaction between equimolar amounts of the phosphoryl dichloride **S35.22** and ethyl 2-methyl-3-hydroxypropionate **S37.11,** to yield the monoester product **S37.12.** The reaction is conducted in acetonitrile at 70° in the presence of diisopropylethylamine. The product **S37.12** is then reacted, under the same conditions, with one molar equivalent of ethyl lactate **S37.13,** to give the diester product **S37.14.**

[0251] Using the above procedures, but employing, in place of ethyl 2-methyl-3-hydroxypropionate **S37.11** and ethyl lactate **S37.13,** sequential reactions with different hydroxyesters **S37.2,** the corresponding products **S37.3** are obtained.

Scheme 37



S34.7 S37.4

Scheme 37 Example 1



S34.6 S37.6

Scheme 37 Example 2



S34.6 S37.8

Scheme 37 Example 3



S35.22 S37.10

Scheme 37 Example 4



S35.22 S37.12



S37.14

[0252] 2,2-Dimethyl-2-aminoethylphosphonic acid intermediates can be prepared by the route in Scheme 5. Condensation of 2-methyl-2-propanesulfinamide with acetone give sulfinyl imine **S38.11** (J. Org. Chem. 1999, 64, 12). Addition of dimethyl methylphosphonate lithium to **S38.11** afford **S38.12.** Acidic methanolysis of **S38.12** provide amine **S38.13.** Protection of amine with Cbz group and removal of methyl groups yield phosphonic acid **S38.14,** which can be converted to desired **S38.15** (Scheme 38a) using methods reported earlier on. An alternative synthesis of compound **S38.14** is also shown in Scheme 38b. Commercially available 2-amino-2-methyl-1-propanol is converted to aziridines **S38.16** according to literature methods (J. Org. Chem. 1992, 57, 5813; Syn. Lett. 1997, 8, 893). Aziridine opening with phosphite give **S38.17** (Tetrahedron Lett. 1980, 21, 1623). Reprotection) of **S38.17** affords

S38.14.

Scheme 38a



S38.16 R = Cbz, R'SO2

S38.17

S38.14

ENUMERATED REFERENCED EMBODIMENTS

[0253]

1. A compound, including enantiomers thereof, of Formula 1A, or a pharmaceutically acceptable salt or solvate thereof,



1A

wherein:

A^0 is A^1, A^2, or A^3;

A^1 is



;

A^2 is



;

A^3 is:



;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, Y^3, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

Y^3 is O, $S(O)_{M2}$, S, or $C(R^2)_2$;

R^x is independently H, R^1, R^2, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 and R^{2a} are independently H, R^1, R^3, or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or, when taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c}, R^{3d}, or R^{3e}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is R^{3e}, -CN, N_3 or $-NO_2$;

R^{3b} is $(=Y^1)$;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$,-$OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$,-$N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^{3e} is F, Cl, Br or I;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18

carbon atoms;

R^5 is H or R^4, wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_{M2}R^5$, or $-SO_{M2}W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

provided that the compound of Formula 1A is not of the structure 556-E.6



556-E.6

or its ethyl diester.

2. The compound of embodiment 1 wherein R^{2a} is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl

3. The compound of embodiment 1 wherein R^{2a} is selected from the group consisting of H, halo, alkyl, azido, cyano, or haloalkyl.

4. The compound of embodiment 1 wherein R^2 is selected from selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl.

5. The compound of embodiment 1 that has the formula 1B



1B

6. The compound of embodiment 1 that has the formula 1C



1C

7. The compound of embodiment 1 that has the formula 1D



1D

8. The compound of embodiment 1 that has the formula 1E



1E

9. The compound of embodiment 1 that has the formula 1F



1F

10. The compound of embodiment 1 that has the formula 1G



1G

11. The compound of embodiment 1 that has the formula 1H



1H

12. The compound of embodiment 1 that has the formula 1I



1I ;

wherein:

Y^4 is N or $C(R^3)$.

13. The compound of embodiment 1 that has the formula 1J



1J

14. The compound of embodiment 1 wherein R^{2a} is halo, alkyl, azido, cyano, or haloalkyl.

15. The compound of embodiment 1 wherein R^x is a naturally occurring amino acid.

16. A compound, enantiomers thereof, or a pharmaceutically acceptable salt or solvate thereof that is of the general structure of formula I

(I)



wherein

B is Base;

Z is O, S, or $C(R^k)_2$;

R^{3e} is F, Cl, Br or I;

A^{6k}-$CH_2P(Y^k)(A^{5k})(Y^{k2}A^{5k})$, -$CH_2P(Y^k)(A^{5k})(A^{5k})$, or

-$CH_2P(Y^k)(Y^{k2}A^{5k})(Y^{k2}A^{5k})$, optionally substituted with R^k;

A^{5k} is H, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, haloalkyl, cycloalkyl, aryl, haloaryl, or heteroaryl, optionally substituted with R^k;

Y^k is O or S;

Y^{k2} is O, N(R^k), or S; and

each R^2 and R^{2a} is independently selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl; and

each R^k is independently selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl; provided that the compound of Formula 1A is not of the structure 556-E.6



556-E.6

or its ethyl diester.

17. The compound of embodiment 16 wherein R^{2a} is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl

18. The compound of embodiment 16 wherein R^{2a} is selected from the group consisting of H, halo, alkyl, azido, cyano, or haloalkyl.

19. The compound of embodiment 1 selected from:

1. a) Formula 1A wherein A^0 is A^3;
2. b) Formula 1A wherein A^0 is



3. c) Formula 1A wherein:

A^0 is



and

each R^2 and R^{2a} is H;

4. d) Formula 1A wherein:

A^3 is



;

R^3 is $-N(R^x)(R^x)$;

each R^2 and R^{2a} is H.

5. e) Formula 1A wherein:

A^0 is



;

and each R^2 and R^{2a} is H.

20. The compound of embodiment 1, wherein A^3 is of the formula:



M12d

wherein:

Y^{2b} is O or $N(R^2)$; and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

21. The compound of embodiment 1 wherein A^3 is of the formula:



2

M12b

22. The compound of embodiment 1 wherein A^3 is of the formula:



wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.

23. The compound of embodiment 1 wherein A^3 is of the formula:



wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.

24. The compound of embodiment 1 wherein A^3 is of the formula:



25. The compound of embodiment 1 wherein A^3 is of the formula:



;

wherein:

Y^{1a} is O or S;

Y^{2b} is O or N(R^2); and

Y^{2c} is O, N(R^y) or S; and

each R^2 and R^{2a} is independently selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl.

26. The compound of embodiment 1 wherein A^3 is of the formula:



wherein each R is independently H or alkyl.

27. The compound of embodiment 1 which is isolated and purified.

28. A compound of formula MBF I, or prodrugs, solvates, or pharmaceutically acceptable salts or esters thereof



(MBF I)

wherein

each K1 and K2 are independently selected from the group consisting of A^{5k} and -$Y^{k2}A^{5k}$;

Y^{k2} is O, N(R^k), or S;

B is Base;

A^{5k} is H, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, haloalkyl, cycloalkyl, aryl, haloaryl, or heteroaryl, optionally substituted with R^k; and

R^k is independently selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, azido, haloalkyl, cycloalkyl, aryl, haloaryl, and heteroaryl; provided that when B is adenine, then both K1 and K2 are not simultaneously both -OH or -OEt.

29. The compound of embodiment 28 wherein B is selected form the group consisting of 2, 6-diaminopurine, guanine, adenine, cytosine, 5-fluoro-cytosine, monodeaza, and monoaza

analogues thereof.

30. The compound of embodiment 28 wherein MBF I is of the formula



MBF I

31. The compound of embodiment 1 wherein B is selected from the group consisting of adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine.

32. The compound of embodiment 1 wherein B is selected form the group consisting of adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, and 7-deazaguanine.

33. The compound of embodiment 1 that is selected from Table Y.

34 The compound of embodiment 28 wherein K1 and K2 are selected from Table 100.

Table 100

K1	K2	Ester
Ala	OPh	cPent
Ala	OCH_2CF_3	Et
Ala	OPh	3-furan-4H
Ala	OPh	cBut
Phe(B)	OPh	Et
Phe(A)	OPh	Et
Ala(B)	OPh	Et
Phe	OPh	sBu(S)
Phe	OPh	cBu
Phe	OCH_2CF_3	iBu
Ala(A)	OPh	Et
Phe	OPh	sBu(R)

K1	K2	Ester
Ala(B)	OPh	CH_2cPr
Ala(A)	OPh	CH_2cPr
Phe(B)	OPh	nBu
Phe(A)	OPh	nBu
Phe	OPh	CH_2cPr
Phe	OPh	CH_2cBu
Ala	OPh	3-pent
ABA(B)	OPh	Et
ABA(A)	OPh	Et
Ala	OPh	CH_2cBu
Met	OPh	Et
Pro	OPh	Bn
Phe(B)	OPh	iBu
Phe(A)	OPh	iBu
Phe	OPh	iPr
Phe	OPh	nPr
Ala	OPh	CH_2cPr
Phe	OPh	Et
Ala	OPh	Et
ABA	OPh	nPent
Phe	Phe	nPr
Phe	Phe	Et
Ala	Ala	Et
CHA	OPh	Me
Gly	OPh	iPr
ABA	OPh	nBu
Phe	OPh	allyl
Ala	OPh	nPent
Gly	OPh	iBu
ABA	OPh	iBu
Ala	OPh	nBu
CHA	CHA	Me
Phe	Phe	Allyl
ABA	ABA	nPent

K1	K2	Ester
Gly	Gly	iBu
Gly	Gly	iPr
Phe	OPh	iBu
Ala	OPh	nPr
Phe	OPh	nBu
ABA	OPh	nPr
ABA	OPh	Et
Ala	Ala	Bn
Phe	Phe	nBu
ABA	ABA	nPr
ABA	ABA	Et
Ala	Ala	nPr
Ala	OPh	iPr
Ala	OPh	Bn
Ala	Ala	nBu
Ala	Ala	iBu
ABA	ABA	nBu
ABA	ABA	iPr
Ala	OPh	iBu
ABA	OPh	Me
ABA	OPh	iPr
ABA	ABA	iBu

wherein Ala represents L-alanine, Phe represents L-phenylalanine, Met represents L-methionine, ABA represents (S)-2-aminobutyric acid, Pro represents L-proline, CHA represents 2-amino-3-(S)cyclohexylpropionic acid, Gly represents glycine;

K1 or K2 amino acid carboxyl groups are esterified as denoted in the ester column, wherein

cPent is cyclopentane ester ; Et is ethyl ester, 3-furan-4H is the (R) tetrahydrofuran-3-yl ester; cBut is cyclobutane ester; sBu(S) is the (S) secButyl ester; sBu(R) is the (R) secButyl ester; iBu is isobutyl ester; CH_2cPr is methylcyclopropane ester, nBu is n-butyl ester ; CH_2cBu is methylcyclobutane ester; 3-pent is 3-pentyl ester ; nPent is nPentyl ester; iPr is isopropyl ester , nPr is nPropyl ester ; allyl is allyl ester; Me is methyl ester; Bn is Benzyl ester; and

wherein A or B in parentheses denotes one stereoisomer at phosphorus, with the least polar isomer denoted as (A) and the more polar as (B).

35. A compound of formula B, and the salts and solvates thereof.



(B)

wherein:

A^3 is:



;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$; and when Y^2 joins two phosphorous atoms Y^2 can also be $C(R^2)(R^2)$;

R^x is independently H, R^1, R^2, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 and R^{2a} are independently H, R^1, R^3, or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$,-$OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$,-$N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_{M2}R^5$, or $-SO_{M2}W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; wherein A^3 is not $-O-CH_2-P(O)(OH)_2$ or $-O-CH_2-P(O)(OEt)_2$.

36. The compound of embodiment 35 wherein m2 is 0, Y^1 is O, Y^2 is O, M12b and M12a are 1, one Y^3 is $-OR^x$ where R^x is W^3 and the other Y^3 is $N(H)R^x$ where R^x is



37. The compound of embodiment 36 wherein the terminal R^y of R^x is selected from the group of esters in Table 100.

38. The compound of embodiment 36 wherein the terminal R^y of R^x is a C1-C8 normal, secondary, tertiary or cyclic alkylene, alkynylene or alkenylene.

39. The compound of embodiment 36 wherein the terminal R^y of R^x is a heterocycle containing

5 to 6 ring atoms and 1 or 2 N, O and/or S atoms in the ring.

40. The compound of embodiment 1 having the formula XX:



(XX)

41. The compound of embodiment 1 having the formula XXX:



(XXX)

42. A pharmaceutical composition comprising a pharmaceutical excipient and an antivirally-effective amount of the compound of embodiment 1.

43. The pharmaceutical composition of embodiment 32 that further comprises a second active ingredient.

44. A combination comprising the compound of embodiment 1 and one or more antivirally active ingredients.

45. The combination of embodiment 44 wherein one or more of the active ingredients is selected from Table 98.

46. The combination of embodiment 45 wherein one of the active ingredients is selected from the group consisting of Truvada, Viread, Emtriva, d4T, Sustiva, or Amprenavir antiviral compounds.

47. The combination of embodiment 44 wherein one or more of the active ingredients is selected from Table 99.

48. The combination of embodiment 47 wherein one of the active ingredients is selected from the group consisting of Truvada, Viread, Emtriva, d4T, Sustiva, or Amprenavir antiviral compounds.

49. The combination of embodiment 46 for use in medical therapy.

50. The combination of embodiment 48 for use in medical therapy.

51. The pharmaceutical composition of embodiment 42 for use in medical therapy.

52. The pharmaceutical composition of embodiment 43 for use in medical therapy

53. The compound of embodiment 1 for use in antiretroviral or antihepadinaviral treatment.

54. A method of preparing the compound of embodiment 1 according to the Examples or Schemes.

55. Use of a compound of embodiment 1 for preparing a medicament for treating HIV or a HIV associated disorder.

56. A method of therapy for treating HIV or HIV-associated disorders with the compound of embodiment 1.

57. A method of treating disorders associated with HIV, said method comprising administering to an individual infected with, or at risk for HIV infection, a pharmaceutical composition which comprises a therapeutically effective amount of the compound of any of embodiments 1-28.
58. A compound of Table Y, provided the compound is not



556-E.6

or its ethyl diester.

EXAMPLES AND EXEMPLARY EMBODIMENTS

EXAMPLES:

[0254]



2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosylbromide (2)

Tann et al., JOC 1985, 50, p3644

Howell et al. JOC 1988, 53, p85

[0255] To a solution of **1** (120 g, 258 mmol), commercially available from Davos or CMS chemicals, in CH_2Cl_2 (1 L) was added 33% HBr / Acetic acid (80 mL). The mixture was stirred at room temperature for 16 h, cooled with ice-water, and slowly neutralized over 1-2 h with $NaHCO_3$ (150 g / 1.5 L solution). The CH_2Cl_2 phase was separated and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and washed with $NaHCO_3$ until no acid was present. The organic phase was dried over $MgSO_4$, filtered and concentrated under reduced pressure to give product **2** as a yellow oil (~115 g).





2-deoxy-2-fluoro-3,5-di-O-benzoyl-□-D-arabinofuranosyl-9H-6-chloropurine (3)

Ma et al., J. Med. Chem. 1997, 40, 2750

Marquez et al., J. Med. Chem. 1990, 33, 978

Hildebrand et al., J. Org. Chem. 1992, 57, 1808

Kazimierczuk et al. JACS 1984, 106, 6379

[0256] To a suspension of NaH (14 g, 60%) in ACETONITRILE (900 mL), 6-chloropurine (52.6 g) was added in 3 portions. The mixture was stirred at room temperature for 1.5 h. A solution of **2** (258 mmol) in ACETONITRILE (300 mL) was added dropwise. The resulting mixture was stirred at room temperature for 16 h. The reaction was quenched with Acetic acid (3.5 mL), filtered and concentrated under reduced pressure. The residue was partitioned between CH_2Cl_2 and water. The organic phase was dried over $MgSO_4$, filtered and concentrated. The residue was treated with CH_2Cl_2 and then EtOH (~1:2 overall) to precipitate out the desired product 3 as a yellowish solid (83 g, 65% from **1**).



2-deoxy-2-fluoro-□-D-arabinofuranosyl-6-methoxyadenine (4)

[0257] To a suspension of **3** (83 g, 167 mmol) in Methanol (1 L) at 0°C, NaOMe (25% wt, 76 mL) was added. The mixture was stirred at room temperature for 2 h, and then quenched with Acetic acid (~11 mL, pH=7). The mixture was concentrated under reduced pressure and the resultant residue partitioned between hexane and water (approximately 500 mL hexane and 300 mL water). The aqueous layer was separated and the organic layer mixed with water once

again (approximately 300 mL). The water fractions were combined and concentrated under reduced pressure to ~100 mL. The product, **4,** precipitated out and was collected by filtration (42 g, 88%).



2-deoxy-2-fluoro-5-carboxy-□-D-arabinofuranosyl-6-methoxyadenine (5)

Moss et al. J. Chem. Soc. 1963, p1149

[0258] A mixture of Pt/C (10%, 15 g (20-30% mol equiv.) as a water slurry) and $NaHCO_3$ (1.5 g, 17.94 mmol) in H_2O (500 mL) was stirred at 65°C under H_2 for 0.5 h. The reaction mixture was then allowed to cool, placed under a vacuum and flushed with N_2 several times to completely remove all H_2. Compound **4** (5.1 g, 17.94 mmol) was then added at room temperature. The reaction mixture was stirred at 65°C under O_2 (balloon) until the reaction was complete by LC-MS (typically 24-72h). The mixture was cooled to room temperature and filtered. The Pt/C was washed with H_2O extensively. The combined filtrates were concentrated to ~ 30 mL, and acidified (pH 4) by the addition of HCl (4N) at 0°C. A black solid precipitated out which was collected by filtration. The crude product was dissolved in a minimum amount of Methanol and filtered through a pad of silica gel (eluting with Methanol). The filtrate was concentrated and crystallized from water to give compound **5** (2.5 g) as an off-white solid.



(2'R, 3'S, 4'R, 5'R)-6-Methoxy-9-[tetrahydro 4-iodo-3-fluoro-5-(diethoxyphosphinyl)methoxy-2-furanyl]purine (6)

Zemlicka et al., J. Amer. Chem. Soc. 1972, 94, p3213

[0259] To a solution of **5** (22 g, 73.77 mmol) in DMF (400 mL), DMF dineopentyl acetal (150

mL, 538 mmol) and methanesulfonic acid (9.5 mL, 146.6 mmol) were added. The reaction mixture was stirred at 80-93°C (internal temperature) for 30 min, then cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic phase was separated and washed with $NaHCO_3$ followed by brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure. The residue and diethyl (hydroxymethyl)phosphonate (33 mL, 225 mmol) were dissolved in CH_2Cl_2 (250 mL) and cooled down to -40°C. A solution of iodine monobromide (30.5 g, 1.1 mol) in CH_2Cl_2 (100 mL) was added dropwise. The mixture was stirred at -20 to -5°C for 6 h. The reaction was then quenched with $NaHCO_3$ and $Na_2S_2O_3$. The organic phase was separated and the water phase was extracted with CH_2Cl_2. The combined organic phases were washed with brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give product **6** (6 g, 15.3%).

Alternative Procedure for the Preparation of 6

[0260] A solution of **5** (2.0 g, 6.7 mmol) in THF (45 mL) was treated with triphenyl phosphine (2.3 g, 8.7 mmol) under N_2. Diisopropyl azodicarboxylate (1.8 g, 8.7 mmol) was added slowly. The resultant mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to dryness. The residue was dissolved in CH_2Cl_2 (20 ml), and then treated with diethyl(hydroxymethyl)phosphonate (4.5 g, 27 mmol). The mixture was cooled to -60°C and then a cold solution of iodine monobromide 2 g, 9.6 mmol) in CH_2Cl_2 (10 ml) was added. The reaction mixture was warmed to -10°C and then kept at -10°C for 1 h. The reaction mixture was diluted with CH_2Cl_2, washed with saturated aqueous $NaHCO_3$, and then with aqueous sodium thiosulfate. The organic phase was separated, dried over $MgSO_4$, and concentrated under reduced pressure to dryness. The reaction mixture was purified by silica gel chromatography (eluting with 25% ethyl acetate in CH_2Cl_2, then switching to 3% methanol in CH_2Cl_2) to afford product **6** (0.9 g, 33 %).



(2'R, 5'R)-6-Methoxy-9-[3-fluoro-2,5-dihydro-5-(diethoxyphosphinyl)methoxy-2-furanyl]purine (7)

[0261] To a solution of compound **6** (6 g, 11.3 mmol) in acetic acid (2.5 mL) and methanol (50 mL), NaClO (10-13%) (50 mL) was added dropwise. The reaction mixture was then stirred for 0.5 h and concentrated under reduced pressure. The residue was treated with ethyl acetate

and then filtered to remove solids. The filtrate was concentrated and the residue was purified by silica gel chromatography to give product **7** (4 g, 88%).



(2'R, 5'R)-9-(3-fluoro-2,5-dihydro-5-phosphonomethoxy-2-furanyl)adenine di sodium salt (8)

[0262] A solution of compound **7** (2.3 g, 5.7 mmol) in methanol (6 mL) was mixed with ammonium hydroxide (28-30%) (60 mL). The resultant mixture was stirred at 120°C for 4 h, cooled, and then concentrated under reduced pressure. The residue was dried under vacuum for 12 h. The residue was dissolved in DMF (40 mL) and bromotrimethylsilane (3.5 mL) was added. The mixture was stirred at room temperature for 16 h, and then concentrated under reduced pressure. The residue was dissolved in aqueous $NaHCO_3$ (2.3 g in 100 mL of water). The solution was evaporated and the residue was purified on C-18 (40 µm) column, eluting with water. The aqueous fractions were freeze dried to give di-sodium salt **8** (1.22 g, 57%).



Example of Monoamidate Preparation (9)

[0263] Di sodium salt **8** (25 mg, 0.066 mmol), (S)-Ala-O-cyclobutyl ester hydrochloride (24 mg, 2 eq., 0.133 mmol) and phenol (31 mg, 0.333 mmol) were mixed in anhydrous pyridine (1 mL). Triethylamine (111 µL, 0.799 mmol) was added and the resultant mixture was stirred at 60°C under nitrogen. In a separate flask, 2'-Aldrithiol (122 mg, 0.466 mmol) and triphenylphosphine (103 mg, 0.466 mmol) were dissolved in anhydrous pyridine (0.5mL) and the resulting yellow solution was stirred for 15-20 min. The solution was then added to the solution of **8** in one portion. The combined mixture was stirred at 60°C under nitrogen for 16 h to give a clear yellow to light brown solution. The mixture was then concentrated under reduced pressure. The resultant oil was dissolved in CH_2Cl_2 and purified by silica gel chromatography (eluting with a linear gradient of 0 to 5% MeOH in CH_2Cl_2) to give an oil. The resulting oil was dissolved in acetonitrile and water and purified by preparative HPLC (linear gradient, 5-95% acetonitrile in water). Pure fractions were combined and freeze-dried to give mono amidate **9** as a white

powder.



Example of bis amidate preparation (10)

[0264] Di sodium salt **8** (12 mg, 0.032 mmol) and (S)-Ala-O-n-Pr ester hydrochloride (32 mg, 6 eq., 0.192 mmol) were mixed in anhydrous pyridine (1 mL). Triethylamine (53 µL, 0.384 mmol) was added and the resultant mixture was stirred at 60°C under nitrogen. In a separate flask, 2'-Aldrithiol (59 mg, 0.224 mmol) and triphenylphosphine (49 mg, 0.224 mmol) were dissolved in anhydrous pyridine (0.5 mL) and the resulting yellow solution was stirred for 15-20 min. The solution was then added to the solution of **8** in one portion. The combined mixture was stirred at 60°C under nitrogen for 16 h to give a clear yellow to light brown solution. The mixture was then concentrated under reduced pressure. The resultant oil was dissolved in CH_2Cl_2 and purified by silica gel chromatography (eluting with a linear gradient of 0 to 5% MeOH in CH_2Cl_2) to give an oil. The resulting oil was dissolved in acetonitrile and water and purified by preparative HPLC (linear gradient, 5-95% acetonitrile in water). Pure fractions were combined and freeze-dried to give bis amidate as a white powder.

Example of Monoamidate Preparation (11)

[0265]



[0266] Compound **8** (1.5g, 4 mmol) was mixed with ethyl alanine ester HCl salt (1.23g, 8 mmol) and phenol (1.88 g, 20 mmol). Anhydrous pyridine (35 mL) was added followed by TEA (6.7 mL, 48 mmol). The mixture was stirred at 60 °C under nitrogen for 15-20 min. 2'-Aldrithiol (7.3 g) was mixed in a separate flask with triphenylphosphine (6.2 g) in anhydrous pyridine (5 mL) and the resultant mixture was stirred for 10-15 min to give a clear light yellow solution. The solution was then added to the above mixture and stirred overnight at 60 °C. The mixture was

concentrated under reduced pressure to remove pyridine. The resultant residue was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution (2x) and then with saturated sodium chloride solution. The organic layer was dried over sodium sulfate, filtered and then concentrated under reduced pressure. The resultant oil was dissolved in dichloromethane and loaded onto a dry CombiFlash column, 40g, eluting with a linear gradient of 0-5% methanol in dichloromethane over 10 min and then 5% methanol in dichloromethane for 7-10 min. Fractions containing the desired product were combined and concentrated under reduced pressure to give a foam. The foam was dissolved in acetonitrile and purified by prep HPLC to give **11** (0.95 g).

[0267] Dissolved **11** (950 mg) in small amount of acetonitrile and let stand at room temperature overnight. Collected solid by filtration and washed with small amount of acetonitrile. Solid was GS-327625. Filtrate was reduced under vacuum and then loaded onto Chiralpak AS-H column equilibrated in Buffer A, 2% ethanol in acetonitrile. Isomer A, **12,** was eluted out with Buffer A at 10mL/min for 17mins. After which Buffer 13, 50% methanol in acetonitrile, was used to elute isomer **13** out from the column in 8mins. Removed all solvent and then re-dissolved in acetonitrile and water. Freeze-dried the samples (Mass - 348 mg).



Example 11b

[0268] 1H NMR (CDCl3) δ 8.39 (s, 1H) δ 8.12 (s, 1H) δ 6.82 (m, 1H) δ 5.96-5.81 (m, 4H) δ 4.03-3.79 (m, 10H) δ 3.49 (s, 1H) δ 3.2 (m, 2H) δ 1.96-1.69 (m, 10H) δ 1.26 (m, 4H) δ 0.91 (m, 12H) 31P NMR (CDCl3) 20.37 (s, IP) MS (M+1) 614

Example 12b

[0269] 1H NMR (CDCl3) δ 8.39 (s, 1H) δ 8.13 (s, 1H) δ 7.27-7.11 (m, 5H) δ 6.82 (s, 1H) δ 5.97-5.77 (m, 4H) δ 4.14-3.79 (m, 6H) δ 3.64 (t, 1 H) δ 2.00-1.88 (bm, 4H) δ 1.31 (dd, 3H) δ 0.91 (m, 6H). 31P NMR (CDCl3) δ 20.12 (s, 0.5P) δ 19.76 (s, 0.5P) MS (M+1) 535

Example 13b

[0270] ^{1}H NMR ($CDCl_3$): δ 8.39 (s, 1H), 8.13 (s, 1H), 6.81 (m 1H), 5.95 (m, 1H), 5.81(s, 1H),

4.98 (m, 2H), 3.90 (m, 2H), 3.37 (m, 1H), 3.19 (m, 1H), 1.71 (m, 4H), 1.25 (m, 12H), 0.90 (m, 6H)

[0271] Mass Spectrum (*m/e*): $(M+H)^+$ 586.3

Example 14

[0272] ^1H NMR ($CDCl_3$): δ 8.38 (s, 1H), 8.12 (s, 1H), 6.80 (m 1H), 5.93 (m, 1H), 5.79 (s, 1H), 4.02 (m, 6H), 3.42 (m, 1H), 3.21 (m, 1H), 1.65 (m, 4H), 1.35 (m, 8H), 0.92 (m, 12H)

[0273] Mass Spectrum (*m/e*): $(M+H)^+$ 614.3

Example 15

[0274] ^1H NMR ($CDCl_3$): δ 8.38 (s, 1H), 8.12 (s, 1H), 6.80 (m 1H), 5.93 (m, 2H), 5.80 (s, 1H), 3.91 (m, 6H), 3.42 (m, 1H), 3.30 (m, 1H), 1.91 (m, 2H), 1.40 (m, 6H), 0.90 (m, 12H)

[0275] Mass Spectrum (*m/e*): $(M+H)^+$ 586.3

Example 16

[0276] ^1H NMR ($CDCl_3$): δ 8.37 (s, 1H), 8.17 (s, 1H), 6.80 (m 1H), 6.18 (s, 1H), 5.93 (m, 1H), 5.79 (s, 1H), 4.02 (m, 6H), 3.46 (m, 1H), 3.37 (m, 1H), 1.61 (m, 4H), 1.32 (m, 10H), 0.92 (m, 6H)

[0277] Mass Spectrum (*m/e*): $(M+H)^+$ 614.3

Example 17

[0278] ^1H NMR (CD_3OD): δ 8.29 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 6.00 (s, 1H), 5.96 (m, 1H), 4.04 (m, 8H), 1.66 (m, 4H), 1.38 (m, 6H), 0.98 (m, 6H)

[0279] Mass Spectrum (*m/e*): $(M+H)^+$ 558.3

Example 18

[0280] ^{1}H NMR (CD_3OD): δ 8.29 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 5.99 (s, 1H), 5.96 (m, 1H), 4.04 (m, 8H), 1.67 (m, 4H), 1.23 (m, 6H), 0.95 (m, 6H)

[0281] Mass Spectrum (*m*/*e*): $(M+H)^+$ 558.3

Example 19

[0282] ^{1}H NMR (CD_3OD): δ 8.29 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 5.99 (s, 1H), 5.96 (m, 1H), 4.03 (m, 8H), 1.66 (m, 8H), 0.93 (m, 12H)

[0283] Mass Spectrum (*m*/*e*): $(M+H)^+$ 586.3

Example 20

[0284] ^{1}H NMR (CD_3OD): δ 8.25 (s, 1H), 8.17 (s, 1H), 7.21 (m, 10H), 6.80 (m 1H), 5.91 (s, 1H), 5.72 (m, 1H), 4.04 (m, 6H), 3.50 (m, 2H), 2.90 (m, 4H), 1.47 (m, 8H), 0.92 (m, 6H)

[0285] Mass Spectrum (*m*/*e*): $(M+H)^+$ 738.4

Example 21

[0286] ^{1}H NMR (CD_3OD): δ 8.24 (s, 2H), 7.33 (m, 10H), 6.81 (m 1H), 5.88 (s, 1H), 5.84 (m, 1H), 5.12 (m, 4H), 3.94 (m, 4H), 1.35 (m, 6H)

[0287] Mass Spectrum (*m*/*e*): $(M+H)^+$ 654.3

Example 22

[0288] ^{1}H NMR(CDCl3) δ 8.38 (d, 1H) δ 8.12 (d, 1H) δ 7.31-7.10 (m, 5H) δ 6.81 (m, 1H) δ 5.98-5.75 (m, 4H) δ 4.23-3.92 (M, 7H) δ 3.65 (m, 1H) δ 1.63 (m, 3H) δ 1.26 (m, 4H) δ 1.05-0.78 (m, 3H) 31P NMR δ21.01 (s, 0.6P) δ 20.12 (s, 0.4P) MS (M+1) 521

Example 23

[0289] ^{1}H NMR (CDCl3) δ 8.40 (d, 1H) δ 8.13 (d, 1H) δ 7.30-7.10 (m, 5H) δ 6.82 (m, 1H) δ 5.99-5.77 (m, 3H) δ 4.22-3.92 (m, 6H) δ 3.61 (m, 1H) δ 1.65 (m, 4H) δ 1.26-0.71 (m, 6H) 31P NMR (CDCl3) δ 20.99 (s, 0.6P) δ 20.08 (s, 0.4P) MS (M+1) 535

Example 24

[0290] ^{1}H NMR (CDCl3) δ 8.39 (d, 1H) δ 8.08 (d, 1H) δ 7.28-6.74 (m, 10H) δ 5.90 (m, 4H) δ 4.37 (m, 1H) δ 4.05 (m, 5H) δ 3.56 (m, 2H) δ 2.99 (m, 2H) δ 1.55 (m, 2H) δ 1.22 (m, 3H) δ 0.88 (m, 3H) 31P NMR (CDCl3) δ 20.95 (s, 0.5P) δ 20.01 (s, 0.5P) MS (M+1) 611

Example 25

[0291] ^{1}H NMR (CDCl3) δ 8.38 (d, 1H) δ 8.11 (s, 1H) δ 7.31-7.11 (m, 5H) δ 6.82 (s, 1H) δ 5.96-5.76 (m, 4H) δ 4.22-3.63 (m, 6H) δ 2.17 (bm, 2H) δ 1.65 (m, 2H) 1.30 (m, 4H) δ 0.88 (m, 3H). 31P NMR (CDCl3) δ 20.75 (s, 0.5P) δ 19.82 (s, 0.5P) MS (M+1) 521

Example 26

[0292] ^{1}H NMR (CDCl3) δ 8.40 (d, 1H) δ 8.09 (d, 1H) δ 7.27-6.74 (m, 10H) δ 5.93-5.30 (m, 4H) δ 4.39 (m, 1H) δ 4.14-3.77 (m, 4H) δ 3.58 (m, 2H) δ 2.95 (m, 2H) δ 1.90 (m, 3H) δ 1.26 (m, 1H) δ 0.85 (m, 6H). 31P NMR (CDCl3) δ 20.97 (s, 0.5P) δ 20.04 (s, 0.5P) MS (M+1) 611

Example 27

[0293] ^{1}H NMR (CD3OD): 8.31 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 6.02 (s, 1H), 5.98 (m, 1H), 4.98 (m, 2H), 4.01 (m, 2H), 3.66 (m, 4H), 1.23 (m, 12H)

[0294] Mass Spectrum (m/e): (M+H)+ 530.2

Example 28

[0295] ^{1}H NMR (CD3OD): 8.31 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 6.01 (s, 1H), 5.98 (m, 1H), 4.03 (m, 2H), 3.86 (m, 4H), 3.68 (m, 4H), 1.92 (m, 2H), 0.93 (m, 12H)

[0296] Mass Spectrum (m/e): (M+H)+ 558.3

Example 29

[0297] ^{1}H NMR (CD3OD): 8.29 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 5.99 (s, 1H), 5.97 (m, 1H), 4.01 (m, 8H), 1.66 (m, 8H), 1.32 (m, 8H), 0.96 (m, 12H)

[0298] Mass Spectrum (m/e): (M+H)+ 642.4

Example 30

[0299] ^{1}H NMR (CD3OD): 8.25 (s, 1H), 8.16 (s, 1H), 7.24 (m, 10H), 6.80 (m 1H), 5.90 (s, 1H), 5.71 (m, 1H), 5.25 (m, 4H), 4.57 (m, 2H), 4.51 (m, 2H), 4.05 (m, 2H), 3.46 (m, 2H), 2.92 (m, 6H)

[0300] Mass Spectrum (m/e): (M+H)+ 706.4

Example 31

[0301] ^{1}H NMR (CD3OD): 8.32 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 6.00 (s, 1H), 5.97 (m, 1H), 3.93 (m, 4H), 3.71 (s, 3H), 3.60 (s, 3H), 1.51 (m, 26H)

[0302] Mass Spectrum (m/e): (M+H)+ 666.5

Example 32

[0303] ^{1}H NMR (CDCl3) δ 8.39 (s, 1H) δ 8.17 (d, 1H) δ 7.32-6.82 (m, 5H) δ 6.82 (s, 1H) δ 5.98-5.81 (m, 3H) δ 4.27-3.64 (m, 6H) δ 1.94 (m, 1H) δ 0.90 (m, 6H). 31P NMR (CDCl3) δ 21.50 (s, 0.5P) δ 21.37 (s, 0.5P) MS (M+1) 521

Example 33

[0304] ^{1}H NMR (CDCl3) δ 8.39 (s, 1H) δ 8.13 (s, 1H) δ 7.27 - 7.14 (m, 5H) δ 6.85 (s, 1H) δ 5.97-5.77 (m, 4H) δ 4.186-4.05 (m, 7H) δ 1.60 (m, 3H) δ 1.29 (m, 7H) δ 0.90 (m, 3H) 31P NMR (CDCl3) 20.69 (s, 0.6P) δ 19.77 (s, 0.4P) MS (M+1) 549

Example 34

[0305] ^{1}H NMR (CDCl3) δ 8.39 (d, 1H) δ 8.07 (d, 1H) δ7.27 - 6.74 (m, 10H) δ 5.91 (m, 2H) δ 5.69 (m 2H) δ 5.27 (m, 2H) δ 4.55 (m, 2H) δ 4.30 (m, 1H) δ 3.69 (m, 1H) δ 2.95 (m, 1H) δ 5.05 (m, 2H) 31P NMR (CDCl3) δ 20.94 (s, 0.5P) δ 19.94 (s, 0.5P) MS (M+1) 595

Example 35

[0306] ^{1}H NMR (CDCl3) δ 8.39 (d, 1 H) δ 8.11 (d, 1 H) δ 7.28-7.10 (m, 5 H) δ 6.82 (s, 1 H) δ 5.98 - 5.76 (m, 3 H) δ 4.18 - 3.56 (m, 4 H) δ 3.59 (m, 1 H) δ 1.74 - 0.70 (m, 12 H). 31P NMR (CDCl3) δ 21.00 (s, 0.6 P) δ 20.09 (s, 0.4 P). MS (M + 1) 549

Example 36

[0307] ^{1}H NMR (CDCl3) δ 8.39 (d, 1 H) δ 8.12 (d. 1 H) δ 7.29 (m, 2 H) δ 7.15 (m, 3 H) δ 6.82 (s, 1 H) δ 5.94 (dd, 1 H) δ 5.80 (s, 3 H) δ 5.02 (m, 1 H) δ 4.23 - 3.58 (m, 6 H) δ 2.18 (s, 3 H) δ 1.23 (m, 6 H). 31P NMR (CDCl3) δ 21.54 (s, 0.5 P) δ 21.43 (s, 0.5 P). MS (M + 1) 507

Example 37

[0308] ^{1}H NMR (CD3OD): 8.30 (s, 1H), 8.25 (s, 1H), 6.84 (m 1H), 6.00 (s, 1H), 5.95 (m, 1H), 4.06 (m, 8H), 1.31 (m, 12H)

[0309] Mass Spectrum (m/e): (M+H)+ 530.3

Example 38

[0310] ^{1}H NMR (CD3OD): 8.25 (s, 1H), 8.16 (s, 1H), 7.24 (m, 10H), 6.84 (m 1H), 5.91 (s, 1H), 5.75 (m, 1H), 4.08 (m, 6H), 3.60 (m, 2H), 2.90 (m, 4H), 1.21 (m, 6H)

[0311] Mass Spectrum (m/e): (M+H)+ 682.4

Example 39

[0312] ^{1}H NMR (CD3OD): 8.25 (s, 1H), 8.16 (s, 1H), 7.22 (m, 10H), 6.81 (m 1H), 5.90 (s, 1H), 5.72 (m, 1H), 4.02 (m, 6H), 3.63 (m, 2H), 2.90 (m, 4H), 1.58(m, 4H), 0.87(m, 6H)

[0313] Mass Spectrum (m/e): (M+H)+ 710.4

Example 40

[0314] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.22 (m, 8H), 6.95 (m, 1H), 6.82 (m 1H), 5.90 (m, 2H), 5.72 (m, 1H), 3.95 (m, 4H), 3.63 (m, 1H), 3.07 (m, 1H), 2.81 (m, 1H), 1.55 (m, 2H), 0.86 (m, 3H)

[0315] Mass Spectrum (m/e): (M+H)+ 597.4

Example 41

[0316] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.20 (m, 9H), 6.96 (m, 1H), 6.81 (m 1H), 5.97 (m, 2H), 5.73 (m, 1H), 4.05 (m, 2H), 3.60 (m, 1H), 3.02 (m, 1H), 2.81 (m, 1H), 1.13 (m, 6H)

[0317] Mass Spectrum (m/e): (M+H)+ 597.5

Example 42

[0318] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.33 (m, 10H), 6.83 (m, 1H), 5.92 (m, 2H), 5.15 (m, 2H), 4.25 (m, 4H), 3.20 (m, 1H), 1.90 (m, 4H)

[0319] Mass Spectrum (m/e): (M+H)+ 595.6

Example 43

[0320] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.15 (m, 5H), 6.83 (m, 1H), 5.98 (m, 2H), 4.10 (m, 5H), 2.50 (m, 4H), 2.01 (m, 3H), 1.22 (m, 3H)

[0321] Mass Spectrum (m/e): (M+H)+ 567.3

Example 44

[0322] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.15 (m, 5H), 6.83 (m, 1H), 5.98 (m, 2H), 4.10 (m, 5H), 2.57 (m, 1H), 1.80 (m, 6H), 1.25 (m, 3H)

[0323] Mass Spectrum (m/e): (M+H)+ 547.7

Example 45

[0324] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.17 (m, 5H), 6.85 (m, 1H), 5.99 (m, 2H), 4.66 (m, 1H), 4.12 (m, 3H), 1.56 (m, 4H), 1.28 (m, 3H), 0.88 (m, 6H)

[0325] Mass Spectrum (m/e): (M+H)+ 549.3

Example 46

[0326] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.12 (m, 10H), 6.83 (m, 1H), 5.99 (m, 2H), 5.72 (m, 1H), 4.10 (m, 4H), 3.65 (m, 1H), 3.02 (m, 1H), 2.79 (m, 1H), 2.50 (m, 1H), 1.89 (m, 6H)

[0327] Mass Spectrum (m/e): (M+H)+ 623.4

Example 47

[0328] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.15 (m, 10H), 6.82 (m, 1H), 5.99 (m, 2H), 5.73 (m, 1H), 3.99 (m, 4H), 3.65 (m, 1H), 3.05 (m, 1H), 2.85 (m, 1H), 1.02 (m, 1H), 0.51 (m, 2H), 0.20 (m, 2H)

[0329] Mass Spectrum (m/e): (M+H)+ 609.3

Example 48

[0330] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.20 (m, 9H), 6.96 (m, 1H), 6.81 (m 1H), 5.97 (m, 2H), 5.73 (m, 1H), 4.71 (m, 1H)), 4.05 (m, 2H), 3.60 (m, 1H), 3.02 (m, 1H), 2.81 (m, 1H), 1.49 (m, 2H) 1.07 (m, 3H), 0.82 (m, 3H)

[0331] Mass Spectrum (m/e): (M+H)+ 611.2

Example 49

[0332] ^{1}H NMR (CD3OD): 8.20 (m, 2H), 7.25 (m, 6H), 6.82 (m 1H), 5.95 (m, 2H), 5.68 (m, 1H), 3.93 (m, 6H), 3.50 (m, 1H), 3.20 (m, 1H), 2.81 (m, 1H), 1.90 (m, 1H), 0.95 (m, 6H)

[0333] Mass Spectrum (m/e): (M+H)+ 617.3

Example 50

[0334] ^{1}H NMR (CD3OD): 8.23 (m, 2H), 7.18 (m, 10H), 6.96 (m, 1H), 6.81 (m 1H), 5.94 (m, 2H), 5.72 (m, 1H), 4.81 (m, 1H)), 4.05 (m, 2H), 3.60 (m, 1H), 3.02 (m, 1H), 2.81 (m, 1H), 2.25 (m, 2H) 1.81 (m, 4H)

[0335] Mass Spectrum (m/e): (M+H)+ 609.3

Example 51

[0336] ^{1}H NMR (CD3OD): 8.25 (m, 2H), 7.20 (m, 9H), 6.96 (m, 1H), 6.81 (m 1H), 5.97 (m, 2H), 5.73 (m, 1H), 4.71 (m, 1H)), 4.05 (m, 2H), 3.60 (m, 1H), 3.02 (m, 1H), 2.81 (m, 1H), 1.49 (m, 2H) 1.07 (m, 3H), 0.82 (m, 3H)

[0337] Mass Spectrum (m/e): (M+H)+ 611.4

Example 52

[0338] ^{1}H NMR (CD_3OD): δ 8.29 (m, 1H), 8.25 (m, 1H), 7.20 (m, 5H), 6.85 (m, 1H), 5.97 (m, 2H), 4.85 (m, 1H), 4.15 (m, 2H), 3.95 (m, 1H), 2.28 (m, 2H), 1.99 (m, 2H), 1.77 (m, 2H) 1.26 (m, 3H)

[0339] Mass Spectrum (*m/e*): $(M+H)^+$ 533.3

Example 53

[0340] ^{1}H NMR (CD_3OD): δ 8.29 (m, 1H), 8.25 (m, 1H), 7.20 (m, 5H), 6.85 (m, 1H), 5.98 (m, 2H), 5.18 (m, 1H), 4.03 (m, 7H), 2.15 (m, 1H), 1.95 (m, 1H), 1.26 (m, 3H)

[0341] Mass Spectrum (*m/e*): $(M+H)^+$ 549.2

Example 54

[0342] ^{1}H NMR (CD_3OD): δ 8.24 (m, 2H), 6.85 (m, 1H), 6.01 (m, 2H), 4.43 (m, 2H), 4.09 (m, 5H), 1.38 (m, 3H) 1.23 (m, 3H)

[0343] Mass Spectrum (*m/e*): $(M+H)^+$ 513.2

Example 55

[0344] ^{1}H NMR for mixture of diastereomers at phosphorus (300 MHz, CD_3OD ref. solv. resid. 3.30 ppm):
δ
(ppm) = 8.22-8.27 (m, 2H), 7.09-7.34 (m, 5H), 6.84 (br s, 1H), 5.93-6.02 (m, 2H), 5.00-5.14 (m, 1H), 4.01-4.26 (m, 2H) 3.89-3.94 (m, 1H), 1.50-1.88 (m, 8H), 1.23, (br t, 3H, J = 6.8). ^{31}P NMR for mixture of diastereomers at phosphorus(121 MHz, ^{1}H decoupled):
δ
(ppm) = 23.56, 22.27 (~60:40 ratio).

EXEMPLARY EMBODIMENTS:

[0345]



Example	R1	R2	Ester	MW
55	Ala	OPh	cPent	546.5
54	Ala	OCH_2CF_3	Et	512.36
53	Ala	OPh	3-furan-4H	548.47
52	Ala	OPh	cBut	532.47
50	Phe(B)	OPh	Et	582.53
56	Phe(A)	OPh	Et	582.53
57	Ala(B)	OPh	Et	506.43
51	Phe	OPh	sBu(S)	610.58
58	Phe	OPh	cBu	608.57
49	Phe	OCH_2CF_3	iBu	616.51
59	Ala(A)	OPh	Et	506.43
48	Phe	OPh	sBu(R)	610.58

Example	R1	R2	Ester	MW
60	Ala(B)	OPh	CH_2cPr	532.47
61	Ala(A)	OPh	CH_2cPr	532.47
62	Phe(B)	OPh	nBu	610.58
63	Phe(A)	OPh	nBu	610.58
47	Phe	OPh	CH_2cPr	608.57
46	Phe	OPh	CH_2cBu	622.59
45	Ala	OPh	3-pent	548.51
64	ABA(B)	OPh	Et	520.46
65	ABA(A)	OPh	Et	520.46
44	Ala	OPh	CH_2cBu	546.5
43	Met	OPh	Et	566.55
42	Pro	OPh	Bn	594.54
66	Phe(B)	OPh	iBu	610.58
67	Phe(A)	OPh	iBu	610.58
41	Phe	OPh	iPr	596.56
40	Phe	OPh	nPr	596.56
79	Ala	OPh	CH_2cPr	532.47
68	Phe	OPh	Et	582.53
69	Ala	OPh	Et	506.43
70	ABA	OPh	nPent	562.54
39	Phe	Phe	nPr	709.71
38	Phe	Phe	Et	681.66
37	Ala	Ala	Et	529.47
71	CHA	OPh	Me	574.55
36	Gly	OPh	iPr	506.43
35	ABA	OPh	nBu	548.51
34	Phe	OPh	allyl	594.54
33	Ala	OPh	nPent	548.51
32	Gly	OPh	iBu	520.46
72	ABA	OPh	iBu	548.51
73	Ala	OPh	nBu	534.48
31	CHA	CHA	Me	665.7
30	Phe	Phe	Allyl	705.68
29	ABA	ABA	nPent	641.68

Example	R1	R2	Ester	MW
28	Gly	Gly	iBu	557.52
27	Gly	Gly	iPr	529.47
26	Phe	OPh	iBu	610.58
25	Ala	OPh	nPr	520.46
24	Phe	OPh	nBu	610.58
23	ABA	OPh	nPr	534.48
22	ABA	OPh	Et	520.46
21	Ala	Ala	Bn	653.61
20	Phe	Phe	nBu	737.77
19	ABA	ABA	nPr	585.57
18	ABA	ABA	Et	557.52
17	Ala	Ala	nPr	557.52
74	Ala	OPh	iPr	520.46
75	Ala	OPh	Bn	568.5
16	Ala	Ala	nBu	585.57
15	Ala	Ala	iBu	585.57
14	ABA	ABA	nBu	613.63
13b	ABA	ABA	iPr	585.57
12b	Ala	OPh	iBu	534.48
77	ABA	OPh	Me	506.43
78	ABA	OPh	iPr	534.48
11b	ABA	ABA	iBu	613.63

wherein Ala represents L-alanine, Phe represents L-phenylalanine, Met represents L-methionine, ABA represents (S)-2-aminobutyric acid, Pro represents L-proline, CHA represents 2-amino-3-(S)cyclohexylpropionic acid, Gly represents glycine;

K1 or K2 amino acid carboxyl groups are esterified as denoted in the ester column, wherein

cPent is cyclopentane ester ; Et is ethyl ester, 3-furan-4H is the (R) tetrahydrofuran-3-yl ester; cBut is cyclobutane ester; sBu(S) is the (S) secButyl ester; sBu(R) is the (R) secButyl ester; iBu is isobutyl ester; CH_2cPr is methylcyclopropane ester, nBu is n-butyl ester ; CH_2cBu is methylcyclobutane ester; 3-pent is 3-pentyl ester ; nPent is nPentyl ester; iPr is isopropyl ester , nPr is nPropyl ester ; allyl is allyl ester; Me is methyl ester; Bn is Benzyl ester; and

wherein A or B in parentheses denotes one stereoisomer at phosphorus, with the least polar isomer denoted as (A) and the more polar as (B).

[0346] All literature and patent citations above are hereby expressly incorporated by reference at the locations of their citation. Specifically cited sections or pages of the above cited works are incorporated by reference with specificity. The invention has been described in detail sufficient to allow one of ordinary skill in the art to make and use the subject matter of the following Embodiments. It is apparent that certain modifications of the methods and compositions of the following Embodiments can be made within the scope and spirit of the invention.

[0347] In the embodiments hereinbelow, the subscript and superscripts of a given variable are distinct. For example, R_1 is distinct from R^1.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP00432695A **[0006]**
- EP00432694A **[0006]**
- US4816570A **[0029]**
- US4968788A **[0029]**
- US5663159A **[0029]** **[0170]**
- US5792756A **[0029]**
- WO9119721A **[0031]** **[0031]**
- US6312662B **[0031]**
- US5034394A **[0140]** **[0140]**
- US4724233A **[0140]**
- US5646180A **[0140]**
- US5849911A **[0140]**
- US5563142A **[0140]**
- US5028595A **[0140]**
- US4861759A **[0140]**
- US5519021A **[0140]**
- US6642245B **[0140]**
- US6436989B **[0140]**
- US6476009B **[0140]**
- US5413999A **[0140]**

- US5047407A [0140]
- US4724232A [0140] [0140]
- US5541206A [0140] [0140]
- US5484926A [0140]
- US5366972A [0140]
- US5196438A [0140]
- US4978655A [0140]
- US5210085A [0140]
- WO9615111A [0161]
- US20020103378A1 [0172]
- US6018049A [0172]

Non-patent literature cited in the description

- **DECLERCQ E**Annals of the New York Academy of Sciences, 1994, vol. 724, 438-456 [0003]
- **BARRE-SINOUSSI F**Lancet, 1996, vol. 348, 31-35 [0003]
- **TARRAGO et al.**FASEB Journal, 1994, vol. 8, 497-503 [0003]
- **FRANKEL et al.**Annual Review of Biochemistry, 1998, vol. 67, 1-25 [0003]
- **KATZ et al.**Annual Review of Biochemistry, 1994, vol. 63, 133-173 [0003]
- **VON DER HELM K**Biological Chemistry, 1996, vol. 377, 765-774 [0003]
- **HOTTIGER et al.**Biological Chemistry Hoppe-Seyler, 1996, vol. 377, 97-120 [0003]
- **ASANTE et al.**Advances in Virus Research, 1999, vol. 52, 351-369 [0003]
- **WLODAWER A**Advances in Virus Research, 1999, vol. 52, 335-350 [0003]
- **ESPOSITO et al.**Advances in Virus Research, 1999, vol. 52, 319-333 [0003]
- **L. RATNER et al.**Nature, 1985, vol. 313, 277-284 [0004]
- **L. H. PEARLW. R. TAYLOR**Nature, 1987, vol. 329, 351- [0004]
- **S. WAIN-HOBSON et al.**Cell, 1985, vol. 40, 9-17 [0004]
- **R. SANCHEZ-PESCADOR et al.**Science, 1985, vol. 227, 484-492 [0004]
- **M. A. MUESING et al.**Nature, 1985, vol. 313, 450-458 [0004]
- **SMITH et al.**Clinical Investigator, 1994, vol. 17, 226-243 [0005]
- **JOHNSON et al.**Advances in Internal Medicine, 2000, vol. 45, 1-40 [0005]
- **PORCHE DJ**Nursing Clinics of North America, 1999, vol. 34, 95-112 [0005]
- **ZHOU W**Journal of Medicinal Chemistry, 2004, vol. 47, 133399-3408 [0008]
- Design and Application of Prodrugs**BUNDGAARDHANS**A **T**extbook of Drug Design and DevelopmentHarwood Academic Publishers19910000113-191 [0028]
- **FARQUHAR et al.**J. Pharm. Sci., 1983, vol. 72, 324- [0029]
- **DE LOMBAERT et al.**J. Med. Chem., 1994, vol. 37, 498- [0031]
- **KHAMNEITORRENCE**J. Med. Chem., 1996, vol. 39, 4109-4115 [0031]
- **MITCHELL et al.**J. Chem. Soc. Perkin **T**rans., 1992, vol. II, 2345- [0031]

- **PUECH et al.**Antiviral Res., 1993, vol. 22, 155-174 [0031]
- **BENZARIA et al.**J. Med. Chem., 1996, vol. 39, 4958- [0031]
- **THEODORA W. GREENE**Protective Groups in Organic ChemistryJohn Wiley & Sons, Inc.19910000 [0032]
- **LEO A.**Principles of Modern Heterocyclic ChemistryW.A. Benjamin19680000 [0045]
- The Chemistry of Heterocyclic Compounds, A Series of MonographsJohn Wiley & Sons19500000 [0045]
- J. Am. Chem. Soc., 1960, vol. 82, 5566- [0045]
- McGraw-Hill Dictionary of Chemical TermsMcGraw-Hill Book Company19840000 [0056]
- **ELIEL, E.WILEN, S.**Stereochemistry of Organic CompoundsJohn Wiley & Sons, Inc.19940000 [0056]
- **THEODORA W. GREENE**Protective Groups in Organic SynthesisJohn Wiley & Sons, Inc.19910000 [0060]
- **KOCIENSKI, PHILIP J.**Protecting GroupsGeorg Thieme Verlag Stuttgart19940000 [0060]
- Protecting Groups: An Overview1-20 [0060]
- Hydroxyl Protecting Groups21-94 [0060]
- Diol Protecting Groups95-117 [0060]
- Carboxyl Protecting Groups118-154 [0060]
- Carbonyl Protecting Groups155-184 [0060]
- **SMITH R. et al.**Blood, 2003, vol. 102, 72532-2540 [0091]
- Handbook of Pharmaceutical Excipients19860000 [0109]
- Remington's Pharmaceutical SciencesMack Publishing Co. [0110]
- **IAN T. HARRISONSHUYEN HARRISON**Compendium of Organic Synthetic MethodsJohn Wiley & Sons19710000vol. 1, [0143]
- **IAN T. HARRISONSHUYEN HARRISON**COMPENDIUM OF ORGANIC SYNTHETIC METHODS19740000vol. 2, [0143]
- **LOUIS S. HEGEDUSLEROY WADE**COMPENDIUM OF ORGANIC SYNTHETIC METHODS19770000vol. 3, [0143]
- **LEROY G. WADE, JR.**COMPENDIUM OF ORGANIC SYNTHETIC METHODS19800000vol. 4, [0143]
- **LEROY G. WADE, JR.**COMPENDIUM OF ORGANIC SYNTHETIC METHODS19840000vol. 5, [0143]
- **MICHAEL B. SMITH**COMPENDIUM OF ORGANIC SYNTHETIC METHODSvol. 6, [0143]
- **MARCH, J.**Advanced Organic ChemistryJohn Wiley & Sons19850000 [0143]
- Comprehensive Organic SynthesisSelectivity, Strategy & Efficiency in Modern Organic ChemistryPergamon Press19930000vol. 9, [0143]
- **E. L. ELIEL**Stereochemistry of Carbon CompoundsMcGraw Hill19620000 [0159]
- **LOCHMULLER, C. H.**J. Chromatogr., 1975, vol. 113, 3283-302 [0159]
- **ELIEL, E.WILEN, S.**Stereochemistry of Organic CompoundsJohn Wiley & Sons, Inc.19940000322- [0161]
- **JACOB III**J. Org. Chem., 1982, vol. 47, 4165- [0161]
- Chiral Liquid ChromatographyChapman and Hall19890000 [0161]

- **OKAMOTO**J. of Chromatogr, 1990, vol. 513, 375-378 [0161]
- Organic Phosphorus CompoundsWiley197600009ff- [0163]
- **WISSNER et al.**J. Med Chem., 1992, vol. 35, 1650- [0164]
- **ANDERSON et al.**J. Org. Chem., 1984, vol. 49, 1304- [0164]
- **PATOIS et al.**J. Chem. Soc. Perkin Trans., 1990, vol. I, 1577- [0164]
- **SILVERBURG et al.**Tetrahedron lett., 1996, vol. 37, 771-774 [0164]
- **WATANABE et al.**Tetrahedron lett., 1988, vol. 29, 5763-66 [0164]
- **MITSUNOBU**Synthesis, 1981, 1- [0165]
- **CAMPBELL**J. Org. Chem., 1992, vol. 57, 6331- [0165]
- **ALEXANDER et al.**Collect. Czech. Chem. Commun., 1994, vol. 59, 1853- [0165]
- **CASARA et al.**Bioorg. Med. Chem. Lett, 1992, vol. 2, 145- [0165]
- **OHASHI et al.**Tetrahedron Lett., 1988, vol. 29, 1189- [0165]
- **CAMPAGNE et al.**Tetrahedron Lett., 1993, vol. 34, 6743- [0165]
- **BALTHAZAR et al.**J. Org. Chem., 1980, vol. 45, 5425- [0166]
- **PETRAKIS et al.**J. Am. Chem. Soc., 1987, vol. 109, 2831- [0166]
- **LU et al.**Synthesis, 1987, 726- [0166]
- **MELVIN**Tetrahedron Lett., 1981, vol. 22, 3375- [0166]
- **CASTEEL et al.**Synthesis, 1991, 691- [0166]
- **REDMORE**J. Org. Chem., 1970, vol. 35, 4114- [0166]
- J. Org. Chem., 1995, vol. 60, 2946- [0167] [0193]
- J. Org. Chem., 1973, vol. 38, 3224- [0167]
- J. Chem. Soc., Chem. Comm., 1979, 739- [0168]
- Helv. Chim. Acta., 1985, vol. 68, 618- [0168]
- J. Org. Chem., 1959, vol. 24, 434- [0168]
- J. Am. Chem. Soc., 1956, vol. 78, 2336- [0168]
- Organic Phosphorus CompoundsWiley1976000017- [0169] [0198]
- **QUAST et al.**Synthesis, 1974, 490- [0170]
- **STOWELL et al.**Tetrahedron Lett., 1990, vol. 3261, [0170]
- Comprehensive Organic Functional Group TransformationsPergamon19950000vol. 6, 416ff- [0172]
- **S. R. SANDLERW. KARO**Organic Functional Group PreparationsAcademic Press19860000260ff- [0172]
- Org. Syn. Coll., 1965, vol. 3, 167- [0174] [0174]
- Org. Syn. Coll., 1988, vol. 6, 715- [0174]
- J. Med. Chem., 1989, vol. 32, 357- [0175]
- Can. J. Chem., 1982, vol. 60, 976- [0176]
- Syn., 1986, vol. 303, [0176]
- Chem. Ber., 1985, vol. 118, 468- [0176]
- Tet. Lett., 2001, vol. 42, 5227- [0177]
- Synthesis., 1977, 704- [0178] [0178]
- Synthesis, 1993, 908- [0179]
- Tet. Lett., 1992, 2781- [0179]
- Tet. Lett., 1991, 4251- [0179]
- Synthesis, 1993, 103- [0179]

- Synthesis., 1982, 404- [0180]
- **R. B. WAGNERH. D. ZOOK**Synthetic Organic ChemistryWiley19530000647- [0181]
- **R. B. WAGNERH. D. ZOOK**Synthetic Organic ChemistryWiley19530000645- [0182]
- Chem. Lett., 1972, 373- [0183]
- J. Gen. Chem. USSR, 1983, vol. 53, 480- [0185]
- Zh. Obschei Khim., 1958, vol. 28, 1063- [0185] [0199]
- J. Org. Chem., 1994, vol. 59, 6144- [0185] [0185]
- J. Am. Chem. Soc., 1994, vol. 116, 3251- [0185]
- J. Org. Chem., 2001, vol. 66, 329- [0185] [0231]
- J. Med. Chem., 1995, vol. 38, 1372- [0185] [0190] [0237]
- J. Chem. Soc., Chem. Comm., 1991, 312- [0186] [0187]
- Nucleosides & Nucleotides, 2000, vol. 19, 1885- [0186] [0187]
- Tet. Lett., 1996, 7857- [0186]
- Bioorg. Med. Chem. Lett., 1998, vol. 8, 663- [0186]
- Coll. Czech. Chem. Comm., 1987, vol. 52, 2792- [0187]
- Tet. Lett., 2001, vol. 42, 8841- [0187] [0216]
- J. Org. Chem., 1995, vol. 60, 5214- [0188] [0192]
- J. Med. Chem., 1997, vol. 40, 3842- [0188] [0189]
- J. Med. Chem., 1996, vol. 39, 4958- [0188]
- J. Org. Chem., 1984, vol. 49, 1158- [0188]
- Bioorg. Med. Chem. Lett., 1998, vol. 8, 1013- [0188]
- Tet. Lett., 1996, vol. 37, 3997- [0188]
- Nucleosides Nucleotides, 1995, vol. 14, 871- [0188]
- J. Med. Chem., 1988, vol. 31, 1305- [0188]
- Org. Lett., 2001, vol. 3, 643- [0189]
- Anal. Chem., 1987, vol. 59, 1056- [0190] [0237] [0245]
- J. Chem. Soc. Perkin Trans., I, 1993, vol. 19, 2303- [0190]
- Tet. Lett., 2002, vol. 43, 1161- [0190]
- J. Am. Chem. Soc., 1957, vol. 79, 3575- [0192]
- J. Med. Chem., 1995, vol. 38, 2742- [0192] [0193]
- J. Med. Chem., 1997, vol. 40, 233842- [0193]
- J. Chem. Soc., Chem. Comm., 1991, 1063- [0196]
- J. Med. Chem.20020000vol. 45, 1284- [0198]
- J. Chem. Soc. Chem. Comm., 1991, 312- [0198] [0201]
- Nucleosides and Nucleotides, 2000, vol. 10, 1885- [0198]
- Tet. Letters, 1994, vol. 35, 4097- [0204]
- Organic Phosphorus CompoundsWiley19760000 [0206]
- J. Gen. Chem. USSR, 1983, vol. 32, 367- [0213]
- Synlett., 1998, vol. 1, 73- [0221]
- Aust. J. Chem., 1963, 609- [0225]
- Tet., 1999, vol. 55, 12997- [0225]
- Org. Lett., 2001, 643- [0228]
- Nucleosides and Nucleotides, 2000, vol. 19, 1885- [0231]
- J. Med. Chem., 2002, vol. 45, 1284- [0231]

- J. Med. Chem., 1995, vol. 38, 4648- [0235]
- Syn. Comm., 1995, vol. 25, 3565- [0237]
- J. Org. Chem., 1999, vol. 64, 12- [0252]
- J. Org. Chem., 1992, vol. 57, 5813- [0252]
- Syn. Lett., 1997, vol. 8, 893- [0252]
- Tetrahedron Lett., 1980, vol. 21, 1623- [0252]

Patentkrav

1. Forbindelse, herunder enantiomerer deraf, med formel 1J, eller et farmaceutisk acceptabelt salt eller solvat deraf,



1J

hvor:

A^3 er valgt fra



,



eller



hvor

R^1 uafhængigt er H eller alkyl valgt fra methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, og 3,3-dimethyl-2-butyl;

R^2 er H eller alkyl valgt fra methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, og 3,3-dimethyl-2-butyl; og

Y^{2b} er O eller N(R^2).

2. Forbindelse ifølge krav 1, hvor A^3 har formlen:



.

3. Farmaceutisk sammensætning omfattende en farmaceutisk excipiens og en antiviral virksom mængde af forbindelsen ifølge et hvilket som helst af kravene 1 eller 2.

4. Farmaceutisk sammensætning ifølge krav 3 der yderligere omfatter en anden aktiv bestanddel.

5. Kombination omfattende forbindelsen ifølge et hvilket som helst af kravene 1 eller 2 og én eller flere antiviralt aktive bestanddele.

6. Kombination ifølge krav 5, hvor en af de aktive bestanddele er valgt fra gruppen bestående af Tenofovir Disoproxil (Viread), Emtricitabin (Emtriva), en kombination af Tenofovir og Emtricitabine (Truvada), d4T, Efavirenz (Sustiva) eller Amprenavir antivirale forbindelser.

7. Farmaceutisk sammensætning ifølge kravene 3 eller 4 eller kombinationen ifølge kravene 5 eller 6 til anvendelse i medicinsk terapi.

8. Forbindelse ifølge et hvilket som helst af kravene 1 eller 2 til anvendelse i medicinsk terapi i anti-retroviral eller anti-hepadinaviral behandling.

9. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1 eller 2 til fremstilling af et medikament til behandling af HIV eller en HIV-associeret lidelse.